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Abstract 
 
 
Introduction 
In this study we exploited the recent development of methods that have enabled the analysis of 
RNA present in urine exosomes of prostate cancer patients. We report RNA expression patterns 
that contain diagnostic and prognostic information for prostate cancer, and association with 
response to hormone treatment.  
Methods 
First catch urine following digital rectal examination were collected from 662 men. 3 groups of 
patients were used: Low, Intermediate, and High-risk according to NICE stratification criteria, and 
two control groups: benign and advanced disease. 50-gene transcript expression analysis using 
NanoString technology was performed on 192 samples. Exosomal RNA Next-Generation 
Sequencing was performed on 18 samples for novel biomarker discovery.  
Results 
Expression analysis showed that PCa-specific transcripts such as TMPRSS2/ERG fusion 
transcripts were identifiable in exosomes from PCa urine samples.  LPD analysis highlighted 
expression levels of 15 transcripts with diagnostic potential (significantly up-regulated in cancer 
samples in comparison to benign control) and 17 transcripts with prognostic potential 
(differentialy expressed in high risk and advanced disease in comparison to lower grade disease).  
I also report two gene transcripts (SERPINB5/Maspin, HPRT) that were significantly 
differentially expressed in patients who failed to respond to hormone deprivation therapy for high 
risk/metastatic disease.  Three genes (STEAP4, ARexons4_8 and NAALADL2) were significantly 
differentially expressed in patients who relapsed within 12 months of hormone treatment 
initiation.  
Next-Generation Sequencing of twenty samples identified 45 genes to be significantly 
differentially expressed between non-cancer and cancer samples (28 were up regulated and 17 
down regulated).  33 out of the 45 genes showed a significant linear trend in association with 
cancer risk. 
Conclusions 
Urine Exosomal RNA contains PCa specific transcripts. Gene expression analysis and Next 
Generation Sequencing identified genes that are significantly differentially expressed between 
cancer and non-cancer cases as well as prognostic genes and genes that can predict response to 
hormone treatment 
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1.1 Prostate cancer – an Introduction 
 
The increased testing with serum prostate specific antigen (PSA) in healthy men as well as 
aging populations and public awareness led to increase in prostate cancer (PCa) diagnosis 
making it the most common cancer diagnosed in men (Cancer research UK, 2014 http://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence/common-cancers-compared), and the sixth leading cause of death in 
males worldwide (1,2). Its incidence is strongly age, country and race related with the 
highest incidence being in older men and the highest detection rate in Guadeloupe and 
lowest in south-central Asia. However these statistical figures may not represent an accurate 
picture due to poor cancer registration in some developing nations 
(http://www.cancerresearchuk.org/cancer-info/cancerstats/types/prostate/incidence/uk-
prostate-cancer-incidence-statistics) (3). PCa has a highly unpredictable clinical behaviour 
which is due to its innate multifocality and heterogeneity of progression rate. Unlike most 
other cancers, a large proportion of patients have clinically insignificant and indolent disease 
that will pose no real risk to their life. However due to the limitation of the available 
diagnostic and prognostic measures to identify aggressive PCa these patients often undergo 
unnecessary investigation and radical treatments. This has led to the questioning of prostate 
cancer screening by many, as several trials have shown no significantly decrease in prostate 
cancer-specific mortality in screened populations (3-5). Detection of prostate cancer by PSA 
testing and needle biopsy alone is also unreliable as 30 to 40% of anterior tumour can be 
missed (6,7), as well as a significant proportion of peripheral zone tumours particularly in 
large prostate glands where the 10-core standard biopsy may not adequately sample the 
entire prostate (8).  
There is therefore an unmet need for diagnostic biomarkers that are more specific for 
detecting prostate cancer per se, and which can also discern indolent from clinically 
significant disease.  Such biomarkers would retain the beneficial effect of early detection, 
while minimising the problems of over-diagnosis and over-treatment. 
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1.1.1 The Epidemiology of prostate cancer  
  
In 2010 prostate cancer was reported to be the most common cancer in most Western 
populations including the UK where it accounted for approximately 25% of all new 
diagnosed cancer cases in men in England and Wales (Cancer Research UK) (3,9,10).  
The detection rate of prostate cancer has risen in part due to increased detection via the PSA 
testing since 1986 (11) and diagnosis via surgical treatment for benign prostatic hyperplasia 
(BPH) (11) (12). In the UK alone PCa incidence increased by approximately 10,000 cases 
between 2001 and 2010 (3) however the mortality rate remained unchanged (Table 1.1 and 
Figure 1.1 provide a comparison of incidence rate and mortality rate in the UK. Both figures 
were adopted from Cancer research UK (http://www.cancerresearchuk.org/health-
professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence#heading-
Three)). 
 
Table 1.1: Prostate cancer associated incidence and mortality rate in the UK. 
Mortality England Wales Scotland  Northern 
Ireland 
UK 
Incidence Numbers 2001 26,027 1,746 1,860 509 30,142 
Age standardised Rates 89.9 92.6 64.9 63.1 79.2 
Incidence Numbers 2010 34,892 2,462 2,679 942 40,975 
Age standardised Rates 106.4 114.0 82.1 96.5 104.5  
Mortality Numbers in 2003 8,582 579 786 217 10,164 
Age standardised Rates 27.3 28.6 26.7 25.5 27.2 
Mortality Numbers in 2010 9,082 849 547 243 10,721 
Age standardised Rates   23.8 23.7 22.8 23.5 23.8                              
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1.1.2 Aetiology and risk factors 
 
Various risk factors are associated with prostate cancer including: 
 (1) Age: the most prominent risk factor in prostate cancer is aging. In the UK 
approximately 36% of cases are diagnosed in men aged 75 years and over, and only 1% 
were diagnosed in the under-50s based on histological diagnosis registered by the office for 
national statistics in the UK (Cancer Research UK). The incidence rate is 166 per 100,000 
for men aged 55-59, 560 per 100,000 for men aged 65-69 and 800 per 100,000 for men aged 
75-79 (13) (3). Much of prostate cancer’s detected incidence in various parts of the world 
comes from autopsy studies which reported an increase incidence of PCa in older men with 
a detection rate as high as 100% in men aged 100 (14). The prostate cancer prevention trial 
also reported an increased incidence of PCa in older men - this study was based on 5519 
men and reported age related incidences of 0.7% in men aged 55-60, 20.7% in men 60-64, 
31.5% in men age 65-69 and 47.1% in men over 70 years of age, these findings were based 
on PSA screening and histological diagnosis (TRUS biopsy)(15). To date the natural history 
of prostate cancer is not fully understood however it was thought that with increasing age, 
the production of steroid hormones changes, resulting in a favourable environmental 
conditions for the development and progression of cancer (16,17). 
	
	
 
Figure 1.1: The incidence of PCa in the UK over the last two decades (illustration adopted from 
Cancer research UK. Prostate cancer incidence statistics). Rates are per 100,000 men. 		
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(2) Hereditary: A meta-analysis investigating the risk of developing prostate cancer in the 
presence of a family history showed that relative risk increases with increasing numbers of 
affected family members (18), and malignant PCa is relatively more common at younger 
ages (19,20).  
 
Several genes have been reported to be involved in familial risk of prostate cancer including 
HPC1, HPC2, HPC20, CAPB, HPCX, BRAC1, BRAC2 and HOXB13 (21,22), some of 
which will be briefly discussed here. The HPC1 gene (Hereditary Prostate Cancer 1 on 
chromosome 1 at q24-q25) (23) and the HPCX gene (Hereditary Prostate Cancer X–linked, 
located on the X chromosome at q27-28). Men who inherit the PCa-linked HPC1 allele tend 
to develop prostate cancer before the age of 65 years (24) The HPCX gene has been reported 
to account for 16% of all familial prostate cancer cases and is particularly noticeable in cases 
of affected brothers due to the fact that it is X-linked and so not inherited from the father  - 
the Y chromosome being inherited from the father and the X from the mother) (25). 
The G84E mutation in HOXB13 in prostate cancer was initialy reported by in 2012. This 
mutation was particularly associated with men below the age of 55 years old that had a 
positive family history for prostate cancer (26), these finding was confirmed by another 
study examining the frequency of G84E in HOXB13 in in 2,443 hereditary prostate cancer 
families recruited from an International Consortium for Prostate Cancer Genetics (ICPCG). 
Others also reported i) a significant increase in prostate cancer in men carrying the mutation, 
ii) an associated clinical characteristic of high-risk disease compared to non carriers 
(51%/30%), and iii) significant over-transmittion of the mutation from parents to offspring. 
Several studies also reported an increased risk of prostate cancer in BRAC1+2 mutation 
carriers in comparison to non-carriers (five to two relative risk). The highest risk was for 
carriers of a BRCA2 mutation, particularly as these patients developed poorly differentiated 
aggressive disease (27-30). Another study reported that most of BRAC2 mutation carriers 
develop early onset disease (31). 
Genome-wide association studies have brought attention to inherited SNPs (Single 
Nucleotide Polymorphisms). One study reported 8 out of 300 SNP’s on 8q24 (rs12543663, 
rs10086908, rs1016343, rs13252298, rs6983561, rs620861, rs6983267 rs10090154) to be 
significantly associated with PCa susceptibility, though with no evidence for a link with 
disease aggressiveness. A risk score based on those 8 SNPs identified a 2-fold increased risk 
of PCa between the top and the bottom 1% of the population, with 8% of the top 1% being 
explained by familial risk with first degree relatives (32). A genome wide association study 
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identified 7 further PCa susceptibility loci in 7 regions of 5 different chromosomes (2p21, 
2q31, 4q22, 4q24, 8p21, 11p15, 22q12), the SNP on chromosome 4 having the strongest 
association with family history (rs7679673). By using a polygenic risk score based on these 
SNPs and previously identified ones, they reported that subjects in the top 1% of the risk 
distribution had a three-fold increased risk for prostate cancer and the top 10% have a 
relative increased risk of 2.3 fold in comparison with the general population. They also 
reported that 21.5% of familial PCa could be related to SNPs (33). Another study on 2609 
men showed that prostate cancer specific genetic variants can be used to improve prediction 
of prostate cancer (34). 
 
Epigenetic factors such as DNA-methylation can accompany genomic instability in PCa 
development. DNA-methylation can act as an ancillary to DNA mutations, leading to up- 
and down-regulation of genes and interruption of their normal functions, which may, for 
example predispose to increases in genetic alterations through the inactivation of tumour 
suppressor genes such as DNA repair genes, leading to the development of cancer (35). 
 
(3) Race: African-American men have been reported to have a higher incidence of prostate 
cancer with more aggressive disease. In the USA, people of African-American descent tend 
to be more affected by the disease and have poorer outcomes in terms of mortality when 
compared to their white counterparts (36-38). Men of Asian or Oriental origin have the 
lowest reported incidence (22), whereas Caucasians have an incidence between that of 
African-American and Asian populations. A higher incidence of the disease in second 
generation migrant Japanese and Chinese men in the USA as compared to those in their 
native countries support an argument for the contribution of environmental factors, diet and 
life style in the casualty of the disease rather than of differences in genetic structure or 
function (39). 
 
(4) Diet: Several studies have reported a correlation between diet and the incidence of 
prostate cancer, in particular consumption of high levels of animal protein and calcium as 
reported by the EPIC (European Prospective Investigation into Cancer and Nutrition) in 
2008. An 8.7 year follow up on 142,251 men showed that consumption of 35 g a day of 
dairy protein increased the risk of prostate cancer by 32%. Several studies have linked dairy 
protein with an enhanced activity of growth hormones particularly Insulin like Growth 
factor-I (IGF-I) which has been targeted in some studies for prostate cancer therapy (40) 
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(41-43) (44). Dairy calcium may increase PCa by supressing the synthesis of 1,25-
dehydroxyvitamin-D (45). 
Others have correlated prostate cancer with animal fat. This theory was strongly supported 
by a prospective study on a cohort of 51,529 U.S. men, aged 40 through to 75, that found 
directly correlation between total fat consumption and risk of advanced prostate cancer (46). 
Potential mechanisms of action include fat- induced changes in the hormonal milieu, 
induction of oxidative stress, and/or insulin-like growth factor-1 (IGF-1) (47).  
(5) Other factors: There are a numbers of other factors that have been reported to influence 
prostate cancer including, obesity, vasectomy, physical inactivity, sexual activity, sexual 
transmitted disease, infection with human papillomavirus, smoking, and alcohol 
consumption (48). 
 
 
1.2 Clinical presentation and diagnosis 
 
Presentation: The majority of prostate cancer patients are asymptomatic. Diagnosis in such 
cases is based on abnormalities detected by screening with serum levels of prostate-specific 
antigen (PSA) or findings on digital rectal examination (DRE). In addition, prostate cancer 
can be an incidental pathologic finding when tissue is removed during transurethral resection 
to manage obstructive symptoms from benign prostatic hyperplasia. Patients may also 
present with symptoms of metastatic disease. 
 
Symptoms of primary disease are usually secondary to prostate volume rather than cancer 
symptoms per se. These syptoms usually include lower urinary tract symptoms (LUTS) 
urine retention and or haematuria. However patients with benign prostatic hyperplasia alone 
will exhibit similar symptoms. 
 
Symptoms of advanced disease result from any combination of lymphatic, haematogenous, 
or contiguous local spread. Skeletal manifestations are especially common, symptoms 
depends on the site of metastasis that usualy manifest as a localised bone pain. Other 
symptoms comprise lower limb neurological defect due to spinal cord compression which is 
the most common sign in axial metastasis (more then 70% of people who die of prostate 
carcinoma have metastatic disease in their bones (49)). Beside bones, liver and lungs can 
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also be affected. Metastasis can also take the lymphatic route leading to enlarged lymph 
nodes that can cause symptoms due to pressure on other organs such as the ureters and 
swelling in the lower limb due to lymph congestion seconadary to blockage in the lymph 
circulation. Symptoms of malignancy including lethargy, weight loss and anaemia, are also 
common and usually are secondary to marrow infiltration or destruction by metastasis. 
 
Diagnosis can be attained by combination of clinical history, examination, and 
investigations: clinically a raised PSA or abnormal DRE raise the suspicion of PCa, 
histologically prostate tissue can be obtained through TRUS-guided biopsy of the prostate or 
prostate tissue through TURP (in which case cancer in not expected (TURP is done as a 
treatment for symptomatic BPE (benign enlargement of the prostate)), and radiologically by 
the mean of CT or MRI staging. Clinically a raised PSA and or abnormal DRE are an 
indication for trans rectal biopsy of the prostate. A DRE provides a rudimentary assessment 
of the local extent of the tumour and clinical staging. The histological assessment provides 
histological grading on the disease aggressiveness. According to the American Joint 
Committee on Cancer (AJCC) clinical staging is as follows: T1  - tumour present, but not 
detectable by DRE, T2: the tumour can be felt (palpated) on DRE, but has not spread outside 
the prostate, T3: the tumour has spread through the prostatic capsule (not detectable by 
DRE), T4: the tumour has invaded other nearby structures. 
Radiological staging by means of magnetic resonance imaging (multi-parametric MRI), 
Imaging technology is used in some centres in first line investigation of patients with raised 
PSA, followed up with a subsequent target and random biopsy in case of radiologically 
identifiable disease. The advantage of this is being able to identify clinically impalpable 
disease, anterior lobe tumours (small foci or anterior lobe tumours), and preventing biopsy-
related artefacts in patients that require a post biopsy MRI for staging porposes (to assess 
whether the tumour is localised to within the prostate capsule, or has invaded locally, or 
metastasised to lymph nodes). MRI and CT (Computer Tomography) scans are typically 
used post-biopsy in most centres for staging. In clinically advanced disease (PSA>100 
and/or locally advanced tumour on DRE) a bone nucleotide scan can be used to detect bone 
metastasis.  
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1.3 Histopathology of prostate cancer 
 
1.3.1 Macroscopic pathology 
 
The prostate gland consists of three main zones, which differ histologically and biologically. 
The Peripheral zone constitutes the bulk of the prostate, forming about 70% of the glandular 
part of the organ, and is the sub-capsular portion of the posterior aspect of the prostate gland 
that surrounds the distal urethra where its ducts open. The Central zone surrounds the 
ejaculatory ducts and forms about 25% of the glandular prostate; its ducts open mainly into 
the middle prostatic urethra. The Transition zone constitutes about 5% of the prostate and 
consists of two small lobes that surround the urethra proximal to the ejaculatory ducts. Its 
ducts open close to the sphincteric part of the urethra (50) (Figure 1.2).  
 
 
The majority of prostate malignancies arise in the Peripheral zone, which accounts for 
approximately 75% of all prostate cancers. The remaining 25% are found in the Transition 
zone (20%) and Central zone (5%).  
 
	
	
Figure 1.2: The various components of the prostate around the urethra. Illustration adopted from 
Elsevierimages.com (http://www.elsevierimages.com/image/25271.htm). 	
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Tumours in different prostatic zones have different pathological behaviours. Peripheral zone 
tumours are usually large in volume and are well known for their heterogeneity (Gleason 
scores varying from 3 to 5) and multifocality. Transition zone tumours arise in or near foci 
of benign prostatic hyperplasia and are smaller and better differentiated (Gleason 1-2) (51). 
Central zone carcinomas are the rarest, but highly aggressive with a distinct route of spread 
from the gland via the ejaculatory ducts and seminal vesicles routes that contrasts with 
spread of tumours from the other zones (52).  
 
Most prostate malignancies (95%) are adenocarcinoma. The remaining morphological 
variants are uncommon; they include ductal carcinoma variants, mucinous carcinoma, 
adenosquamous carcinoma and sarcomatoid carcinoma and metastases from other sites (53).  
 
1.3.2 Microscopic pathology 
 
The stem cells of prostate acini have been hypothesised to be the origin of prostate cancer 
(54). Between these cells and the final secretory cells, different intermediate or transit cells 
can be observed [stem cells, early progenitors intermediate stem cells, late progenitors 
intermediate stem cells, secretory cells (Figure 1.3, 1.4), and every one of them has been 
proposed to be able to evolve into malignant cells, perhaps explaining the biological 
variability of prostatic cancer (55).  
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Histologically, Gleason’s grading system is by far the most common prostate cancer grading 
method accepted and widely used. It is based on tissue architecture and the degree of tumour 
differentiation, cytological features do not play a role in the assessment (56). This grading 
system relies on identifying the 2 or 3 most dominant architectural patterns that get allocated 
as grades from 1 to 5, from the most differentiated (Gleason 1), to the least differentiated 
(Gleason 5). The two scores added together provide a ‘Gleason sum’, which range from 2 to 
10 however in cases where there is a 3 dominant grade it does not get added to the over all 
Gleason sum but may have clinical weight when it comes to offer treatment options. 
Gleason grading is an independent predictor of outcome and correlates with crude survival, 
tumour-free survival, and cause-specific survival (57). In addition to the Gleason grading 
system other microscopic features such as micro-vascular invasion and perineural infiltration 
can help predict the aggressiveness of the disease (58). 
 
1.3.3 PIN 
 
HG-PIN (High Grade Prostatic Intraepithelial Neoplasia) is a histopathological change that 
is considered to be the most likely precursor of invasive carcinoma of the prostate (59,60). 
There are numerous publications that support this hypothesis, including the many shared 
similarities between PIN and carcinoma of the prostate, such as the pattern of spread through 
 
Figure 1.3: Stem cell model of the normal prostate 
acini (Adopted from Maitland & Collins (55)). 
 	
	
Figure 1.4: Stem cell model showing the malignant 
transformation of prostate acini, with stem cell loss, 
malignant transformation of intermediate stem cells and 
secretory cells. Every one of these cells can be the final 
differentiation of the prostate cancer, and for this reason 
the prostate cancer has different phenotypes (Adapted 
from Maitland & Collins (55)). 
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prostatic ducts, the multifocal nature, the predominance in the Peripheral zone, and the 
association with raised PSA (61-64). Other morphological similarities that PIN shares with 
prostate cancer but to a lesser extent include: 1) neovascularisation; studies showed that the 
number of microvessels in HG-  PIN is greater than that in benign prostatic epithelium, but 
less than that in adenocarcinoma (65), 2) basal cell layer disruption is present in 56% of 
cases of HG-PIN and the amount of disruption increases with increasing grade of PIN (61), 
3) evidence of increased expression of a proteolytic enzyme (type IV collagenase) in PIN 
and cancer when compared with benign epithelium, this is thought to induce fragmentation 
of the stroma during invasion (61,66). 4) The frequency, severity, and extent of PIN 
increases in prostates with cancer compared to benign glands, 82% and 43% respectively as 
shown by several studies (61,62,67,68). 5) One of the strongest lines of evidence that 
support PIN as a precursor of carcinoma of the prostate is that they share similar genetic 
alterations such as the TMPRSS2/ERG fusion gene (69-72). Benign prostatic acini and ducts 
consist the histological architecture of PIN, where they are lined by atypical dysplastic cells 
depending on its grade (Figure 1.5). In HG-PIN there is partial destruction of the basal cell 
layers shown by 34BE12 cytokeratin immunostaining, in contrast in prostate 
adenocarcinoma there is a complete destruction.  
 The cytological changes in PIN include prominent nuclei and nuclear enlargement in most 
cells, as well as crowding and increased density of cytoplasm (73). 
  
 
Figure 1.5: Changes in the prostatic epithelium through increasing grades from PIN to early invasive 
carcinoma, according to the disease-continuum concept. Low grade PIN consists of very mild dysplasia. 
High grade PIN, corresponds to moderate to severe dysplasia and carcinoma in situ. The disruption of the 
basal cell layer accompanies the architectural and cytological features of high grade PIN and appears to be a 
requirement for stromal invasion. The basement membrane is retained with high grade PIN and early 
invasive carcinoma. (Illustration taken from a review by D. Bostwick (73)).  
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The incidence and extent of PIN appears to increase with patient age and predates the onset 
of prostate cancer by more than 10 years. It was reported that the onset of PIN in men in 
their 20s and 30s were 9% and 22% frequency respectively, they also showed that most foci 
of PIN in young males were low grade, and higher grade were found more commonly with 
advancing age (67,74). There is also evidence that PIN is influenced by race and 
geographical location and has increased sensitivity to androgens, characteristics that are 
strongly shared with prostate cancer (73,75). Several studies reported a higher frequency of 
PIN in Afro-American men compared to Caucasian men in the same age group (76-78). 
Despite the resemblances between HG-PIN and prostatic carcinoma, it is not clear what 
proportion of HG-PIN progresses to invasive carcinoma, and which remains stable. 
 
 
1.4 Clinico-pathological staging 
 
The TNM prostate cancer staging is used to assess the extent of the disease including; extent 
of local tumour ‘T’, lymph node status ‘N’, and distant metastasis ‘M’, which impacts on the 
appropriate treatment modality for the patient. The TNM staging system is widely accepted 
for this purpose (79).  
Based on the TNM staging system, tumours can be classified into 3 main categories (Figure 
1.6): 
(1) Organ confined disease (T1 to T2 N0M0) 
(2) Locally advanced disease (T3 to T4) 
(3) Advanced disease with metastasis (N1, M1) 
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1.5 Treatment 
 
Decisions on prostate cancer treatment are based on adequate disease staging histologically 
and radiologically, taking into consideration the patient suitability for the treatment (age and 
comorbidities). 
 
1.5.1 Localised and locally advanced prostate cancer 
 
This stage is defined by primary tumour that is confined to the prostate gland and has not 
breached the prostate capsule and invaded to adjacent organs. This could be determined 
from the clinical, histological, and radiological staging. The treatments options for this 
group of patients are dependent on the cancer progression risk as reported by the National 
Institute for Health and Care Excellence (NICE) (table 1.2). 
 
 
 
	
Figure 1.6: The TNM staging of prostate cancer. Illustration taken from The National Cancer Institute 
(http://www.yourcancertoday.com/Cancers/Prostate-Cancer/78). 	
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1.5.1.1 low risk group 
 
For men in the low risk group all treatment options are offered including: 
 
1- Active surveillance can be offered if subsequent radical treatment is suitable in case of 
disease progression (the patient is reassessment with serial PSA, DRE, Biopsy and MRI 
as required until the end of the active surveillance period when the tumour is 
reclassified). 
The European Association of Urology (EAU) recommends that patients should be 
informed of two randomised trials (80) (81) that compared radical prostatectomy (RP) 
vs. Watchful waiting (WW) in localised PCa before offering these treatment options. In 
the SPCG-4 study (80) (confined to men < 65 years of age) the survival benefit was 
similar before and after 9 years of follow-up. The number of patients that were needed 
to be treated to avert one death was 15 overall and seven for men < 65 years of age. 
However, physical symptoms, anxiety, and a depressed mood were lower, and a sense 
of well-being and self-assessed quality of life were better in the RP group than in the 
WW group. In the PIVOT-trial (81), a preplanned analysis of a sub-group of men with 
low-risk tumours showed that RP did not significantly reduce all-cause mortality. This 
option is more suitable for T1a and b disease. Reports stress that T1c tumours are 
mostly significant and should not be left untreated because up to 30% of T1c tumours 
are locally advanced at final histopathological analysis (82,83). The 2011 EAU 
Guidelines suggest that a PSA doubling time in <3 yr or a biopsy progression indicates 
the need for active intervention (84). 
 
Table 1.2:  NICE Risk stratification for men with localised prostate cancer 
This table is illustrated from NICE clinical guidelines 
(http://www.nice.org.uk/nicemedia/live/14348/66226/66226.pdf) 
 
Level of risk PSA  Gleason 
Score 
 Clinical Stage 
Low risk  <10 ng/ml And ≤6 And T1-T2a 
Intermediate 
risk  
10-20 ng/ml Or 7 Or T2b 
High risk >20 ng/ml Or 8-10 Or ≥ T2c 
High-risk localised prostate cancer is also included in the definition of locally advanced prostate 
cancer.  
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2- Radical treatment with curative intent, in the form of radical surgery (radical 
prostatectomy) or radiotherapy (external beam and brachytherapy) (85). Stage T2a 
patients with a 10-year life expectancy should be offered radical prostatectomy (RP) 
because 35-55% of them will have disease progression within 5 years if not treated 
(86,87). The outcome in terms of mortality when comparing radical radiotherapy (RT) 
and prostatectomy in patients with localised disease, has been shown to be similar (88). 
 
1.5.1.2 Intermediate Risk 
 
A policy of watchful waiting (WW) has been proposed for some patients with intermediate-
risk localised tumours (89), however, when the tumour is palpable or visible on imaging, 
and is clinically confined to the prostate, disease progression can be expected in most long-
term survivors - the median time to progression of untreated T2 disease has been reported as 
6-10 years. Stage T2b disease will progress in >70% of patients within 5 years (90) for this 
reason radical prostatectomy is the recommended standard treatment for patient with a life 
expectancy of >10 years (91). These recommendations are based on two large randomised 
control trials that showed a significant reduction in disease-specific mortality in favour of 
RP when comparing RP to WW (81,92). 
 
1.5.1.3 High Risk 
 
This group of patients is subclassified to 1) high-risk (T3aN0M0) and 2) very-high-risk 
(T3b-T4N0 or N1) according to the EAU guidelines 2013. 
1) For patients in the high-risk group, the treatment options remain controversial. The 
management decisions are made after case-by-case discussion by a multidisciplinary team, 
including urologists; radiation oncologists, medical oncologists and radiologists, and 
treatment should be offered to patients with regard to their own individual circumstances. 
WW is only offered to patients with < 10 years life expectancy. 
Surgical treatment is an option for patients with clinical stage T3a however it has been 
traditionally discouraged, mainly because patients have an increased risk of positive surgical 
margins and lymph  node metastases and/or distant relapse (93,94). 
The recommended treatment option for this group of patients is a combination of androgen 
deprivation treatment and radiotherapy. Several randomised studies of radiotherapy 
combined with ADT versus radiotherapy alone have shown a clear advantage for 
	 17	
combination treatment, (95). 
2) Patients in the very-high-risk group generally have a significant risk of disease 
progression and cancer-related death if left untreated. The optimal treatment approach 
therefore often necessitates multiple modalities in the form of RP or Radical Radiotherapy in 
combination with hormonal treatment, both of these treatment modalities showed 
comparable results in a recent US study (96). 
 
1.5.2 Metastatic disease 
 
The main treatment modality for patients with distant metastasis is hormone deprivation by 
means of surgical or medical castration. This treatment option is also suitable for individuals 
who have a locally advanced (non-organ confined) tumour, patients not fit for radical 
treatment or those with short life expectancy and patients who opt to avoid medical 
treatment. Men with locally advanced PCa in whom local therapy is not mandatory, WW is 
a treatment alternative to hormone depreviation with equivalent oncologic efficacy (84). 
 
The principle of hormone treatment prove the fact that prostate cells depend on androgens 
such as testosterone and dihydrotestosterone for growth and survival via stimulation of the 
cytoplasmic androgen receptor (AR). Androgen withdrawal by hormonal manipulation or 
surgical castration increase apoptosis and abates the tumour (97,98). The former treatment 
modality relies on the use of luteinizing hormone-releasing hormone (LHRH) analogues to 
induce a state of androgen depletion by causing a depletion of pituitary gonadotropin 
releasing hormone (99), while surgical castration is achieved by bilateral orchiectomy (the 
androgen hormone is mainly produced by the testicles under the influence of LH and FSH). 
Other modes of anti-androgen treatment include the use of steroid or non-steroid based 
androgen receptor inhibitors, as well as oestrogen therapy (this will influence the androgen 
release from the adrenal gland). 
Hormone depletion is initially effective but eventually fails with development of castrate 
resistance tumour, a stage that is inevitable in the natural course of prostate cancer. The 
median time to castrate resistant stage is 18 months, with lifetime expectancy of 12 months 
from the point of developing resistance (100) although these figures are improving on the 
new chemotherapy treatments (101). Various molecular mechanisms are involved to bring 
about this stage of androgen-withdrawal insensitivity. Some of these mechanisms are briefly 
explained here:  
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1) AR gene amplification resulting in high levels of androgen receptor, which allow 
cancer cells to respond to low levels of androgens, or by allowing enhance ligand 
binding that enable these cells to use very low level of androgen for growth 
(102,103). 
 
2)  Activation of AR by ligand dependent binding. AR mutations can broaden its 
specificity and allow its activation by non androgenic steroid molecules as well as 
antiandrogens (104) (105). Patients who show signs of disease progression despite 
antiandrogen treatment usually have the antiandrogen medication withdrawn, which 
can lead to disease regression (106-108). The majority of these mutations are thought 
to be in the ligand binding domains (98,109,110). AR can also be activated by 
ligand-independent mechanisms such as by growth factors including insulin-like 
growth factor, keratinocyte GF, epidermal GF, cytokines, IL6 and deregulation of the 
signal transduction pathways for example by overexpression of the tyrosine kinase 
receptor Her-2/neu (111,112). Other factors that may contribute to cancer growth in 
states of androgen sensitivity or insensitivity are released by bone stromal cells, 
osteoblasts, osteoclasts and ECM as a result of interaction with metastatic cancer 
cells (113). 
 
3)  Co-activators and co-repressors of AR regulation: the balance between co-activators 
and co-repressors that are normally used for intermediary signalling between AR and 
downstream transcription modulation can influence AR activation particularly in 
androgen independant disease (mechanisms unknown) (114). 
 
4) Bypass Pathway: by which AR activation is completely bypassed, allowing cancer 
cells to develop the ability to survive independently of androgen stimulation, by 
decreasing apoptosis through the Ras/Raf/MAP kinase cascade (115-117) and 
inactivation of tumour-suppressor genes (109). Neuroendocrine cells can survive in a 
low androgen environment, and their proliferation can stimulate disease progression 
by the action of secreted neuropeptides, such as serotonin and bombesin, which can 
increase the proliferation of neighboring cancer cells in a low-androgen environment 
(118). 
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1.6 Controversy in the screening and diagnosis of prostate cancer 
 
1.6.1 Screening controversy 
 
Due to the innate heterogeneity of prostate cancer, the decision about whether to pursue 
early PCa detection is complex, as treatment may not necessarily be to the benefit of all 
patients. On the other hand, prostate cancer remains the second most common cause of male 
cancer deaths, catching it early could in theory save lives. Differentiating between patients 
whose cancer will remain clinically insignificant and those whose disease will progress and 
kill them is a challenge that we need to overcome in order to reduce over-treatment and offer 
appropriate treatment for aggressive disease. Screening for prostate cancer to detect 
aggressive disease is a priority as the ethos of screening is to detect the disease at an early 
curable stage that can prolong and improve a patient’s quality of life. To date, screening for 
prostate cancer relies mainly on PSA testing and digital rectal examination (DRE), each of 
which lack sensitivity and specificity. There is therefore a real clinical challenge and an 
unmet need for improved diagnostic screening and follow up of patients with prostate cancer 
(119). Current screening investigations and their drawbacks are discussed below. 
 
1.6.1.1 Digital rectal examination (DRE) 
 
The DRE is examiner-dependent, and serial examinations over time are best. A nodule 
detectable by DRE is usually suspicious for malignancy and warrants evaluation; in 
addition, findings such as prostate asymmetry, difference in texture, and sponginess are 
important clues and should be considered in conjunction with the PSA level.  
Cysts, stones and benign nodules can resemble the above findings and cannot be accurately 
differentiated from cancer based on DRE findings alone. Therefore, a high index of 
suspicion is maintained. 
In case of cancer detection, the DRE findings form the basis of clinical staging of the 
primary tumour (ie, tumour clinical [T] stage). It can also sometimes form the basis of 
clinical management particularly in advanced stage (local metastasis) where the patient can 
be spared a prostate biopsy and get treated with hormone manipulation.  However in cases 
where a tumours is present and there is no corresponding increase in PSA, the DRE finding 
are not relied upon and patients will still need to undergo a biopsy in order to confirm a 
diagnosis of PCa. In my current practice at the NNUH, most patients diagnosed with 
prostate cancer have abnormal PSA readings and or abnormal DRE (small impalpable 
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disease), a small number of patients get diagnosed following histological examination from 
tissues obtained through transurethral resection of the prostate. 
 
1.6.1.2 Prostate Specific Antigen (PSA)  	
PSA is a 33-kDa-glycoprotein enzyme with serine protease activity encoded by the KLK3 
gene; it is a member of the tissue kallikrein family of serine proteases that also includes 
KLK2 and KLK4. Mature PSA is formed as a result of two proteolytic cleavages of two 
inactive precursor peptides, pre-proenzyme PSA (pre-proPSA) and pro-PSA. It is primarily 
produced by epithelial cells lining of the acini and ducts of the prostate gland from which it 
is secreted into the prostatic ducts in high concentrations (120). Its main function is to 
facilitate sperm motility by liquefying the seminal fluid through the breakdown of 
semenogelin and fibronectin (122). It was also found to affect the function of the IGF by the 
breakdown of its binding protein-3 (IGFBP3) (121). In cancer it was found to facilitate 
metastasis by activating the latent transforming growth factor (TGF-ß) (122,123).  
Serum PSA is broken down by the liver with a 2.2- to 3.2-day serum half-life, its serum 
concentration is normally low, however it can be affected by various conditions other than 
for prostate cancer such as: benign prostatic hyperplasia, infection or inflammation of the 
prostate, urine infection, urine retention, instrumentation for example urethral catheterisation 
or cystoscopy, digital rectal examination, and sexual intercourse (120,124), limiting its 
specificity and clinical utility particularly as screening test. Due to those limitations prostate 
cancer screening remain controvertial. Some completely oppose it as it is thought to lead to 
unnecessary invasive diagnostic tests (TRUS biopsy) that may identify clinically 
insignificant cancer and unnecessary treatment and treatment-related complications, as well 
as financial burden to the health care system (125,126); in the other hand some consider it 
necessary as it is thought to reduce metastatic burden and mortality that reduce the costs to 
the health care system (127). 
 
Over-diagnosis can be defined in many ways, and includes: the diagnosis of cancer that 
would not be diagnosed clinically, the diagnosis of a cancer that will not kill a given patient 
left untreated and in an epidemiologic sense, it is the difference in ‘incidence’ in a screened 
population and a matched unscreened population. There is clear evidence that screening is 
closely associated with over-diagnosis and that it increases the incidence/mortality ratio 
from 2 to approximately 5 in the United States where screening is prevalent (128). To 
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evaluate the efficacy of PCa screening, two large randomised trials have been published: the 
Prostate, Lung, Colorectal, and Ovary (PLCO) trial in the United States and the European 
Randomised Study of Screening for Prostate Cancer (ERSPC) in Europe (129,130). After a 
follow-up period of 7 years in the PLCO trial, the incidence of PCa per 10,000 man-years 
was 116 in the group that received regular PSA and DRE, and 95 in the control group (an 
incidence ratio of 1.22) (129). The incidence of death per 10,000 man-years was 2.0 in the 
screened group and 1.7 in the control group (rate ratio: 1.13). So it was concluded that PCa-
related mortality in screen-detected individuals was very low and not significantly different 
between the two study groups. On the other hand in the ERSPC trial with a median follow- 
up of 9 years, the cumulative incidence of PCa was 8.2% in the screened group and 4.8% in 
the control group (130). The absolute risk difference was 0.71 deaths per 1000 men. This 
means that 1410 men would need to be screened and 48 additional cases of PCa would need 
to be treated to prevent 1 death from PCa. The ERSPC investigators concluded that PSA 
based screening reduced the rate of death from PCa by 20% but was associated with a high 
risk of overtreatment.  
Like other serine proteases, serum PSA exists mostly in a complexed and inactive form; 
however, a small proportion remains in a free but active form. Free VS Bound PSA: Some 
studies suggested that determining the Free to Total PSA ratio in serum can improve the 
PSA specificity by allowing for a clearer distinction between patients with PCa and patients 
with benign prostate hyperplasia (BPH). For example men with a PSA between 4-10ng/ml 
and a PSA ratio of 25% have a 10% risk of PCa which increases to 60% if the PSA ratio is 
>25% (131). However other studies suggest that these calculation can only be useful in men 
with a prostate volume of less than 40 gram in size (132), and there is no clear guidance or 
set ratio for clinical use. For this reason free to total PSA ratio is only used in some units to 
determine whether to rebiopsy patients with persistently raised PSA. 
Despite all the efforts put into these trials the question remains as to whether early detection 
of organ confined prostate cancer with earlier treatment would improve life expectancy.  
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1.6.2 Diagnosis controversy 
 
Prostate cancer diagnosis relies on: transrectal ultrasound scan (TRUS) guided prostate 
biopsy, histological and radiological staging, all of which lack sensitivity and specificity that 
more often than not will expose patients to more invasive procedures and morbidity. Each of 
these tests is discussed individually below. 
 
1.6.2.1 Trans-rectal ultrasound scan (TRUS) guided prostate biopsy  
 
It is well established that standard sextant prostate biopsies underestimate prostate cancer 
incidence. Some studies have reported 15 to 23% false negative results, even in patients who 
have undergone repeat biopsies, this being particularly true for younger patients with lower 
PSA readings (133,134). For this reason some patients are required to undertake more 
invasive diagnostic tools such as extended TRUS biopsies or template biopsies of the 
prostate. 
A study undertaken with 2,887 patients, reported that an extended 12 site biopsy scheme 
may be more appropriate in patients with a normal rectal examination which are <60 years 
old or have a PSA of <7 ng/ml, since they may harbour smaller tumours that are more 
susceptible to sampling error (135). 
 
1.6.2.2 Histology 
 
To overcome the complexity of tumour heterogeneity and multifocal pattern of prostate 
cancer, the Gleason score was introduced. However histological grading relies on predicting 
cancer grade in the small amount of tissue removed by thin-core needle biopsies (The 
average 20-mm, 18-G core samples are a 0.04% of the average gland volume (40 ml). This 
makes biopsies prone to sampling errors that mostly manifest as missing higher or lower 
grade components resulting in under-grading in 42% of cases and over-grading in 15% of 
cases. As a result this leads to discrepancies between biopsy and post-prostatectomy 
histologies that can greatly affect the survival rate and clinical outcomes (57,136). It is also 
appreciated the tumours may be lumped into the same group whereas they may behave 
differently biologically. An example being that of a Gleason 7 (4+3) tumour, which is likely 
to be more aggressive then a Gleason 7 (3+4) tumour (53,57,137,138). (See paragraph 1.3.2 
for more explanation about Gleason grading). 
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1.6.2.3 Magnetic resonance imaging MRI 
 
At present MRI and other imaging modalities are used in the staging of prostate cancer. MRI 
is particularly useful to assess the extent of local metastasis, but has previously had no 
established role in cancer detection (139). There are however newly emerging technologies 
such as proton three-dimensional magnetic resonance spectroscopic imaging and diffusion-
weighted MRI that if used in combination increase the specificity for prostate cancer 
detection (140). These are playing an increasing role in screening for prostate cancer but 
have a high cost to the health service. 
 
To date prostate cancer screening, diagnosis management and follow up still remain a 
challenge. For this reason researchers have been looking for the ideal biomarker(s) for 
several decades, as summarised below. 
 
 
 
1.7 Prostate cancer biomarkers 
 
1.7.1 Biomarker definition  
 
A dictionary definition of a biomarker is a measurable indicator of some biological state or 
condition. Biomarkers are often measured and evaluated to examine normal biological 
processes or pathogenic processes. 
A biomarker is a molecule whose detection provides information about a disease beyond the 
standard clinical parameters that are gathered by the clinician 
(http://www.cancer.gov/dictionary). Based on biological properties, biomarkers may also be 
specific cells, molecules, or genes, gene products, enzymes, or hormones. 
To qualify a biomarker for clinical use, several criteria are required including: 
1- Safety: 
Sampling access: the marker must be present in peripheral body tissue and/or fluid 
(e.g., blood, urine, saliva). 
2- Sensitivity: 
Must be associated as sensitively as possible with damage of a particular tissue, in a 
quantifiable manner. 
3- Specificity:  
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It must have a high specificity for the disease. 
4- Implementable in the clinic: 
It must be easy to detect or quantify in assays that are both affordable and robust. 
 
1.7.2 Biomarker limitations 
 
Although interest in biomarkers is increasing, controversies regarding what constitutes a 
robust biomarker and how to rigorously investigate biomarkers remain. 
Sawyers et al., (141) stated seven common roles for biomarkers to address specific clinical 
questions when managing patients suspected to have a malignancy  this broadly included: 
1. Disease disposition: patient’s risk of developing cancer. 
2. Screening: earlier detection of patients with cancer. 
3. Diagnostic: high sensitivity and specificity. 
4. Grading and prognosis: disease aggressiveness and mortality risk. Most likely 
clinical outcome if therapy is not administered. 
5. Predictive: Which therapy is most appropriate?  
6. Monitoring: Is therapy effective? Does the patient’s disease recur?  
7. Pharmacogenomics: Do genetics predict response to therapy or the risk for an 
adverse reaction to the prescribed therapeutic dose? 
A single prostate cancer biomarker required to cover all the above-mentioned criteria would 
be a major challenge. Several studies have suggested that a multiplex panel of biomarkers 
can outperform PSA or any other single marker (142), hence in the last decade the search 
has changed from looking for a single markers to a panel of biomarkers that in combination 
can more accurately assess the clinical needs of the patient. 
 
1.7.3 Prostate cancer molecular biomarkers 
 
Since the adoption of PSA testing in 1980, there have been a number of advances in DNA 
analysis and RNA transcriptome profiling, via methods such as whole-genome sequencing 
and microarrays. These new technologies have enabled detailed analyses of cancer biology 
(143,144) and have led to the discovery of  several biomarkers from for example: tissue 
samples (obtained either by biopsy, surgical resection or tissue cultures) circulating tumour 
cells, and bodily fluids (blood and urine). These biomarkers include proteins, metabolites, 
RNA transcripts, DNA mutations and epigenetic modifications of DNA. A few biomarkers 
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have shown potential clinical utility, but none have actually fulfilled clinical needs. Some of 
the most popular biomarkers are discussed below. 
 
• PCA3 (prostate cancer gene 3 or DD3). The PCA3 gene consists of 4 exons and is 
located on chromosome 9 at q21–22 (145,146). It encodes a prostate-specific noncoding 
mRNA that is known to be overexpressed in over 90% of prostate cancer tissues in 
comparison to benign prostate (145,146). In 2009 an RNA-based urine test based on 
transcription-mediated amplification became available as a diagnostic test (147). The FDA 
approved the PCA3 test in 2012, to be used only in the clinical setting where a patient has a 
negative prostate biopsy in the presence of consistently rising PSA. It has superior 
specificity to PSA but inferior sensitivity (58 and 69% respectively (148)). Unlike PSA, 
PCA3 levels are independent of prostate size (149). 
 
• AMACR (Alpha-Methylacyl-CoA Racemase). Several studies have reported 
AMACR mRNA and protein to be overexpressed in prostate cancer cells when compared 
with benign prostate epithelial cells (150,151). This gene encodes a protein that is localised 
to mitochondria and peroxisomes. It is an isomerase enzyme that plays a key role in 
peroxisomal β-oxidation of dietary branched-chain fatty acids and C27-bile acid 
intermediates (152) by catalysing the conversion of (R)-α-methyl-branched-chain fatty acyl-
CoA esters to their (S)-stereoisomers. This pathway may have two aspects of relevance for 
prostate carcinogenesis: (i) the main sources of branched chain fatty acids in humans (milk, 
beef, and dairy products) have been implicated as dietary risk factors for prostate cancer 
(153); and (ii) peroxisomal β -oxidation generates hydrogen peroxide (154), a potential 
source of procarcinogenic oxidative damage (155,156). Analysis of mRNA levels of 
AMACR revealed an average 9-fold up-regulation in clinical prostate cancer specimens 
compared with normal. Western blot and immunohistochemical analysis have confirmed up-
regulation at the protein level and localises the enzyme predominantly to the peroxisomal 
compartment of prostate cancer cells. On needle biopsy specimens, AMACR has 
demonstrated high sensitivity (97%) and specificity (100%) as a diagnostic biomarker for 
prostate cancer (157). Low AMACR gene expression has also been correlated with 
metastasis and biochemical recurrence of prostate cancer (158). However, AMACR is not 
specific to prostate cancer (159) and has been reported as not being suitable for non-invasive 
detection in urine (142). It has been found to be most useful as a tissue biomarker when 
prostate biopsy cores yield ambiguous pathological results.  
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• GSTP1 (Glutathione S-Transferase Pi 1).  This gene encodes the eukaryotic 
peptide chain release factor GTP-binding subunit ERF3A, an enzyme that plays an 
important role in detoxification of xenobiotics by catalysing the conjugation of many 
hydrophobic and electrophilic compounds with reduced glutathione. One of the most 
common alterations found in prostate cancer is the Hypermethylation of the CpG Island at 
the promoter of GSTP1 which leads to the loss of GSTP1 expression (160). These changes 
are found in approximately 90% of prostate cancer tissue but not normal prostate tissue. It is 
also found to correlate with disease recurrence independent of Gleason score and 
pathological stage (161-164). These findings have also been reported in urine DNA, with an 
ability to identify the presence of prostate cancer with sensitivities ranging from 19 to 76% 
and specificity from 56 to 100% (164,165). However, using GSTP1 CpG island 
hypermethylation as a single marker for molecular screening and diagnosis of prostate 
cancer is limited due to its low sensitivity, and presence in other cancers (166). 
 
• TMPRSS2/ERG fusion gene (transmembrane protease serine 2 / v-ets avian 
erythroblastosis virus E26 oncogene homolog). ERG	is	member	of	the	ETS	(Erythroblast	Transformation	Specific)	family	that	also	contain	ETV1,	ETV4	and	ETV5	(167)	which	can	be	 involved	 in	 chromosomal	 translocations	 in	 malignancies	 in	 several	 organs.	 In	prostate	 cancer	 the	 most	 common	 translocation	 is	 the	 TMPRSS2/ERG gene fusion 
formed as a result of a chromosomal rearrangement that fuses the androgen sensitive 
promoter of TMPRSS2 with 3’ coding exons of ERG, bringing ERG transcription (168) 
under the control of androgen regulation. The encoded protein is a transcription factor that 
can regulate multiple genes and cellular pathways leading to PCa (169). A TMPRSS2/ERG 
is found in ~50% of prostate cancer and is specific for this disease (170). This gene fusion, 
which leads to ERG overexpression, can be an early event in prostate cancer due to its 
expression in PIN lesions (171) (172). However these findings has been questioned by some 
authors as they showed that ERG overexpression is less common in (PIN) (173). ERG 
rearrangements are hypothesised to promote carcinogenesis by activating cell differentiation 
programs and modulating the prostate cancer cell phenotype by a wide range of processes, 
including: cell growth, proliferation, differentiation and migration. It has been reported to 
function via the disruption of AR signaling (174-176), activation of the Wnt pathway, 
induction of epithelial-to-mesenchymal transition (177), by activating TGF-b/BMP signaling 
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(178), and cooperation with PI3K to drive carcinogenesis (179,180).  
Formation of a TMPRSS2/ERG alone is not linked to a poorer prognosis per se (167), 
however, there is an associated worse patient survival when i) two or more copies of a 
TMPRSS2/ERG are present, ii) when combined with the loss of the PTEN tumour suppressor 
gene (181-183), iii) when linked with AR overexpression, possibly by promoting the 
development of a more poorly differentiated invasive cancer cells.  
 ERG overexpression in normal prostate tissue can induce the expression of genes in the 
plasminogen pathway which can lead to invasion.  ERG down-regulation in the metastatic 
prostate cancer cell line (VCap) inhibited the invasive nature of these cells (184). This 
inhibition effect is thought to be secondary to a decrease in the expression of the proto-
oncogene c-MYC which is caused by the down-regulation of ERG (169). An alternative 
hypothesis is the down-regulation of genes involved in cell death pathways and 
overexpression of genes involved in the WNT pathway and histone deacetylase 1 (HDAC1) 
(185). TMPRSS2/ERG rearrangements appear to differ in incidence between different 
prostatic zones. Some studies have reported that cancers arising in the para-urethral region 
(Transition zone) have a lower prevalence of TMPRSS2/ERG rearrangements compare to the 
Peripheral zone (186).  
However, as TMPRSS2/ERG is absent in about 50% of prostate cancers, its use as a 
biomarker will only be as part of a multiplexed assay with other biomarkers (187,188). For 
example in a study of more than 1300 men, combined measurement of PCA3 and 
TMPRSS2/ERG in urine was shown to outperformed serum PSA alone for prostate cancer 
diagnosis (191). Beside its diagnostic advantages in prostate cancer TMPRSS2/ERG also has 
prognostic value as shown by studies who demonstrated that TMPRSS2/ERG expressing 
tumours have increased risk of recurrence after radical treatment (189,190). 
Those cancers lacking ERG alterations may harbour overexpression of SPINK1 (191) or 
mutations in the SPOP gene (192). Prostate cancer may also be assigned to different 
prognostic categories based on copy number of ERG alteration (193) or by examining a 
combination of ERG and PTEN gene status sometimes in combination with other genes 
(194,195). A combination of AURKA and MYCN gene amplifications predicted the 
occurrence of lethal neuroendocrine prostate cancer (196). Analysis of microarray 
expression profiles and combinations of expression profiles and patterns of gain and loss 
have also been used to identify diagnostic categories and prognostic biomarkers (197). 
 
• Matrix Metalloproteinase MMPs or matrixins. These proteins are a family of zinc 
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binding, calcium dependent endopeptidases. They belong to the ‘Metzincin’ superfamily of 
endopeptidases, which consist of three further multi-gene families, the serralysins, the 
astacins and the adamalysins (ADAMs) (198). MMPs are reported to participate in numerous 
disease processes including prostate cancer. Matrix metalloproteinases have been implicated 
in invasion and metastasis of human malignancies by breaching the extracellular matrix and 
thereby facilitating metastasis. 	
• SPINK1 (Serine protease inhibitor Kazal-type 1). This gene encodes a trypsin 
inhibitor protein (199) that is secreted from the pancreatic acinar cells. It functions as a 
serine protease inhibitor, involved in inflammation response and prevention of trypsin-
catalysed premature activation of zymogens within the pancreas and the pancreatic duct 
(200,201). SPINK1 overexpression is reported in association with prostate cancer, 
particularly with high grade disease giving it a prognostic potential (202,203). SPINK1 
over-expression has been associated with approximately 10% of ETS rearrangement-
negative cancers, and more aggressive disease (191,204,205). Its overexpression was also 
demonstrated in the aggressive 22RV1 prostate cancer cell line, where its knockdown 
weakens their invasiveness (191). SPINK1 also has the potential to serve as a PCa biomarker 
in that urine sediment multiplexed qPCR assay showed that SPINK1 outperformed serum 
PSA or PCA3 alone as diagnostic markers. SPINK1 expression is also an independent 
predictor of biochemical recurrence after resection (191,206). SPINK1 overexpression has 
been associated with Chromophobe renal cell carcinoma (207). 
 
1.7.4 Circulating tumour cells 	
Circulating tumour cells (CTCs) originate from primary tumours or metastatic deposits and 
find their way to the blood by invading blood vessels. In PCa, circulating tumour cells that 
exhibit features of prostate cancer such as expressing PSA, AMACR or genomic 
abnormalities such as AR-amplification, PTEN loss, and TMPRSS2/ETV fusions, have been 
isolated from patients with metastatic disease giving them a potential diagnostic use. Some 
studies have shown that CTCs from whole blood can be also used as prognostic markers in 
patients with metastatic disease (183,208). They also have the potential to provide 
information of the molecular structure of an individual patient’s tumour, to profile for 
elements that predict for sensitivity or resistance to therapy (209). So far enumeration of 
CTCs – as measured by the Cell Search assay – has been approved by the FDA only for use 
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as an aid to monitor men with metastatic disease in combination with other clinical 
assessments, however measurement of CTCs to determining patient response and drug 
efficacy is still under research. 
Due to the invasiveness and difficulty acquiring tissue for screening and diagnosis of 
prostate cancer, researcher looked for less invasive more accessible sources of biomarkers 
such as urine as discussed below: 
 
 
1.8 Urine biomarkers 	
Urine offers a non-invasive source of prostate bio-molecules that have the potential to be 
used as biomarkers. Due to the anatomic connection between the prostate and the urinary 
tract (urethra) via the prostatic ducts and the main ejaculatory duct (figure 1.2), prostatic 
exfoliates including cells, proteins and microvesicles have a direct access to urine flow 
particularly when stimulated by prostatic massage. This offers the ability to measure gene 
expression from all foci of cancer within a prostate, and thereby assess the heterogeneity of 
prostate cancer (142,187,210). Its differentially expressed transcripts in PCa tissue were also 
found to be differentially expressed in urine samples (211).  
DNA, RNA, and protein-based markers harvested from cells, microvesicles or whole urine 
can thus be considered for the detection of prostate cancer. The challenge however is to find 
a set of markers that has good performance characteristics and at the same time is easy to 
detect in urine. 
To date, several urine markers has been reported (Table 1.3), some of which have been 
proposed as potential diagnostic markers for early PCa detection e.g. GSTP-1 (glutathione-
S-transferase P1), PCA3 (prostate cancer antigen 3, DD3), TB-15 (thymosin b15) and 
TMPRSS2/ERG (212) of which only PCA3 has progressed to clinical use.  
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Prostate cancer cells can be detected in urine; however, these can break up shortly after urine 
sample collection. We therefore aimed in this study to exploit other biological products that 
could withstand surviving in urine for longer periods and could be used as a source of 
biomarkers. Exosomes and other microvesicles appeared to have this property. 		
1.8.1 Exosomes 
 
It is well documented that eukaryotic cells release extracellular vesicles including apoptotic 
bodies, exosomes, and other microvesicles (213,214). Extracellular vesicles differ in their 
cellular origins and sizes, for example, apoptotic bodies are released from the cell membrane 
as the final consequence of cell fragmentation during apoptosis, and they have irregular 
  Type of marker 
 
  DNA RNA Protein Metabolite 
8-OhdGa 8-Hydroxydeoxyguanosine +   + 
AMACR a-Methylacyl coenzyme A racemase  + +  
ANXA3 Annexin A3   +  
BHUAEa Basic human urinary arginine amidase   +  
BIRC5 Baculoviral IAP repeat-containing 5 (alias survivin)  + +  
F3 Coagulation factor III (thromboplastin, tissue factor)   +  
FGF1  Fibroblast growth factor 1 (acidic)   +  
FN1 Bladder tumour fibronectin   +  
GOLM1 Golgi membrane protein 1 (alias GOLPH2)  +   
GSTP1 Glutathione S-transferase P 1 +    
LOHa  Loss of heterozygosity +    
MCM5 Minichromosome maintenance complex component 5   +  
MMP9 Matrix metalloproteinases 9   +  
PCA1a Prostate cancer antigen 1   +  
PCA3 Prostate cancer antigen 3  +   
PIPa Prostatic inhibin-like peptide   +  
PSA Urinary prostate specific antigen   +  
S100A9 S100 calcium binding protein A9 (alias calgranulin B)   +  
SARa Sarcosine    + 
SPINK1 Serine peptidase inhibitor, Kazal type 1  +   
SRD5A2 Steroid 5-alpha-reductase type 2   +  
TERT Telomerase reverse transcriptase  +   
TF Urinary transferring   +  
TFF3 Trefoil factor 3  +   
TMSB15A Thymosin beta 15a   +  
VEGF Vascular endothelial growth factor   +  
Table 1.3 Urine biomarkers  
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shapes with a range of 1–5 mm in size (214,215). 
Exosomes are specialised vesicles, 30 to 100nm in size with a cup-shape morphology that 
are actively secreted by a variety of normal and tumour cells and are present in many 
biological fluids, including serum and urine. They carry membrane and cytosolic 
components including protein and RNA into the extracellular space (216-218). These 
microvesicles form as a result of inward budding of the cellular endosomal membrane 
resulting in the accumulation of intraluminal vesicles within large multivesicular bodies. 
Through this process trans-membrane proteins are incorporated into the invaginating 
membrane while the cytosolic components are engulfed within the intraluminal vesicles that 
form the exosomes, which will then be released, into the extracellular space (219,220) 
(Figure 1.7). This process is usually regulated by multiple enzymes including: calpain, 
flippase, floppase, scramblase and gelsolin (221). 
So far urine exosomes have been examined in several studies for renal and prostatic 
pathology and have been reported to be stable in urine. mRNA isolated from urine exosomes 
had a better preserved profile than cell-isolated mRNA from the same samples (222,223), 
which makes them much better for potential biomarker use. 
 
    
 
Figure 1.7: A schematic representation showing the intracellular formation and release of microvesicles into 
extracellular space. 
Invagination of the cellular plasma membrane forms the endosome, in turn budding from the limiting 
membrane into the lumen of endosomes generates intraluminal vesicles (ILVs) in the so called multi-
vesicular body (MVB).  
Owing to the biophysical properties, MVBs can be exocytic, (ie can fuse with the plasma membrane with 
subsequent release of their contents as exosomes). This schema was adopted from 
(http://www.biochemistry.unimelb.edu.au/research/res_hill-areas.html). 	
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1.8.1.1 Exosome Function 
 
Exosomes function as a means of transport for biological material between cells within an 
organism. As a consequence of their origin, exosomes exhibit the mother-cell’s membrane 
and cytoplasmic components such as proteins, lipids and genomic materials. Some of the 
proteins they exhibit regulate their docking and membrane fusion, for example the Rab 
proteins, which are the largest family of small GTPases (224). Annexins and flotillin aid in 
membrane  trafficking and fusion events (225). Exosomes also contain proteins that have 
been termed exosomal-marker-proteins, for excample Alix, TSG101, HSP70 and the 
tetraspanins CD63, CD81 and CD9. Exosome protein composition is very dependant on the 
cell type of origin. So far a total of 13,333 exosomal proteins have been reported in the 
ExoCarta database, mainly from dendritic, normal and malignant cells (Figure 1.8).  
Besides proteins, 2,375 mRNAs and 764 microRNAs have been reported (Exocarta.org) 
which can be delivering to recipient cells. Exosomes are rich in lipids such as cholesterol, 
sphingolipids, ceramide and glycerophospolipids (226-228) which play an important role in 
exosome biogenesis, especially ILV formation (229). 
 
 
Figure 1.8: A graphical representation of the protein composition of exosomes categorised by function 
performed. This graph was adopted from a review by Mathivanan et al.,(214). 	
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1.8.1.2 Mechanisms of exosome mediated intracellular communication 
 
A number of mechanisms have been described that are used by exosomes for interaction 
with target cells. 
1) Fusion with a target cell: this leads to the transfer of lipids, proteins and RNAs to the 
target cell. The proteins and lipids can change the target cell’s membrane characteristics eg 
the transfer of CD41 antigen from platelet-derived SMVs to tumour and endothelial cell 
membranes (230,231), and transfer of arachidonic acid from platelet derived microvesicles 
to leucocyte and endothelial cells (232). The transferred RNAs can be translated into 
functional proteins within the recipient cell (233).  
2) Release of their cargo by endocytosis, internalise through distinct endocytic pathways 
without fusing with the plasma membrane. 
3) Binding to a target cell and initiating a signalling response: exosomes are characterised by 
membrane proteins such as LAMP-2 that are not abundant in the cell of origin (234). 
Membrane proteins can bind and interact with a target cell in two ways: i) in a juxtacrine 
fashion and ii) by protease cleaved exosomal membrane proteins that can act as ligands for 
cell surface receptors in the target cell (214,235,236).  
4) Exosomes can release their cargo resulting in the release of signalling molecules and 
proteins into the extracellular space. For example tumours cells can secrete vesicles that 
contain metalloproteinases which when released can be responsible for extracellular matrix 
digestion and increased mobility of tumour cells (237).  
 
1.8.1.3 Exosomes in malignancy 
 
The role of exosomes in cancer remains to be fully elucidated; they appear to function as 
both pro- and anti-tumour effectors. Either way cancer cell-derived exosomes appear to have 
distinct biologic roles and molecular profiles. They can have unique gene expression 
signatures (RNAs, miRNAs) and proteomics profiles compared to exosomes from normal 
cells (238,239). Large numbers of differentially expressed mRNAs in exosomes from 
melanocytes compared with melanoma-derived exosomes has also been reported (238).  
This indicates that exosomal mRNAs may contribute to important biological functions in 
normal cells, as well as promoting malignancy in tumour cells. This study also found that 
cancer cell-derived exosomes have a closer relationship to the originating cancer cell than 
normal cell derived exosomes do to a normal cell, which highlights the potential of using 
	 34	
exosomes as a source of diagnostic biomarkers (238). mRNA expression in melanoma 
exosomes has been linked to the advancement of the disease (233) supporting the idea that 
exosomes can  promote tumour growth. A similar finding was reported in glioblastoma 
(240), highlighting their potential as prognostic markers. 
Experiments in mice have shown that cancer-derived exosomes can induce an anti-tumour 
immune response. It has been demonstrated that exosomes isolated from malignant effusions 
are an effective source of tumour antigens which are used by the host to present to CD8+ 
cytotoxic T cells, dramatically increasing the antitumour immune response (241). 
On the other hand exosomes have also exhibited an involvement in cancer development and 
metastasis as described below: 
1- Contribution to cancer invasion by promoting the proteolytic cascade required for the 
localised degradation of the extracellular matrix via lytic enzymes. In a melanoma study, 
exosomes exhibited uPA and MMPs proteins that are associated with inducing cell adhesion, 
migration and metastatic growth (242). Novel exosomal derived proteins such as sytenin-1 
have been shown to enhance melanoma cell migration invasion and metastasis (243,244). 
Exosomal activity in cancer is not restricted to intracellular activity only. A study on human 
fibrosarcoma and melanoma cell line exosomes which  contained the full-length (60kDa) 
and the proteolytically processed (43kDa) form of MT1-MMP, reported an efficient 
extracellular matrix (ECM) degrading enzyme which plays an important role in tissue 
homeostasis and cell invasion. Furthermore they demonstrated that the exosomal MT1-
MMP was functionally active and able to activate pro-MMP-2 and degrade type 1 collagen 
and gelatin and promote metastasis (237). 
 
2- Induction of angiogenesis, a lifeline for the tumour mass:  
Exosomes are rich in pro-angiogenic growth factors, including VEGF, FGF-2, and also 
proteases (245-249) that play a key role in activating the VEGF/VEGFR pathway in 
endothelial cells and promote angiogenesis (250). 
Annexin A1, a protein that functions as a key regulator of pathological angiogenesis has 
been found in malignant cell-exosomes (251,252), as has annexin A2, which has multiple 
roles in regulating cellular function, including angiogenesis, proliferation, apoptosis, cell 
migration, adhesion and invasion (253). 
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3- Induction of transformation  
A melanoma study concluded that normal melanocytes can acquire invasiveness through up-
take of melanoma-derived exosomes (238). In an in vivo study on mice, others showed that 
exosomes facilitated the ability of aggressive melanoma to metastasise to bone marrow by 
the transfer of Met oncoprotein from tumour-derived exosomes to bone marrow progenitor 
cells (254). They also showed that reducing Met expression in exosomes diminished this 
effect. Tumour derived exosomes also induced vascular permeability at the pre-metastatic 
sites to facilitate metastasis. Exosome production was increased in the melanoma cells, and 
the Rab family (RAB1A, RAB5B, RAB7 and RAB27A) that regulate membrane trafficking 
and exosome formation, were highly expressed. Rab27A RNA interference decreased 
exosome production and resulted in reduction in tumour growth and metastasis (254). The 
introduction of melanoma exosomes into sentinel lymph nodes (by injecting melanoma 
exosomes into mice foot pads) was reported to produce a molecular signal that affected 
melanoma cell recruitment, extracellular matrix deposition, and vascular proliferation in 
those lymph nodes (255). Melanoma metastasis was correlated to Stabilin 1 and VEGF-B 
expression that promote and maintain the survival of neovasculature that is necessary for 
melanoma growth leading to poor prognosis (256). While up-regulation of ephrin receptor 
beta4 promoted migration and proliferation of melanoma cells (257) (258). These findings 
demonstrated that melanoma exosomes are capable of directly tuning a remote lymph node 
toward a microenvironment that facilitates growth and metastasis in lymph nodes even in the 
local absence of tumour cells. Thus melanomas and perhaps other tumours can take 
advantage of an efficient exosomal messenger mechanism to prepare a site for eventual 
metastasis (259). A similar study demonstrated that proteins and exosomes secreted by 
tumour cells have the potential to modulate their microenvironment and facilitate 
angiogenesis and metastasis (260). In an in vivo study on lung cancer cell lines, it was 
demonstrated that the most aggressive type of cancer cells (A549) exhibited the strongest 
response to platelet-derived exosomes that are known to play a role in cancer metastasis. 
They also demonstrated in this study that when mice were injected with tumour cells (Large 
Lung cell Carcinoma, LLC) covered with platelet derived microvesicles they had 
significantly more metastatic foci in their lungs and bone marrow when compared to 
genetically identical animals injected with LCC cells not covered with platelet derived 
microvesicles (230).  
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4- Modulating the immune response and preventing cytotoxic effects on tumour cells. 
Kim et al., (261) showed in a study that microvesicles carrying Fas ligand, resulted in T-cell 
apoptosis and consequently prevented the cytotoxic effects on tumour cells. Another study 
showed that MV-associated CD46, helped cancer cells to escape from complement-induced 
lysis (262), and that fusion of MVs with monocytes inhibited their differentiation and 
promoted immunosuppressive cytokine release (263).  
 
5- Drug resistance: A study on prostate cancer cell lines showed that PCa vesicles are 
involved in drug resistance and that cancer cells (DU145), that are normally sensitive to 
camptothecin treatment, become resistant to camptothecin-induced apoptosis after being co-
cultured with vesicles isolated from the camptothecin-resistant cell line RC1. Conversely, 
RC1 cells, cocultured with vesicles isolated from DU145, underwent apoptosis when treated 
with camptothecin, suggesting the role of vesicles in mediating drug resistance and 
susceptibility (264). 
 
1.8.1.4 Exosomes and prostate cancer 
 
Several studies have examined the role of exosomes in prostate cancer. Some showed in 
their work that prostate cancer derived vesicles can stimulate fibroblast activation and lead 
to cancer development by increasing cell motility and preventing cell apoptosis. Similarly 
vesicles from activated fibroblasts are, in turn, able to induce migration and invasion in the 
PC3 cell line (265). Others reported that vesicles from hormone refractory PCa cells are able 
to induce osteoblast differentiation via the Ets1 which they contained, suggesting a role for 
vesicles in cell-to-cell communication during the osteoblastic metastasis process (266,267). 
Cell-to-cell communication was also emphasised in another study that showed that vesicles 
released from the human prostate carcinoma cell line DU145 are able to induce 
transformation in a non-malignant human prostate epithelial cell line (264). 
Besides the in vivo evidence on the active role of exosomes in cancer and cancer metastasis, 
it was also reported that exosomes are present in high levels in the urine of cancer patients 
(268), and that unlike cells, exosomes have remarkable stability in urine (269). Furthermore 
presence of exosomes was verified in prostatic secretions in 2006 (270), identifying them as 
a potential source of prostate cancer biomarkers. 
A study using nested PCR-based approach, showed that tumour exosomes are harvestable 
from urine samples from PCa patients and that they carry biomarkers specific to PCa 
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including KLK3, PCA3 and TMPRSS2/ERG mRNAs. PCA3 transcripts were detectable in all 
patients including subjects with low grade disease, however TMPRSS2/ERG transcripts were 
only detectable in high Gleason grades. They also demonstrated in this study that i) mild 
prostate massage increased the exosomal secretion into the urethra and subsequently into the 
collected urine fraction ii) that tumour exosomes are distinct from exosomes shed by normal 
cells, and iii) they are more abundant in cancer patients (210). This study took the first step 
in developing new methods and identifying novel markers for the diagnosis and prognosis of 
PCa. 
 
 
1.9 Gene transcripts tested in this study 
 
This project was performed as a part of a larger international project (Movember GAP 
Global Action for Prostate cancer) that has been led by Professor Cooper and Dr Jeremy 
Clark. The 50 genes including the housekeeping genes selected for the first set of gene 
expression analysis were chosen by 7 different groups that are participating in the 
Movember project (See table 1.4). 
 
• Matrix metalloproteinase and serine proteases 
 
TIMP4, Maspin (SERPINB5), MMP26 and Hepsin are markers that belong to families of 
matrix metalloproteinase and serine proteases that participate in many aspects of tumour 
growth and metastasis. 
 
• MMP26 (Endometase/matrilysin-2/matrix metalloproteinase 26) is one of the 
smallest members of the MMP family of zinc-catalysed proteolytic enzymes. Its activity is 
regulated by specific Tissue Inhibitors of MetalloProteinases including TIMP1, TIMP2 and 
TIMP4 with the latter having the greatest inhibitory potency (271,272). It is known to 
promote the invasion of human prostate cancer cells via cleavage of the basement membrane 
and multiple components of the ECM such as fibronectin, type IV collagen, fibrinogen, 
gelatins, vitronectin, as well as non­ECM proteins such as insulin-like growth factor-binding 
protein- 1 and α-1 protease inhibitor (271,273-275). It also activates the zymogen form of 
MMP-9, an enzyme that plays a critical role in ECM remodeling (276). MMP-26 mRNA has 
been shown to be widely expressed in epithelial cell prostate carcinomas (271,275) with 
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significantly higher levels in PCa cells when compared to prostatitis, benign prostate 
hyperplasia and normal prostate tissue (276). Several studies suggested that MMP26 plays a 
role in early cancer stages prior to development of invasive disease. This theory has been 
supported by several studies on epithelial tissues that express MMP26 including breast 
cancer. The expression of MMP26 in human breast tissue was shown to be significantly 
higher during pre-invasive ductal carcinoma in situ, when compared to infiltrating ductal 
carcinoma, atypical intraductal hyperplasia, and normal breast epithelia adjacent to them 
(272). In a similar study on prostate cancer tissue, using Western blot analysis and 
immunohistochemistry, it was shown that MMP-26 is significantly overexpressed in HGPIN 
when compared to adjacent cancer areas in the same tissues and that it has the lowest 
expression in non-neoplastic tissues (277), however a comparison between Gleason grades 
was not made in this study. As HGPIN is considered the pre-invasive precursor form of 
prostate cancer, they concluded that MMP26 plays an important role during disease 
progression. Another study using quantitative real time PCR on human prostate tissue, 
showed significant overexpression and Gleason correlation of MMP26 compared to benign 
tissue, however HGPIN was not included in this study (278). 
 
• TIMP4 (tissue inhibitor of metalloproteinases 4) is one of a family of four 
molecules that are produced and secreted into the extracellular milieu. It is a potent 
endogenous inhibitor of MMP-26 (272) and plays an key part in the degradation of the 
extracellular matrix that is integral in tumourigenesis (198) (279). Their overall structure can 
be divided into a highly conserved N-terminal domain responsible for its MMP inhibition, 
and a variable C- terminal domain which may impart distinct properties to the four TIMPs 
(280).  Similar to MMP26, TIMP-4 is thought to play an important role in disease 
progression. TIMP-4 was reported to be overexpressed in breast DCIS compare to IDC and 
normal tissue (272), similar findings was reported in prostate cancer (281). Due to the direct 
inhibition of the MMPs in a 1:1 fashion, the relative levels of the TIMP and the activated 
MMP determines the proteolytic potential of tumours in some contexts. Hence much of the 
cumulative data relating to TIMPs and MMPs in prostate cancer indicate that TIMP 
expression decreases in cancer, while the ratio of MMPs to TIMPs increases. In other 
contexts, an increase in TIMPs is associated with tumour progression (279). In Pancreatic 
adenocarcinoma studies showed that unlike MMP26, TIMP-4 intensity tends to diminish 
with higher cancer grades with its expression lowest in poorly differentiated tumours, a 
similar finding was reported in a study on prostate adenocarcinoma (278,282). 
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• HPN (Hepsin) is a trans-membrane serine protease, expressed in human tissues such 
as liver, kidney and prostate (283,284). It physiological function is not fully understood, 
however in vitro studies it has been shown to activate clotting factors VII, XII, and IX, pro-
urokinase, and pro-hepatocyte growth factor (pro-HGF) (285-287). In prostate cancer 
studies, Hepsin was shown to be consistently unregulated with approximately10-fold 
increase in cancer tissue when compared to benign control, its up-regulation was also shown 
to correlate with the disease progression as shown by several studies. At mRNA level 
several studies reported correlation between Hepsin overexpression and prostate cancer 
grades with the highest expression in higher grade disease (288,289) (278). These finding 
was confirmed by using a monoclonal antibody against Hepsin in various prostate tissues, 
where weak expression of Hepsin in normal prostate tissue, BPH and low-grade disease 
(G2/3) were reported and high Hepsin expression in advanced prostate cancer (G4/5) and 
bone metastasis (290,291). Low Hepsin expression was also reported in hormone-refractory 
prostate cancer when compared to clinically localised disease (292). The role of Hepsin in 
prostate cancer is not fully understood however studies have shown that it has the ability to 
promote cancer progression in several mechanisms. Being a proteolytic enzyme it can 
degrade extracellular matrix protein allowing cancer metastasis, Hepsin-overexpressing in 
transgenic mice was shown to have a role in the disorganisation of the basement membrane 
and promotion of cancer progression and metastasis (293). Beside its direct proteolytic 
ability, Hepsin can also activate proteases of the plasminogen/plasmin pathway by 
converting pro-uPA to active uPA which in turn activates matrix-degrading 
metalloproteinases (294). In vitro studies have also shown that Hepsin can activate growth 
factors such as pro-HGF (Pro Hepatocyte Growth Factor) (290,295) which is a potent 
stimulator for the receptor tyrosine kinase c-Met, which in turn plays an important role in 
tumour progression (296) (297). In an in vitro study, it was shown that in cases of human 
prostate cancer metastasis to bone, the proteolysis of the bone matrix protein (DQ-collagen I 
and DQ-collagen IV) was reduced by inhibiting the matrix metallo- serine and cysteine 
proteases (298). This study also reported that the secretion of cathepsin was increased in 
DU145 cells (Metastatic hormone sensitive Human prostate cancer cell line) when they were 
grown in vitro on human bone fragments. By using a SCID-human model of prostate bone 
metastasis, they also reported increased secretion of cathepsin B protein and activity in 
DU145, PC3, and LNCaP bone tumours. 
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• Maspin (mammary serine protease inhibitor) is a serine protease inhibitor and a 
member of the serpin superfamily. It has been characterised as a class II tumour suppressor 
by its ability to promote apoptosis and inhibit cell invasion. However the detailed molecular 
mechanism of its function as a tumour suppressor is still poorly understood. So far, several 
Maspin targets have been identified including inhibition of serine protease urokinase-type 
plasminogen activator (uPA) that plays an important role in human prostate cancer 
metastasis to bone (as described below) (299) (300). As well as targeting the single-chain 
tissue-type plasminogen activator (sc-tPA) (301), interferon regulatory factor 6 (IRF6) 
(302), β1-integrin (303) (304) collagen I (305) and glutathione S-transferase (GST) (306) all 
of which play an important role in cancer growth and metastasis. uPA is a serine protease 
that is present in several physiological locations, including blood stream and the 
extracellular matrix. It is also expressed in both osteoblast and osteoclast cells during bone 
remodeling whether in physiological or pathological state (10–15). One of its functions is to 
convert plasminogen to plasmin (21) - another serine protease capable of cleaving fibrin in 
thrombolysis (22, 23), degrading extracellular matrix (ECM) components (24, 25), and 
activating other zymogen proteases such as pro-MMP-9 (26–28) that can promote tumour 
growth by osteolysis and angiogenesis leading to cancer growth and bone metastasis. In an 
in vivo study in rats it was demonstrated that uPA promoted prostate cancer metastasis to 
bone (307), thus by controlling uPA activity, Maspin has the ability to affect MMP- 
dependent proteolysis and bone metastasis. In a mouse model it was shown that Maspin has 
the ability to inhibit mammary tumour cell growth invasion and motility (308) (29–33). This 
explains Maspin up-regulation in premalignant prostate cancer epithelial cells and constant 
down-regulation at the critical transition from noninvasive, low-grade to highly invasive, 
high-grade prostate cancer as reported by some studies (309), similar findings was 
documented in breast cancer (310). A study on lung adenocarcinoma, reported that Maspin 
expression was associated with a better-differentiated phenotype and better prognosis (311), 
on the other hand several studies reported its down-regulation on progression to tumour 
invasion and metastasis (306,312). 
 
•          GOLM1 (Golgi membrane protein 1) is a resident cis-Golgi membrane protein of 
unknown function. GOLM1 dysregulation has been reported in 20 common types of cancer 
including kidney, bladder, prostate (313) and hepatocellular cancer where its upregulation 
were initially detected (314). The epithelial origin of GOLM1 in prostate cancer was also 
documented (315) as well as its up-regulation in PCa at the mRNA level (316) (317). 
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GOLPH2 (aka GOLM1) expression was reported to be significantly higher in prostate cancer 
tissue compared to benign. Its upregulation was detected in (84%) of AMACR-negative 
prostate cancer cases (318). Multiplexing GOLM1 mRNA with other biomarkers including 
SPINK1, PCA3 and TMPRSS2/ERG was shown to be a significant predictor of PCa (206), 
furthermore a secretory form of GOLM1 protein was identified in culture supernatants of a 
prostate cancer cell line. This secretion was inhibited by brefeldin A which is a protein 
transport inhibitor (319) (320). A full length version was detectable in the urine of PCa 
patients (315), the origin of which was thought to be either due to secretion or alternatively 
released from within exosomes (321). 
 
• HOXC4 and HOXC6 (Homeobox C4 and Homeobox C6) HOX or Homeotic 
genes are developmental genes that play a critical role in embryogenesis by coding 
functional regulatory proteins (322). In the human genome there are a total of 39 HOX genes 
located on 4 different chromosomes (323) each of which contains a homeodomain (324). 
HOX genes have been known to play important roles in the development of cancers, 
including poor cell-differentiation, a main feature of malignant cells. Embryogenesis studies 
demonstrated that the lack of HOX expression can lead to undifferentiated cells (325), on the 
other hand HOXC8 over-expression has been shown to be associated with failure of cell 
differentiation in prostate cancer, suggesting that it is involved in the acquisition of the 
invasive and metastatic character of this malignancy (326). Similarly another study reported 
over-expression of HOXC8, HOXC4 and HOXC6 in malignant cell lines of PCa and lymph 
node metastases using RT-PCR (327). They also demonstrated that over-expression of 
HOXC8 in LNCaP PCa cells supressed transactivation via the androgen receptor suggesting 
that HOX gene dysregulation plays a role in androgen independence by requiring adaptation 
to low androgen signalling (327). In whole genome profiling comparing 28 PCa samples and 
12 normal prostates, a study demonstrated upregulation of HOXC6 along with 55 other 
genes in the tumour samples (328). They also showed that silencing HOXC6 expression 
(using small-interfering RNA (HOXC6 siRNA)) in both androgen-dependant LNCaP cells 
and C4-2 androgen-independent cell lines lead to decreased cell proliferation rates by 
inducing apoptosis. It was also demonstrated that over-expression of HOXC6 prevented 
LNCaP cells from HOXC6 siRNA-induced apoptosis possibly by promoting cell survival by 
modulating AR-stimulated gene expression, repressing expression of filamin A (FLNA) and 
preventing apoptosis by targeting tumour suppressor p53 regulating targets such as (IGFBP-
3 and PA26) (329) (330). Besides HOXC6 and HOXC4 other HOX genes play a significant 
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role in cancer by promoting tumour vascularisation, metastasis and cell proliferation (331). 
 
• KLK2 (Human Kallikrein 2) is a member of the kallikrein gene family and is 
located on chromosome 19 at q13-4 (332). It is a serine protease with trypsin-like activity, 
and is mainly expressed in the prostate gland (333). Its expression is regulated by androgens 
and androgen receptor (AR) signaling (334) and is often co-expressed with KLK3 (PSA) 
within the same tissue. One of its functions is to cleave PSA into its enzymatically active 
mature form (335). It also plays important roles in prostate cancer initiation and metastasis 
(336). Via its protease activity, and by activating members of the matrix metalloprotease 
family and uPA (uPA function is discussed earlier in this chapter) it promotes extracellular 
matrix degradation and metastasis (337). KLK2 has also been found to enhance AR 
transactivation (ARA70) that may result in alteration of PCa formation and promotion of 
prostate cancer cell growth (338). In castrate resistant prostate cancer specimens, KLK2 
over-expression was found to correlate with high cell proliferation rate and a lower cell 
apoptotic index, while knock down has the opposite effect (338). Serum levels of KLK2 
have been shown to differentiate organ-confined from non-organ-confined prostate cancer, 
different disease grades, and also, benign from malignant disease when the PSA levels are 
low (339-341). 
 
• KLK4 (Human Kallikrein4) is a member of the human KLK family that is 
androgen regulated (342,343). Unlike other kallikreins that encode an extracellular 
functional protein, KLK4 is primarily localised to the cell nucleus and cytoplasm (343-345). 
It is highly expressed in prostate epithelial basal cells. Several studies have shown that the 
expression of KLK4 is significantly higher in prostate cancer tissue when compared to 
benign and that it has a proliferative effect on cancer cells possibly through cell cycle 
regulation (346). Ectopic expression of KLK4 was also reported to dramatically increases 
cell proliferation and motility in PCa cell lines, and that its over-expression has significant 
effects on cell cycle–related gene expression (346). It was also demonstrated that 
knockdown of endogenous KLK4 in LNCaP cells by small interfering RNA has significant 
effects on inhibiting cellular proliferation. Similarly a study on the PC-3 prostate cancer cell 
line reported that KLK4 transfection induced cellular migration and invasion through 
repression of E-cadherin and increased expression of vimentin in these cells (345). 
 
• DLX1 (Distal-less homeobox 1) encodes a member of a homeobox transcription 
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factor gene family (347). It encodes a nuclear protein (348) that regulates transcriptional 
signals from multiple TGF-{beta} superfamily members. DLX1 was initially found to be 
expressed in the proximal and distal component of the first pharyngeal where it controls 
craniofacial patterning, and the differentiation and survival of inhibitory neurons in the 
forebrain (347). The androgen regulated prostate-expressed DLX1 was reported to be up 
regulated in prostate cancer by several authors, however its role in cancer is not fully 
understood. In a study on human prostate specimens obtained by radical prostatectomies  
DLX1 was reported to be the most significantly over-expressed of 26 genes including the 
PCA3 gene in transition zone disease when compared to benign tissue (349). In ‘Ingenuity’ 
pathway analysis they showed that DLX1 significantly represented 2 biological functions: 
cellular movement in benign tissue and epithelial carcinoma respectively. Similarly other 
studies documented that DLX1 and DLX2 expression resulting in altered regulation of genes 
in prostate cancer cells and epithelial-neuronal cell conversion (348) (350). 
 
• TDRD1 (Tudor domain containing 1) belongs to a family of Tudor domain 
containing proteins. It was initially identified as a testicular cancer-related gene (351), 
Physiologically, its main role is in spermatogenesis where it represses transposable elements 
and prevents their mobilisation, a process that appears to be essential for germline integrity 
(352) as its knockout in mice is associated with defective spermatogenesis (353). TDRD1 is 
not transcribed in normal prostate epithelium (351), however it is known to be over-
expressed in prostate cancer (354,355). Several studies indicated that the over-expression of 
ERG alone is not sufficient for the development of prostate cancer (173,356,357) however 
its coexpression with TDRD1 can promote PCa, a study using RNA expression array 
analysis and qRT-PCR, found that TDRD1 was strongly and strictly coexpressed with ERG 
in primary prostate cancer (358). Another study using a transcriptome-wide analysis of 28 
primary prostate cancers found that TDRD1 is highly coexpressed with ERG (359,360), In 
this cohort, 14 tumours over-expressed ERG with TDRD1 ranking highest of the genes that 
were coexpressed with it. Two other studies using expression arrays, also found that TDRD1 
ranked highest among differentially expressed genes with ERG-positive prostate cancer 
(178,361) they also showed that (TDRD1) is the most differentially expressed gene between 
ERG rearrangement-positive and -negative prostate cancer with it being significantly over-
expressed in ERG-positive compared with ERG-negative and normal prostate tissue samples 
(178) (359). Others reported that TDRD1 over-expression in ERG-positive prostate cancer is 
secondary to DNA methylation of the TDRD1 promoter by ERG, leading to TDRD1 over-
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expression (353). 
 
• CAMKK2 (Calcium/Calmodulin-Dependent Protein Kinase Kinase 2, Beta) 
This protein phosphorylates the downstream kinases CaMK1 and CaMK4, components of 
the calcium/calmodulin-dependent (CaM) kinase cascade. It also phosphorylates AMP-
activated protein kinase (AMPK). In prostate cancer the expression of this gene is reported 
to be up-regulated by several authors (316,362) (363), some of whom reported an increase in 
its expression in the transition from PIN to PCa  (364). In a mouse model (transgenic 
adenocarcinoma of mouse prostate), it was reported that increased CaMKK2 expression was 
associated with cancer progression, with it being higher in castration resistant xenografts and 
markedly higher in the AR-expressing PCa cell line LNCaP (365). In LNCaP CaMKK2 
mRNA and protein appear to be induced by androgen hormone (dihydrotestosterone), its 
withdrawal suppressed CaMKK2 expression (365). These findings are in concordance with 
earlier studies which showed an increase in CaMKK2 mRNA expression with exposure to 
synthetic androgen R1881 (363,366). Other study also showed that the knockdown of 
CaMKK2 expression in LNCaP cells arrested the cell cycle at its G1 phase reducing cell 
proliferation (365). They also reported that AR induced CaMKK2 expression in turn feeds 
back to positively regulate the transcriptional activity of the AR forming a regulatory 
feedback loop that is important in prostate cancer progression. In contrast, the expression of 
CAMKK2 has been reported to diminished in high grade PCa and that its down-regulation is 
associated with poor prognosis. They also concluded from this study that androgen 
deprivation therapy may cause down-regulation of CAMKK2 that in turn could lead to AR 
hypersensitivity to androgen and disease progression (367). 
    
 
• IMPDH2 (Inosine Monophosphate Dehydrogenase 2) This gene encodes a rate-
limiting enzyme that plays a key role in the de novo synthesis of purine nucleotides and is 
thus involved in maintaining cellular guanine deoxy- and ribonucleotide pools needed for 
DNA and RNA synthesis. This is particularly true in lymphocytes which have a dependent 
biosynthesis pathway, making IMPDH a target for immunosuppressive therapy. Two 
isoforms of IMPDH exist in humans, type I and type II , both encoding proteins of 514 
amino acids (368). IMPDH II up-regulation stimulates IMPDH activity, which in turn is up-
regulated in cancers and is associated with rapidly proliferating tumour cells (369) (370). In 
contrast, IMPDH inhibition leads to a decrease in DNA and RNA synthesis by depleting 
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guanine nucleotides in cells which in turn leads to cell cycle block and cell death (371). In a 
study on gene expression microarrays for prostate cancer biomarkers it was shown that 
IMPDH II is significantly over-expressed in prostate cancer in comparison to benign tissue. 
They also showed that serum levels of IMPDH II were also significantly raised in patients 
with prostate cancer and were associated with clinicopathological features (372). In contrast, 
inhibition of IMPDH induces cell growth arrest and cell death in the androgen-independent 
prostate cancer cell line PC-3 (373). 
 
• Androgen receptor (AR) splicing (AR exon 3 to 9). AR-regulated genes play a role 
in the state of hormone deprivation. The androgen receptor (AR) is a nuclear hormone 
receptor that regulates target gene expression. The androgen receptor is known to play 
essential roles in prostate cancer from cell viability, to proliferation and invasion in both 
castrate resistant and hormone sensitive prostate cancer cells (374,375). This signaling 
pathway is the key molecular determinant in castrate resistance PCa (376) and makes it a 
potential target for treatment with second generation AR antagonists as shown by several 
authors (377,378). In androgen sensitive prostate cancer, it is known that AR regulates genes 
such as KLK3 and TMPRSS2/ETS fusions that in turn regulate cell cycle progression through 
G1/S cell-cycle regulation (379,380). In androgen-independent castrate resistant cells the 
regulatory effect of AR is believed to continue through selective regulation of expression of 
FoxA1, CDC20 and CDKN3 that up-regulate the M-phase cell cycle. Hormone treatments 
are aimed at androgen receptor silencing, however progression to castration resistant PCa 
gradually takes place via mechanisms believed to reactivate the androgen receptor axis 
(381), mitosis stimulation via growth factor pathways, stress induced pro-survival gene and 
cytoprotective chaperone (382). AR has a complex protein signature due to expression of 
splice variants that are still not fully understood or targeted by any of the existing therapies 
(383). So far, 13 variants of AR have been documented, with AR3 being the most 
extensively characterised. AR variants have been shown to be dramatically elevated in 
castrate resistant prostate cancer as well as in specimens of hormone naïve patients who 
progressed after curative surgery, suggesting that AR3 is associated with prostate cancer 
progression (384) (385) (386) as demonstrated by study on 9 AR splicing variants in CRPC 
that found that most of these AR splicing variants were dramatically elevated (386). 
 
• STEAP2/STAMP1 (six transmembrane epithelial antigen of the prostate family 
member 2) is a STEAP family member that encodes a multi-pass membrane protein. It has 
	 46	
been shown to be localised to the Golgi complex, the plasma membrane, and vesicular 
tubular structures in the cytosol by immunofluorescence microscopy. It may have a role in 
endocytic and secretory trafficking pathways (387) acting as ferroreductase and cupric 
reductase, stimulating cellular uptake of both iron and copper (388). It is expressed in 
several tissues including placenta, heart and prostate. STEAP2 over-expression was also 
reported in prostate cancer cells compared to normal epithelial cells that had been micro-
dissected from the same prostate gland. It was also reported that STEAP2 is a highly 
androgen-regulated gene in androgen receptor-positive cells, however this did not prove true 
in receptor-negative cells (387) (389). In addition, ectopic expression of STAMP2 in a 
prostate cancer cell line appeared to increase cell proliferation and cancer progression. 
Furthermore, it was demonstrated that STEAP2 contains a domain associated with apoptosis 
and cancer (anti-apoptotic), suggesting its involvement in cell cycle regulation (390). In an 
in vitro and growth of human tumour xenografts in vivo study it was reported that 
monoclonal antibodies to STEAP1 inhibit intercellular communication (391). 
 
• STEAP4/STAMP2 (six transmembrane epithelial antigen of the prostate 4) is a 
member of the STEAP family that functions as a metalloreductase exhibiting a strong iron 
reductase activity (392), its loss has been reported to lead to metabolic syndrome (393). In 
mice it functions to control inflammatory response, adipocyte development and metabolism. 
Similar to STEAP2, STEAP4 expression is reported in various normal tissues including 
placenta, lung, heart, prostate and adipose (389) (394), and LNCaP prostate cancer cells 
(389). One study (395), reported that STEAP4 inhibits anchorage independent cell growth 
through regulation of phospho-Y397 on focal adhesion kinase (FAK). Furthermore in 
androgen-independent prostate cancer cells (DU145) they reported that CpG sequences in 
the STEAP4 promoter region were frequently methylated, and that demethylation treatment 
induced the expression of STEAP4 in this cell line; this was in contrast with the androgen-
dependent prostate cancer cell line LNCaP in which no methylation was reported. 
 
• MDK: Midkine (Neurite Growth-Promoting Factor 2) This gene encodes a 
retinoic acid-induced, heparin-binding growth factor that is highly expressed during 
embryogenesis, is involved in neurogenesis and epithelial to mesenchymal transition. The 
protein promotes cell growth, survival, migration, and angiogenesis, particularly in 
neoplasia where its expression has been correlated with poor clinical outcome (396,397) 
(398) (399). MDK has been reported to be over-expressed in prostate cancer by several 
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authors, its expression shown to be associated with cell survival and proliferation (399,400). 
The mechanism of MDK action is not fully understood, however it is thought to be the 
product of neuroendocrine-like tumour cells that are believed to arise through a 
neuroendocrine-differentiation (NED) process from malignant luminal epithelial cells or 
possibly from PCa stem cell differentiation (401). These cells play an important role in AR 
signaling reactivation through neuropeptide secretion in the absence of androgens in 
castration resistant prostate cancer (402,403). MDK was also reported to be up-regulated in 
CRPC and that its up-regulation is associated with neuroendocrine differentiation (404). In a 
study on PC-3 and LNCaP cell lines, midkine expression was reported to be increasingly 
raised in end-stage prostate cancer and was thought to be induced by several factors 
including cytokines particularly interleukin-1beta and TNFα that strongly induced midkine 
expression via the nuclear factor-kappa B pathway (399). Midkines were also induced by 
growth factors including epidermal growth factor, androgen, insulin-like growth factor-I, 
and hepatocyte growth factor. The carcinogenic effect of midkines appeared to be through 
the activation of signal-regulated kinase 1/2 and the mitogen-activated protein kinase 
pathways’ p38 and by partially inhibiting TNFα-induced apoptosis. Midkine mRNA was 
detectable in a urine test study that demonstrated its over-expression and therefore 
usefulness as a diagnostic and prognostic urine marker for urothelial transitional cell 
carcinoma (405). 
 
• TERT (Telomerase Reverse Transcriptase) The gene encode a protein enzyme 
with reverse transcriptase activity, and an RNA, which serves as a template for the telomere 
repeat. It is a ribonucleoprotein polymerase that maintains telomere ends by addition of the 
telomere repeat TTAGGG. Its activity is high in the foetus, however it is repressed post-
natally and is very low in normal adult somatic cells. Deregulation of telomerase expression 
is known to be associated with prostate cancer, where the reactivation of the telomerase and 
telomerase over-expression is thought to prevent post-mitotic cell apoptosis (406). Its 
expression was positively correlated with aggressive disease (146). Telomerase expression 
in urine sediments of patients undergoing radical prostatectomy as a treatment for PCa was 
reported positive in approximately 74% of patients and was thought to be predictive of 
biochemical recurrence in these patients. There may also be a possible link between 
increased ERG expression and TERT reactivation, as TERT positive cases also had elevated 
levels of ERG which was associated with higher recurrence rate (205).  
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• FOXM1: (Forkhead box protein M1) plays a key role in cell cycle mitotic division 
at the S and G2/M phases (407), and regulates the expression of a large array of G2/M-
specific genes, such as Plk1, Nek2, Cyclin B2 and CENPF. It also plays an important role in 
maintenance of chromosomal segregation and genomic stability (408). It’s main role in 
cancer remains unknown; however, it is thought to promote oncogenesis through an 
abnormal impact on its roles in cell cycle and chromosomal/genomic maintenance.  In a 
transgenic mouse studies, that used two mouse lines in which they had put the Rosa26 
promoter to drive expression of the human FoxM1b cDNA transgene: i) a TRAMP mouse 
PCa that recapitulates multiple stages of human prostate cancer (409) and ii) LADY TG 
mice that develop multifocal low grade PIN that progresses to high-grade PIN and early 
invasive prostate carcinomas with progressive neuroendocrine differentiation (410) prostate 
cancer. Another study showed that the increased expression of FoxM1b accelerated 
development, proliferation, and growth of prostatic tumours in both mice lines. Furthermore 
by using prostate cancer cell lines (PC-3, LNCaP, or DU-145) on soft agar they 
demonstrated that when FoxM1 levels was depleted by small interfering RNA transfection a 
significant reduction in proliferation and growth was observed. They concluded from their 
study that FoxM1 regulates development and proliferation of prostate tumours, and that 
FoxM1 could be a novel target for prostate cancer treatment (411). Cell cycle progression 
genes were originally identified as having RNA expression that fluctuated as cells 
progressed through the different stages of the cell cycle (412). For this reason it has been 
proposed that these genes may be useful for prediction of outcome in prostate cancer. In 
breast cancer, genes that have their expression regulated as a function of cell cycle 
progression (CCP) have proven to have prognostic value and have changed clinical care. 
(413-416). These findings led some authors to study the expression of 31 CCP genes 
including FoxM1, CDC20 and CDKN3 in prostate cancer RNA extracts, using qRT-PCR. A 
comparison of disease progression was made between 2 groups of patients (post radical 
prostatectomy, and localised T1a/b disease on TURP) in which they reported that the 
expression of CCP genes was higher in actively growing cells. Their cell cycle score was 
predictive of outcome in both cohorts and provided substantially more prognostic 
information than did clinical variables alone. They also reported that heterogeneity in the 
hazard ratio for the CCP score was not noted in any case for any clinical variables (417). 
 
• CDC20 (Cell Division Cycle 20 Gene) This gene encodes a protein that plays an 
essential role in the regulation of cell division by activating the anaphase promoting 
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complex that initiates chromatid separation and entrance into anaphase; it also plays a role in 
the S and M phases. In prostate cancer, CDC20 is regulated by the androgen receptor, it 
prevents cell apoptosis and increases cell proliferation with its highest expression being in 
metastatic disease (418). CDC20 is inhibited by RASSF1a, tumour suppressor that normally 
prevents mitotic progression in PCa However methylation of RASSF1a in approximately 
75% of PCa leads to its inactivation and disease progression (419). 
 
• CDKN3 (Cyclin-Dependent Kinase Inhibitor 3) This gene encodes a protein that 
is known to prevent the activation of CDK2 kinase. Its mutation and/or over-expression had 
been reported in several cancers including PCa where it is AR regulated. CDKN3 is one of a 
large subset of AR target genes associated with control of cell division in castrate resistant 
prostate cancer cells as reported by several authors (420). It was also identified as one of a 
subset of cell cycle progression genes that can provide a prognostic score for the risk of 
disease recurrence after radical prostatectomy and the risk of death in conservatively 
managed prostate cancer diagnosed by TURP (417). 
 
• MKi67 (Marker Of Proliferation Ki-67) This gene encodes a nuclear coding 
protein that is necessary for cellular proliferation. In immunohistochemical analysis on 
formalin fixed tissue taken from prostate needle biopsies of 111 patients it was shown that 
Ki67 labelling index (LI) strongly correlated to Gleason grade and an increase in 
proliferative activity from low-grade to high-grade disease (421). They also suggested a 
correlation between Ki67 expression and tumour volume and related death. In another 
prospective study on 279 needle biopsies of the prostate it was shown that increased Ki67LI 
strongly correlated with cancer invasion to the seminal vesicles and that it is an independent 
prognostic factor in biopsies with low grade and low volume prostate cancer. They also 
showed in this study that a combination of Gleason score, number of positive cores, 
percentage of tumour in each biopsy and Ki67LI can predict risk of recurrence following 
radical prostatectomy (422). Other studies also highlighted the prognostic use  of Ki67 in 
preoperative core needle biopsies of PCa (423,424). 
 
• AURKA (Aurora Kinase A) This gene encodes a serine/threonine kinase that is 
involved in cell cycle progression by regulating a number of the processes that are crucial to 
mitosis, including centrosome maturation, chromosome separation, and regulation of the 
microtubule network that forms mitotic spindles. AURKA maps to human chromosome 20 at 
	 50	
q13, a locus that is frequently altered (amplified or over-expressed) in human cancers 
including breast and colon, where it is associated with tumour development and progression 
(425). In prostate cancer, AURKA amplification has been identified in 65% of PCas 
(hormone naïve and treated) from patients with poorly differentiated neuroendocrine 
carcinoma (NEPC, also known as small cell carcinoma of the prostate) and in 86% of 
metastases. Neuroendocrine prostate cancer (NEPC), also referred to as anaplastic prostate 
cancer, is a lethal tumour that is known to have aggressive clinical features. It is AR-
negative and has AR independent progression. They are known to secrete neuroendocrine 
proteins such as chromogranin A and express high levels of transcription factors that are 
characteristic of neural processor cells (426,427). They have a predilection to metastasise to 
visceral organs, lytic bone disease, a poor response to androgen ablation, and only briefly 
respond to chemotherapy (428). A meta-analysis of gene expression, reported AURKA as 
one of the top 10 genes that are likely to drive prostate cancer development (429). 
 
• CLU (Clusterin identified as a therapeutic target) CLU is a nine-exon gene that is 
located on chromosome 8 at p21-p12 (430). This gene encodes a secreted protein that 
functions as an extracellular stress-induced cyto-protective chaperone that protects cells 
against apoptosis and cytolysis. It also plays a role in cellular signalling and transcriptional 
regulatory networks that stabilise the cell phenotype at times of stress. This includes 
therapeutic stressors such as treatment induced apoptosis caused by androgen or oestrogen 
withdrawal, radiation, cytotoxic chemotherapy, and biologic agents leading to treatment 
resistance (431,432). CLU over-expression in castrate resistance prostate cancer makes it an 
attractive target for cancer therapy: hence attempts to knockdown CLU using an antisense 
oligonucleotide and siRNA undertaken in a randomised study, which showed increased 
patient survival when they were treated with Docetaxel-Custirsen compared to Docetaxel 
alone (382). CLU was also identified in several urine studies as a prognostic marker for 
prostate cancer at both cellular (433) and exosomal levels (434). 
 
• BRAF (V-Raf Murine Sarcoma Viral Oncogene Homolog B) This gene encodes a 
serine/threonine kinase protein that regulates the extracellular signal-regulated kinase (ERK) 
and mitogen-activated protein kinase (MAPK) signalling pathways, which in turn effect cell 
division, differentiation, and secretion. BRAF mutations have been associated with various 
cancers, including PCa (435). A study on a large cohort of patients with PCa showed that 
RAF pathway rearrangements tend to occur in advanced disease and that the expression of 
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SLC45A3-BRAF or ESRP1-RAF1 induce a neoplastic phenotype that is sensitive to RAF 
activated protein kinase inhibitors (436). A study done on a genetically engineered mice 
model reported that BRAF oncoprotein induced activation of the ERK1/2 and MAPK 
signalling pathways and disruption of PTEN that in turn lead to PI3K-Akt-mTOR signalling 
pathway activation causing up-regulation of c-Myc that lead to castration resistant metastatic 
prostate cancer. They also showed in this study that targeting these pathways with 
therapeutic treatment such as Rapamycin and PD0325901 weakened c-Myc levels and 
reduced metastasis (437). 
 
• OGT (O-linked β-N-acetylglucosamine transferase) This gene encodes an enzyme 
that adds the O-GlcNAc moiety to the free hydroxyl of select serine and threonine residues 
(438). In cancer, OGT over-expression is the result of altered metabolism that renders ATP 
production independent of oxygenation (439).  Cancer cells generate ATP by glycolysis 
hence their increased utilisation rates for glucose and glutamine to compensate for the lack 
of oxygen (Warburg effect) (440). This phenomenon is also thought to alter other signaling 
pathways including the mTOR (mammalian target of rapamycin), AMP-activated protein 
kinase, and the hexosamine biosynthetic pathway (HBP) (441). OGT is also thought to 
regulate a number of cancer associated proteins such as p53, c-Myc and Snail (442-444). In 
breast cancer, metabolic alteration has been shown to increase OGT expression that has a 
profound effect on cancer phenotype, growth and invasion that may be secondary to FoxM1 
up-regulation. Reducing OGT levels blocked breast cancer growth in vivo and in vitro (16). 
Similar finding was reported in prostate cancer where OGT was also found to be over-
expressed in cancer tissue compared with normal epithelium, and linked to a poor clinical 
outcome. Another study showed that OGT inhibition in a prostate cancer cell line (PC3-ML) 
lead to reduction of the aggressive phenotype, matrix metalloproteinase (MMP)-2 and 
MMP-9 expression, as well as inhibition of cell growth and bone metastasis. Findings were 
also associated with decreased FoxM1 levels (445). 
 
• Chronic inflammation and prostate cancer Several authors have reported a link 
between chronic inflammation and prostate cancer (446) thought to be linked to several 
oncogenic mechanisms including DNA damage (due to increased reactive oxygen and 
nitrogen species) and down-regulation of anti-tumour activity (447-449). One cause of 
chronic inflammation is thought to be epidemiological; link has ben reported between PCa 
and diets rich in fats and meat, and low in fruits and vegetables to PCa incidence, which has 
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been hypothesised to be as result of increased eicosanoid and prostaglandin production in 
response to high fatty acid intake (446). We discuss below several genes that may be 
involved. 
 
• PECI (Peroxisomal 3,2-trans-enoyl-CoA isomerase) PECI is an auxiliary enzyme 
that catalyses an isomerisation step required for the beta-oxidation of unsaturated fatty acid. 
PECI is downstream from AMACR in the peroxisomal-branched chain fatty acid β-
oxidation, and is also up-regulated in prostate cancer (450,451). 
 
• SULT1A1 (Sulfotransferase Family, Cytosolic, 1A, Phenol-Preferring member 
1) This gene encodes a cytosolic enzyme that catalyses the sulphate conjugation of 
hormones, such as catecholamine, phenolic drugs, and neurotransmitters. SULT1A1 can 
also bioactivate dietary and environmental pro-carcinogens and promutagens such as the N-
hydroxy metabolite of the food-borne heterocyclic amine, 2-amino-1-methyl-6-
phenylimidazo (4, 5-b) pyridine that may lead to chronic inflammation and carcinogenesis 
(452,453). It can also activate the carcinogenic N-hydroxyarylamines to DNA-binding 
products and can modulate cancer risk. In humans, it was shown that there is a strong 
association between increased SULT1A1 activity and prostate cancer risk irrespective of 
race, and a link to high consumption of over-cooked meat (454). 
 
OR52A2/PSGR (Prostate-specific G-protein coupled receptor) PSGR is a human 
prostate tissue-specific gene and a member of the G-protein coupled odorant receptor family 
that maps to chromosome 11 at p15. It has a high prostrate tissue-specific expression where 
it may play an important role in early prostate cancer development and progression. It is 
significantly over-expressed in PCa in comparison to benign tissue (455). In a quantitative 
real-time PCR experiment on 220 RNA specimens, PSGR was reported to have 89% 
specificity in detecting prostate cancer, its over-expression had prognostic value as it was 
associated with higher grade pT3 disease, and higher levels of serum PSA (456). In a 
transgenic mouse model, it was demonstrated that over-expression of PSGR led to chronic 
inflammatory response which in turn led to PIN (457). Furthermore this study showed that 
PSGR signaling led to the activation of the nuclear factor-κB (NF-κB) or RELA through the 
phosphatidylinositol-3-kinase/Akt (PI3K/AKT) pathway in the initial phase of prostate 
disease (457). Using qRTPCR on post-prostate massage urine sediment, PSGR was shown 
to be detectable in urine and that its over-expression is comparable to PCA3 in predicting 
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prostate cancer (458). Another study also demonstrated its usefulness in a multiplex gene 
panel in increasing the sensitivity and specificity of their urine test in detecting PCa (459). 
 
• PPAP2A (Phosphatidic acid phosphatase type 2A) This gene encodes an enzyme 
that is a member of the phosphatidic acid phosphatase family (PAP). It is an important 
membrane glycoprotein that plays a role in the hydrolysis and uptake of lipids from the 
extracellular space, and regulates cell signaling by modifying the concentrations of lipid 
phosphates to activate intracellular signaling cascades (460). In the prostate, PPAP2A 
expression is stimulated by androgens via activation of sterol regulatory element-binding 
proteins (SREBPs), resulting in an increase in lipogenesis that serves the synthesis of key 
membrane components (phospholipids, cholesterol), which in turn leads to carcinogenesis. 
This gene was shown to be up-regulated in LNCaP cells where it led to increased cell 
proliferation, survival, and altered lipid metabolism (461) (462). Studies have also shown 
that its down-regulation can lead to apoptosis in cancer cell lines and reduced tumour growth 
which makes it a potential therapeutic target for PCa (461). 
 
 
• ANPEP (Alanyl (Membrane) Aminopeptidase) (Prognostic)) encodes a 
membrane-bound zinc-dependent protease called aminopeptidase N (APN) (463) that 
regulates post secretory neuropeptides and their access to cellular receptor. It is also 
involved in intracellular signaling. In cancer, it is though to play an important role in 
neoangiogenesis and vascular endothelial growth factor (VEGF) expression as well as 
facilitating invasion and metastasis of various malignancies, including PCa (464-466). In 
contrast to other cancers (pancreatic and colon) where APN over-expression is associated 
with poor prognosis, in localised PCa, APN over-expression appears to be associated with 
good prognosis (467). Several reports shown that APN is down-regulated in PCa in 
comparison to benign tissue including a study using immunohistochemistry analysis on 278 
samples in which they showed that APN is significantly down regulated in PCa comparing 
to benign tissue as a result of epigenetic silencing of ANPEP as a result of aberrant promoter 
hypermethylation. Hence ANPEP expression in PCa can be a potential prognostic factor 
(467). 
 
• PSMA (Prostate-specific membrane antigen) This gene is located on the short arm 
of chromosome 11 and encodes a type II transmembrane glycoprotein that is known for its 
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enzymatic activities. It acts as a glutamate carboxypeptidase that belongs to the M28 
peptidase family (468). Its expression was reported in a number of normal and cancerous 
tissues (469,470). The encoded protein is also known as the prostate-specific membrane 
antigen, a trans-membrane protein expressed in all types of prostatic tissue, however in PCa 
its over-expression is highly restricted to the epithelial cells and was reported to be 
diagnostic and prognostic as its up-regulation was shown to be grade dependent (471). 
Furthermore its its activity increases as cells become more androgen independent (472,473). 
The mechanism of PSMA involvement in PCa is poorly understood however some studies 
showed that through the stimulation of phospho-p38 (P-p38) PSMA increases cell 
proliferation, migration and survival (474). Its usefulness as a prostate cancer diagnostic 
marker are questionable at the serum level as variable results has been reported (475), 
however its diagnostic usefulness appear to improve when used in a gene panel for urine 
analysis (459). 
 
• NAALADL2 (N-acetyl-L-aspartyl-L-glutamate peptidase-like 2) is a member of 
the glutamate carboxypeptidase II family, it is known to be over-expressed in prostate and 
colon cancer. Its expression in prostate cancer is prognostic, being associated with disease 
stage and grade. Its over-expression has also been shown to predict poor survival following 
radical surgical treatment for PCa. Unlike NAALAD1, NAALADL2 is localised to the basal 
cell surface and promotes cancer progression by endorsing adhesion to extracellular matrix 
proteins. It also has effects on cell migration and invasion, and promotes cancer 
development and progression through regulating the levels of Ser133 phosphorylated C-
AMP-binding protein (CREB) (476). 
 
• AGR2 (Anterior gradient 2 homolog (Xenopus laevis)) is also known as secreted 
cement gland protein XAG-2 homolog). This gene is located on chromosome 7 at p21, a 
region known for genetic alterations leading to cancers in different organs including the 
prostate. It encodes a member of the endoplasmatic reticulum (ER) disulphide isomerase 
(PDI) family (477,478) that is  known to facilitate the bio-activation of protein through the 
ER for secretion or membrane association. When these processes fail proteins accumulate in 
the ER, initiating ER stress, cell-cycle arrest, and apoptosis (478). In PCa AGR2 is highly 
up-regulated in comparison to benign tissue. Its up-regulation is associated with high disease 
grades, particularly metastatic disease hence its expression level is associated with poor 
survival (479,480) giving it a prognostic value as a biomarker. This androgen regulated gene 
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(481) has also been shown to play an important role in promoting bone metastasis (482) as 
its over-expression can lead to cancer cell proliferation (483) and its knockdown to cell 
cycle arrest at the G0/G1 phase. Studies also showed that, silencing AGR2 in PCa cells lead 
to significant reduction in cellular attachment to fibronectin collagen I, collagen IV, laminin 
I and fibrinogen as well as lost of integrin expression (α4, α5, αV, β3 and β4 integrins); 
which in turn led to failure in cellular adhesion and reduction in tumour cell migration (483). 
There was also significant reduction in Caspase-3 expression which is a key regulator of 
both extrinsic and intrinsic death signalling pathways, causing a higher resistance to 
apoptosis inflicted by tumour necrosis factor inducing ligand (TRAIL) suggesting that AGR-
2 stimulates prostate cancer metastasis by regulation of cellular adhesion and apoptosis 
(482). Urine analysis for AGR2 showed that its transcripts are detectable and that urine 
AGR2/PSA transcript ratios have better diagnostic accuracy than serum total PSA alone 
(481). 
 
 
 
1.9.1 Genes used for kidney, bladder and blood control 
 
• UPK2 (Uroplakin 2) is a gene that encodes the bladder specific uroplakin 2 protein. 
Unlike other uroplakins, UPK2 contains one transmembrane domain (484) (485) and maps 
to chromosome 11, at 11q23. It forms part of specialised plasma membrane that covers the 
urothelium, called AUM. It is believed to strengthen the urothelium by preventing cell 
rupture during bladder distention.  It was shown to be over-expressed in the urine of patients 
with bladder cancer (485,486).  
 
• SLC12A1 (solute carrier family 12) This kidney-specific protein encodes a 
membrane transport protein that acts as a co-transporter of solutes including sodium, 
potassium, and chloride ions across the cell membrane. It is mainly expressed in the thick 
ascending limb of the loop of Henle and the macula densa of the nephrons where it plays a 
key role in sodium reabsorption into the cells, hence mutations can play an important role in 
hypertension (487,488). SLC12A1 mRNA was detected in urinary exosomes in a study in a 
quest for renal urine biomarkers (489). 
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• PTPRC (Protein Tyrosine Phosphatase, Receptor Type, C). The protein encoded 
by this gene regulates T-cell and B-cell activation through antigen receptor signalling. It is 
mainly expressed in monocytes, neutrophils, B and T- lymphocytes. It has been used as a 
blood control in several prostate cancer studies analysing gene expression in circulating 
tumour cells (490,491). 
 
1.9.2 Housekeeping Genes 
 
• HPRT (Hypoxanthine-guanine phosphoribosyltransferase 1) is an enzyme 
encoded by the HPRT1 gene. This gene has similar expression levels in bladder, blood, 
prostate, and prostate cancer. No prognostic assocation with its expression levels was 
reported, for this reason, this gene is an established housekeeping gene for PCa that is 
frequently used in multi-gene expression profiling of prostate cancer (492) (493). A study 
comparing 13 endogenous control genes for normalisation of gene expression measurements 
in tumour tissues also report this gene to be usable for this purpose (494). 
 
• GAPDH (Glyceraldehyde-3-phosphate dehydrogenase) This gene encodes a 
member of the glyceraldehyde-3-phosphate dehydrogenase protein family. It has been 
established as a housekeeping gene for PCa and was previously used in multi-gene 
expression profiling of primary prostate cancer (492). Another study comparing 13 
endogenous control genes for normalisation of gene expression measurements in tumour 
tissues also report this gene to be usable for this purpose (494). It has also been used for 
normalisation of gene expression data as well as internal controls in miR-644a by several 
authors (495). 
 
• TBP (TATA box binding protein) and ALAS1 (Aminolevulinate, delta-, 
synthase 1) As well as GAPDH and HPRT these genes has been established as 
housekeeping genes for PCa and are frequently used in multi-gene expression profiling of 
primary prostate cancer (492) (493). 
 
• B2M (Beta-2-microglobulin) This gene encodes a serum protein that has been 
reported to have an even expression between bladder, blood, and prostate. This gene was 
also shown to be one of the most stable genes for the normalisation of expression studies in 
invasive breast tumour studies (496) as well as prostate cancer (493).
	 57	
Table 1.4: Summary of the genes tested in this study	 
Gene Gene name Function in PCA Expression Diagnostic 
Expressed 
in low 
grade 
disease 
HGPIN 
Prognost
ic 
increase 
impressi
on in 
higher 
grade 
disease 
AR 
Regula
ted 
Locati
on 
Name of 
the 
Author 
that 
chose the 
gene 
KLK2 Kallikrein 2 - Cancer initiation. 
- Extracellular 
matrix degradation  
- Metastasis. 
- AR 
transactivation and 
cell growth 
Up-
regulated 
yes yes yes Epithel
ial 
Cooper 
PSA/KLK
3  
(Exons 
1,2,3) 
Prostate specific 
antigen/Kallikrein 
3 
- Modulates the 
function of IGF 
- Facilitate tumour 
invasion 
Up-
regulated 
Yes Yes Yes Epithel
ial 
Cooper, 
Doll 
KLK4 Kallikrein 4 - Cell cycle 
regulation and 
proliferative effect.  
- Cell migration 
and invasion 
Up-
regulated 
Yes ? Yes Epithel
ial 
Cooper 
SPINK1 Serine protease 
inhibitor Kazal-
type 1 
- Serine protease 
inhibitor 
- Disease 
progression 
Up-
regulated 
? Yes no ? Cooper 
PCA3 Prostate cancer 
gene 3 or DD3 
- Unknown Up-
regulated 
Yes Yes ? ? Cooper, 
Schalken, 
Nelson, 
Doll 
AMACR Alpha-
Methylacyl-CoA 
Racemase 
- Initiation 
- Progression 
Up-
regulated 
Yes no ? Epithel
ial 
Cooper 
TMPRSS2/
ERG 
 - Activate 
androgen regulated 
transcription factor 
- Cell growth, 
proliferation, 
differentiation and 
migration 
Up-
regulated 
Yes Yes ? Epithel
ial 
Cooper, 
Schalken 
MMP26 Endometase/matri
lysin-2/matrix 
metalloproteinase 
26 
- Disease 
progression and 
metastasis 
- Degrade ECM 
Up-
regulated 
Yes Yes  no Epithel
ial  
Cooper 
TIMP4 Tissue inhibitor of 
metalloproteinases 
- Disease 
progression and 
Down-
regulated 
no yes no Epithel
ial 
Cooper 
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4 metastasis 
- Degrade ECM 
HPN Hepsin - Promote 
metastasis 
- Degrade ECM 
and 
- Proteolitic 
activity 
Up-
regulated 
no Yes  no Epithel
ial 
Cooper 
Maspin Maspin - Tumour 
suppressor 
- Promote 
apoptosis 
- Inhibit cell 
invasion 
Down-
regulated 
yes yes no Epithel
ial 
Cooper 
GOLM1 Golgi membrane 
protein 1 
- Unknown Up-
regulated 
yes no no Epithel
ial 
Cooper 
HOXC4 
and 
HOXC6 
Homeobox C4 
and Homeobox 
C6 
- Poor cell 
differentiation  
- Cell proliferation 
- Vascularization 
and metastasis 
Up-
regulated 
yes ? no Epithel
ial 
Schalken 
DLX1 Distal-less 
homeobox 1 
Unknown Up-
regulated 
yes ?  Transit
ional  
Schalken 
TDRD1 Tudor domain 
containing 1 
Direct target of ERG Up-
regulated 
yes ? ? ? Schalken 
CAMKK2 Calcium/Calmodu
lin-Dependent 
Protein Kinase 
Kinase 2, Beta 
- Cell cycle 
regulation and 
proliferative effect.  
- Induce AR 
transcriptional 
activity leading to 
progression 
Up-
regulated 
Yes Yes Yes Transit
ional 
Mills 
IMPDH2 Inosine 
Monophosphate 
Dehydrogenase 2 
- Cell cycle 
regulation and 
proliferative effect.  
Up-
regulated 
Yes ? ? ? Mills 
ARexon3, 
ARexon4-8 
ARexon9 
Androgen 
Receptor splicing 
- Cell viability 
- Proliferation 
- Progression 
Up-
regulated 
Yes Yes Yes All Cooper 
STEAP2/ 
STAMP1 
 
 
STEAP 4 
Six 
transmembrane 
epithelial antigen 
of the prostate 
family member 2 
 
- Cell growth  
- Metastasis 
Up-
regulated 
Yes Yes Androg
en 
depend
ent 
? Mills 
MDK Midkine. Neurite 
Growth-
Promoting Factor 
2 
- Cell growth and 
survival 
- Cell migration 
- Angiogenesis 
Up-
regulated 
Yes Yes yes ? Cooper 
TERT Telomerase - Prevent Up- Yes Yes no ? Cooper 
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Reverse 
Transcriptase 
apoptosis  
 
regulated 
FoxM1 Forkhead box 
protein M1gene 
- Up-regulate cell 
cycle that lead to 
cell development 
and proliferation. 
Up-
regulated 
Yes Yes 
and 
recurrenc
e 
predictor 
Yes ? Mills 
CDC20 Cell Division 
Cycle 20 Gene 
- Up-regulate cell 
cycle 
- Prevents cell 
apoptosis 
- Proliferation 
Up-
regulated 
Yes Yes Yes ? Mills 
CDKN3 Cyclin-Dependent 
Kinase Inhibitor 3 
- Up-regulate cell 
cycle 
Up-
regulated 
Yes Yes 
and 
recurrenc
e 
predictor 
Yes ? Mills 
MKi67 Marker Of 
Proliferation Ki-
67 
- Development 
and proliferation. 
Up-
regulated 
Yes Yes 
and 
recurrenc
e 
predictor 
Yes ? Cooper 
AURKA Aurora Kinase A - Up-regulate cell 
cycle that lead to 
cell development 
and proliferation. 
Up-
regulated 
no Yes 
And 
metastasi
s 
predictor 
no Neuro 
endocri
ne 
Cooper 
CLU Clusterin 
identified as a 
therapeutic target 
- Stress gene 
protects cells against 
apoptosis and 
cytolysis  
Up-
regulated 
no Yes 
And 
potential 
of 
therapeut
ic target 
no ? Cooper 
BRAF V-Raf Murine 
Sarcoma Viral 
Oncogene 
Homolog B 
- Cell division, 
differentiation, and 
secretion 
Up-
regulated 
no Yes 
And 
potential 
of 
therapeut
ic target 
no ? Cooper 
OGT O-linked β-N-
acetylglucosamine 
transferase 
- Altered 
metabolism 
- Affect cancer 
phenotype, growth 
and invasion 
- FoxM1 up-
regulation 
Up-
regulated 
no Yes 
And 
potential 
of 
therapeut
ic target 
no ? Mills 
PECI Peroxisomal 3,2-
trans-enoyl-CoA 
isomerase 
- Altered 
metabolism 
- Down stream 
from AMCR 
Up-
regulated 
Yes no no ? Mills 
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- Bio-activate 
dietary and 
environmental pro-
carcinogens 
- Chronic 
inflammation 
SULT1A1 Sulfotransferase 
Family, Cytosolic, 
1A, Phenol-
Preferring 
member 1 
- Altered 
metabolism 
- Bio-activate 
dietary and 
environmental pro-
carcinogens 
Up-
regulated 
Yes No No ? Mills 
OR52A2/P
SGR 
Prostate-specific 
G-protein coupled 
receptor 
- Bio-activate 
dietary and 
environmental pro-
carcinogens 
- Activation of the 
nuclear factor-κB 
- Chronic 
inflammation  
Up-
regulated 
Yes Yes No ? Cooper, 
Doll 
PPAP2A Phosphatidic acid 
phosphatase type 
2A 
- Intracellular 
signaling 
- Cell 
proliferation, 
survival, lipid 
metabolism, and 
differentiation 
Up-
regulated 
Yes Yes Yes ? Mills, 
Guido, 
Jenster 
ANPEP Alanyl 
(Membrane) 
Aminopeptidase 
- Intracellular 
signaling 
- Neoangiogenesis 
- Metastasis 
Down-
regulated 
yes yes ? ? Mills, 
Guido, 
Jenster 
NAALAD
L1 
N-acetylated 
alpha-linked 
acidic dipeptidase 
1 
- Stimulation of 
the phospho-p38 
leading to increases 
cells proliferation, 
migration and 
survival 
Up-
regulated 
Yes Yes ? Epithel
ial 
Nills, 
Doll 
NAALAD2 
 
 
 
  
N-acetyl-L-
aspartyl-L-
glutamate 
peptidase-like 2 
- Endorsing 
adhesion to 
extracellular matrix 
proteins 
- Cell migration 
and invasion 
Up-
regulated 
Yes Yes 
And 
recurrenc
e 
predictor 
? ? Mills 
AGR2 Anterior gradient 
2 homolog 
- Cell proliferation 
and adhesion 
- promoting bone 
metastasis 
Up-
regulated 
yes Yes 
And 
Potential 
of 
therapeut
ic target 
? ? Mills 
UPK2 Uroplakin 2 Bladder control - - - - - Cooper 
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SLC12A1 Solute carrier 
family 12 
Kidney Control - - - - - Cooper, 
Mills 
PTPRC Protein Tyrosine 
Phosphatase, 
Receptor Type, C 
Blood control - - - - - Cooper 
GAPDH Glyceraldehyde-3-
phosphate 
dehydrogenase 
House keeping Gene - - - - - Cooper 
TBP TATA box 
binding protein 
House keeping Gene - - - - - Cooper 
ALAS1 Aminolevulinate, 
delta-, synthase 1 
House keeping Gene - - - - - Cooper 
B2M Beta-2-
microglobulin 
House keeping Gene - - - - - Cooper 
HPRT Hypoxanthine-
guanine 
phosphoribosyltra
nsferase 1 
House keeping Gene - - - - - Cooper 
 
 
 
 
1.10 Hypothesis 	
In current clinical practice, PSA is still widely used as a first line test in the diagnosis of 
prostate cancer despite its known drawbacks. The reason for that is the lack of alternatives, 
which may be explained by the heterogeneity and multifocality of prostate cancer that create 
difficulty for a single biomarker to be representative for the whole picture. I believe that a 
multiplex biomarker test could have a better chance at overcoming these issues and be 
successfully incorporated into the existing diagnostic pathway for prostate cancer.  Several 
studies have shown the usefulness of urine tests for PCa diagnosis, and other studies the 
important role of exosomes in prostate cancer. However, urine exosomal biomarkers are still 
very much underexplored. I believe that by studying gene expression in these microvesicles 
we can potentially identify markers that can differentiate between cancer and benign tissue 
(diagnostic) as well as predicting the biopsy outcomes and potential metastasis (prognostic).  
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1.11 Study Aims 	
Urine-based diagnostic tests are non-invasive and are potentially of considerable clinical 
utility for prostate cancer patients. Prostate cells and macromolecules have direct anatomical 
access to urine through the prostatic urethra and ducts that connect the prostate to the urinary 
tract. Biological products that represent the prostate as a whole can therefore be detected in 
first catch urine samples. Prostatic biomarkers in urine are boosted after stimulation of the 
prostate via digital rectal examination (DRE), as has been demonstrated by several authors 
including the study that identified and designed the clinically implemented PCA3 test.  
 
Aim 1: The initial idea for this project was to use urine sediment as a source of biomarkers. 
However urine does not provide an ideal living environment for cells, and so arose the first 
real challenge to the study, to which exosomes appeared to be the answer.  
Aim 2: To identify a good source of biomarkers that could serve the clinical purpose of a) 
screening and diagnosis for PCa, and b) identification of patients with aggressive disease 
that would benefit from radical treatment.  
Aim 3: To work out a way to collect and process urine samples from patients and maximise 
the amount of prostate biological material with the least amount of clinical involvement and 
patient distress.  
Aim 4: To develop methods for extracting the best possible quality and quantity of 
exosomes and their RNA from urine while preserving the biological materials such as cells 
and proteins for future analysis.  
Aim 5: To carry out multiplex analysis of biomarkers using 200 urine samples from patients 
from clinics at the NNUH.  
 
For biomarkers to be accepted into clinical use they must be verified in prospective 
multicenter clinical trials.  Our long-term aim is therefore to link to other centers both in this 
country and worldwide to set up multicenter studies. 
 
 
 
 
All detailed discussion on the above information is presented in Chapter 5
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2. Methods 
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2.1 Study setup and patient recruitment 
 
2.2.1 Public and Patients’ Involvement in the Research Committee 
All the forms used in this project for recruitment including the patient invitation letter, 
information sheet and consent form were reviewed and revised by the public and patients 
involvement in research committee (PPIRES) (See Appendix 5 for forms).  
 
2.2.2 Ethical approval  
The research recruitment process was planned prior to ethical approval application. All 
ethical issues including patient’s involvement in the study, consent, sample anonymity, 
inclusion and exclusion criteria was addressed as the following: 
 
• Invitation letter and information sheet: forms (see Appendix 1 and Appendix 2) were 
provided to all men attending the PSA clinic. This is a dedicated clinic to investigate 
patients that have been referred to the NNUH due to a raised serum PSA test and/or an 
abnormal digital rectal examination.  In addition, I collected samples from a small number of 
men attending the haematuria clinic, which was a dedicated clinic to investigate patients 
referred with haematuria (blood in the urine). The majority of the haematuria patients are 
normal on further clinical investigation.  
These documents invite patients to participate in the research study and give them 
information about the degree of their involvement, ie providing a urine sample directly after 
a direct examination. It also explained the difference between the routine digital rectal 
examination which they would have outside the context of the study and the one they would 
have should they opt to participate in the project. It was also explained that their 
involvement or denial to participate in the research would not affect their clinical course in 
anyway, and that they are free to withdraw their consent in the study at any time without 
providing a reason and without prejudicing future medical care. These forms also clarified 
that the research outcome would not benefit them personally. Contact details of the chief 
investigator were included in these forms in case patients required further information or 
subsequently decided to opt out of the study. 
 
• Consent form: Patient consent to join the study was requested during my 
consultation with them on the day of the clinic and prior to the examination of the prostate. I 
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fully discussed the study with the patients, and encouraged them to ask any questions related 
to the research.  
All individuals asked to consider taking part in research were given full information about 
the research in written forms that were presented in non-technical language to ease 
understanding. Forms given to patients before the clinic including the invitation letter and 
information sheet that explained the project intention in detail and the degree of patient 
involvement. Patients were informed that their participation was voluntary and that refusal 
would not affect in any way their clinical course. In addition, if they decide to participate 
then they could subsequently withdraw their consent for the study at any time without 
providing a reason and without prejudicing future medical care. I also explained that there 
was no direct benefit to them from this project as this was a pilot study that required further 
research in order to reach clinical practice and that information resulting from this research 
will be published in due time. Male patients who were unable or not willing to consent or 
undergo a rectal examination for any reason were excluded. (see appendix 3). 
 
• Digital rectal examination (DRE): All male patients seen in the PSA and haematuria 
clinic would normally (outside the context of this study) have a digital rectal examination as 
part of their routine clinical investigations. This usually involves one finger swipe across the 
surface of the prostate to detect any abnormality or asymmetry that would raise suspicion for 
prostate cancer and would warrant further investigation with a biopsy. The DRE would also 
provide a clinical stage of the disease in case of cancer diagnosis. However for the purpose 
of the research the DRE technique was changed from one, to three swipes across the surface 
of the prostate, aiming to depress the prostate surface by about 1 cm. This technique was 
adopted from the procedure used for the PCA3 urine test, and has enable us to maintain the 
diagnostic purpose of this examination while increasing prostatic secretions into the urethra 
and subsequently the urine. Adopting this system for doing the DRE also helped us 
standardise the procedures and reduce any variability in our data. 
 
• Urine collection: All patients attending the PSA and Haematuria clinics would 
normally have to provide a urine sample for dipstick analysis outside the context of the 
study; however this normally happened when the patient first turned up at the clinic in order 
to facilitate the clinics flow. This routine was changed for the purpose of the research in 
order to obtain a sample following DRE.  However a very small number of men were able to 
provide 2 samples ie before and after DRE (4 patients).  
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• Urine sample anonymisation: All urine samples were labelled with a unique code 
that is only identifiable by the principle investigator.  The file with this important linking 
information was maintained in an encrypted form and backed up on a secure NHS server 
with password protection. 
 
• Inclusion criteria: All male patients who were not thought to have prostate cancer 
were recruited into the control arm, while men who have an established diagnosis of prostate 
cancer and were not on treatment went into the cancer arm. 
 
• Exclusion criteria: Male patients that were post prostate cancer treatment such as 
radical surgery or radiotherapy patients, or who were unable to consent or undergo rectal 
examination for any reason were excluded. 
 
2.2 Clinical Procedure 
 
Patient recruitment took place on a weekly basis in two specialised clinics (PSA and 
Haematuria) at the Norfolk and Norwich University Hospitals NHS Foundation Trust 
(NNUH). 
 
Prostate	cancer	assessment	clinic: Patients with suspected PCa were recruited from the 
PSA clinic on an average of 9 patients a week these are patients refered by their GP due to 
raised PSA or clinically abnormal DRE. All patients had a history taken, examination and 
investigation including DRE and TRUS biopsy (when indicated) as a part of their clinical 
workout. Patients diagnosed with PCa based on histological finding were included in the 
cancer arm. Patients with benign histology were followed up for a period of time, some of 
which were included in the benign arm only if there PSA normalised and their biopsy is 
negative for PCa. Diagnosed cancer patients in the high and advanced risk group had further 
radiological investigations in the form of MRI, CT or bone scan in case of clinical suspicion 
of metastasis.  
 
Benign patients: were recruited from the haematuria clinic on an average of 2 to 3 samples 
per week. Men attending the haematuria clinic also underwent DRE and serum PSA testing 
as part of the haematuria investigation workout. All the patients recruited from this clinic are 
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patients with a normal PSA, have a clinically benign prostate and have a normal haematuria 
investigation including urine dipstick testing for infection, kidney function test and full 
blood count as well as renal ultrasound scan and bladder telescopic investigation. Three 
patients were found to have bladder cancer. Their urine samples were used with caution 
taking these finding into consideration). 
All patients with raised PSA had a prophylactic dose of antibiotics (750mg of ciprofloxacin) 
and trans-rectal ultrasound TRUS guided biopsy 30 min after the initial consultation.  
 
 
2.3 Data collection 
 
2.3.1 History 
I designed and took the patient data required for the study. (See Section 3.6 and Appendix 6 
for details) 
 
2.3.2 Examination  
Patient examination data, including the digital rectal examination finding, were carefully 
recorded and interpreted by myself to state the clinical stage (as per the prostate cancer 
TNM classification) as follows.  
1- No palpable abnormality 
2- (T1 disease are not palpable clinically hence could not comment on this stage) 
3- T2a: the tumour is palpable in half or less than half of one of the prostate gland's two 
lobes. 
4- T2b: the tumour is palpable in more than half of one lobe, but not both 
5- T2c: the tumour is palpable in both lobes but within the prostatic capsule 
6- T3: the tumour has spread through the prostatic capsule  
7- T4: the tumour has invaded other nearby structures (feels solid and fixed) 
Findings that suggested distant metastasis to the bones and lymph nodes such as neuropathy, 
lower limb oedema and retention of urine were also documented and addressed in the 
treatment plan. 
 
 
2.3.3 Digital Rectal Examination (DRE) 
A DRE was performed on all patients as part of their standard clinical investigation see 3.7.2 
for more information 
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All patients were consulted and examined by myself in order to standardise the DRE 
technique and minimise operator related variability. At the start of the project, all DREs 
were done as per the PCA3 test protocol using 3 swipes on each lobe in order to maximise 
the quantity and quality of the prostate microvesicle RNA obtained (497,498).  
The aim of the DRE is to persuade the prostatic biosecretions through the prostatic tubules 
and duct into the prostatic urethra, which will be then carried out by the flowing urine and 
enhance the detection of biomarkers in urine samples as demonstrated by several studies 
including the PCA3 test (498-500). Another evidence was provided by Hendriks et al, (501) 
who demonstrated that prostate biomarkers are significantly higher in urine after DRE in 
comparison to sample without DRE, this has also been proven true for urinary exosomes as 
shown by another study (502). 
 
2.3.4 Trans-rectal ultrasound TRUS 
We recorded the following data for all patients who underwent this procedure: 
1- Histological findings included: numbers of cores taken from each lobe, number of 
positive core in each lobe and percentage of cancers in them, and whether there is 
perineural and or vascular invasion. Gleason major and minor and the overall score. 
2- Ultrasound detected abnormalities such as, calcified lesion, hypoechoic lesion, extra 
capsular spread, and benign gland. 
3- Prostate volume measured in ml by multiplying the prostate height, depth, and width. 
All the TRUS biopsies were performed in the same day of the clinical consultation (if no 
contra indication such as UTI) as a one-stop service for prostate cancer (Clinic in the 
morning, TRUS biopsy in the afternoon) 
 
2.3.5 Radiological staging 
The entire radiological investigations results were recorded including MRI, CT and bone 
scan results. These Scans were done within two weeks from presentation (as a two week 
wait rule basis for PCa). 
 
2.3.6 PSA 
Follow-up PSA measurements were taken for all patients at 3, 6, 12 and 24 months, except 
for those patients that had benign disease (normal PSA and clinically benign prostate). 
Treatment plan and treatment outcome data was collected retrospectively using the hospital 
intranet system. 
	 69	
 
2.4 Sample collection 
Urine samples were collected from 662 men consented to participate in the study in the 
period between January 2012 and 2014. Only two patients refused to consent for sample 
collection during this period. 
20-25 ml urine samples were collected from all patients immediately after clinical 
examination (DRE) in polypropylene ‘Universal’ tubes (Sterilin) containing 5 ml of 
preservative cell culture media/EDTA (RPMI+++ and 10xRPMI). All patients are required 
to have a urine dipstick test prior to prostate biopsy in order to i) exclude urinary tract 
infection (nitrites, bloods and protein as well as pH) which is a contraindication for the 
procedure and ii) identify variables that might affect the research data. 
 
2.4.1 Sample Labelling   
All samples were labelled with a unique code from which only the principle investigator 
could identify the patients. I created and maintained the simple code that referred to the 
experiment and the sample number (Ex M1-1 = Marcelino experiment 1 sample 1). This 
code correlated to patients notes according to the date of the experiment and the sequence 
the patients were seen in the clinic on the day. 																				
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2.5 Sample fraction analysis performed by Movember groups 
Urine sediments were separated into several fractions and analysed by several groups as part 
of the Movember GAP (Global action plan) Urine Biomarker Consortium (except for the 1st 
44 samples that were only used for exosomal RNA analysis), which was led by our 
laboratory and coordinated by Jeremy Clark at UEA. The Consortium consisted of 12 teams 
in 7 countries working on 5 urine fractions analysed in laboratories worldwide by: Mass 
Spec, ELISA, DNA-methylation. Expression analysis of RNA from cells and microvesicles 
was by NanoString, qRT-PCR and RT-PCR. When the study is finished (Dec 2016) data 
will be combined with clinical information to determine the optimal combination of 
biomarkers and fractions for prostate cancer diagnosis and prognosis (Figure 2.1). 
 
 
 				
 
 
 
Figure 2.1 : Source	of	urine	samples	and,	fractions	and	analysis	laboratories. 
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2.6 Sample processing 
 
2.6.1 Sample processing at the NNUH 
At the beginning of the project samples where collected and placed in wet ice until the end 
of the clinic (ie a maximum of three hours) before transport to the laboratory area at the 
University of East Anglia (UEA) for processing. This method was applied for the first 100 
samples until we acquired a centrifuge in a room near the NNUH clinic. Subsequent to this, 
the first steps of the urine processing took place in the NNUH as follows: i) 1 ml of whole 
urine was used to prepare a slide for FISH (Fluorescence in situ Hybridisation) by Rachel 
Hurst - for a parallel line of research running alongside this project in our laboratories. ii)  3 
ml of whole urine was aliquoted for proteomic analysis (sample stores on dry ice until 
transport to the laboratory area for storage at -80°C for future analysis). iii) The urine 
sample was then centrifuged at 2000g for 5 min to sediment and extract the cell pellet, 
which was then stored on ice or in a refrigerator at -6°C (Cell RNA extraction was carried 
out 3 hours later in the laboratory). iv) The supernatant was decanted into a 50ml 
polypropylene tube (Fisher cat. 35-2070) and placed on ice. All the samples were then 
transported to the laboratory area at UEA for further work. The change in the processes of 
sample treatment took place in an attempt to improve microvesicular RNA yields (discussed 
in detail in chapter 3 (3.7.3.5). The sample handling and transportation was in accordance 
with health and safety regulations for transport of human tissue, in summary all the samples 
were double bagged with absorbent material to prevent accidents in case of leakage and then 
placed in a secure box. 
 
2.6.2 Sample processing at the Laboratory 
The urine was distributed and processed for multiple biological fractions as shown in Figure 
2.3. 
The urine cell pellet and supernatant was processed at the UEA laboratory as follows:  
1- Cell pellet: Initially, RNA-only was extracted from the cell pellet using the Qiagen 
RNeasy kit as manufacturer’s instructions. Later, both DNA and RNA were extracted 
from the cell pellet using the Qiagen AllPrepKit as per the manufacturer protocol. 
Nucleotide extractions were initially performed by myself, and subsequently by Dr 
Rachel Hurst.  
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2- Exosome microvesicle harvesting and RNA extraction: The urine supernatant was 
centrifuged at 3,400g for 10 min at 10°C to sediment any residual cell debris, which was 
then discarded. The supernatant was then poured into a 30 ml syringe and filtered through 
both 0.80 and 0.45um Minisart filters (16592k, Sartorius) into a labelled Ultra-15 100 Da 
MWCO filter device for microvesicle harvesting (Figure 2.2). This device contained a 
micropore filter with a cut off of 100 Da. The microvesicles were thereby sieved out of 
the urine by centrifugation at 3,400g for 15min or until the volume was reduced to 
<200µl. 15ml of PBS (Phosphate-Buffered Saline which was prepared earlier in the 
laboratory by dissolving 1 PBS tablet in 100ml of sterile water) was added and the 
sample was re-spun until the volume was 200µl. The PBS wash step was then repeated 
twice more. The remaining liquid in the upper part of the filter was then transferred into a 
1⋅5ml Ambion non-stick tube by pipetting, ready for RNA extraction. 
 
									
 
	
	
Figure 2.2: Filters used in the exosomal harvesting process. Left hand side:  filtering the urine through a 
0.80 um minisart filter (16592k, Sartorius) into a (right hand side) Ultra-15 100,000 Da MW cut-off filter 
device. 
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2.6.3 Exosomal RNA Extraction 
 
Exosomal RNA extraction was performed using the Qiagen MicroNeasy kit as follows. 
• 700µl of Qiagen ‘RLT’ buffer supplied in the Qiagen MicroRNeasy kit was added to 
the ultra-15 filter device to rinse out any remaining microvesicles. RLT was then transferred 
to the pre-prepared and labelled Ambion non-stick tube. 
• 3⋅5µl of DTT (Dithiothreitol; Clelands reagent) was added. Ethanol (100%) was 
added to the samples to create a 35% solution which was mixed by vortexing. The solutes 
were then loaded to the pre-labelled Qiagen micro column and centrifuged at maximum 
speed (13,000g) for 10 seconds in a microcentrifuge. The column was then washed with 
350µl of ‘RW1 Buffer’ (supplied in the Qiagen kit) and spun at maximum speed for 10 
seconds (this step was repeated twice), in the meantime a DNase solution was prepared 
while the columns rested on ice (10µl of DNase I solution was mixed with 70µl of ‘Buffer 
RDD’ for each sample and mixed by inversion). 80µl of the DNase mix was then added 
directly to the membrane of each ‘Mini Elute Column’ and left at room temperature for 15 
minutes. The columns was then washed with 350µl of ‘Buffer RW1’ and 2 rounds of 500µl 
of ‘Buffer RPE’, spinning at max speed for 15 seconds between each step. This was then 
followed by 2 steps of ethanol wash using 80% ethanol and centrifugation at maximum 
speed for 2 minutes. 
• Each ‘Mini Elute Column’ was then placed in a new collection tube to avoid alcohol 
contamination and spun at maximum speed for 5 minutes with the tube lid open to allow the 
filter to dry, followed by a 10 min air dry. 19 µl of pre heated (45°C) Qiagen nuclease free 
water (provided in the kit) was then added to the column which was then placed in a fresh 
non stick Ambion collection tube (into which 1ul of (1ug/ul) glycogen had previously been 
added) and left to rest for 2 minutes at room temperature. The tube was then centrifugated 
for 1 minute at maximum speed to elute the RNA which was stored at -80°C 
 
The RNA was quantified using a Thermo Scientific spectrophotometer which measured the 
relative absorbencies of light of two wavelengths (260:280 absorbance ratio). The quality 
with respect to RNA length was assessed using an Agilent 2100 Bioanalyzer system with an 
Agilent RNA 6000 Pico kit as per the manufacturer’s instructions. The process included gel 
preparation (which rendered the chip as an integrated electrical circuit once loaded) and the 
Gel-Dye mix (that intercalates directly with the RNA during the chip run). 9 RNA samples 
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could assessed on one chip: samples were heated to 70°C and placed on ice to cool down. 
The samples were then loaded into the Pico chip along with a ladder solution (the RNA 
6000 ladder standard is run on every chip as a reference for data analysis). The chip was 
then placed in the Bioanalyzer machine. An electrode was inserted into each well in turn, 
and the RNA was driven by voltage electrophoretically through the gel, which separated the 
molecules by size. The RNA strands with intercalated dye molecules were detected as they 
run off the end of the gel by laser-induced fluorescence and the data was translated into gel-
like images and electropherograms as shown in Figure 2.3. The data was analysed using the 
internal reference ladder. The RNA 6000 ladder contains six RNA fragments ranging in size 
from 0⋅2 to 6 kb (0⋅2 kb, 0⋅5 kb, 1⋅0 kb, 2⋅0 kb, 4⋅0 kb, and 6⋅0 kb). The software 
automatically compares the RNA samples to the ladder fragments to determine their 
concentration and identify the 26s and 18s ribosomal RNA peaks. The RNA Integrity 
Number (RIN score) was generated for each sample on a scale of 1-10 (1=lowest; 
10=highest) as an indication of RNA quality.  Using this tool, sample integrity is no longer 
determined by the ratio of the ribosomal bands, but by the entire electrophoretic trace of the 
RNA sample (Aligent.com) The 18s/28s ratio and an estimation of concentration is also 
produced. 
 The interpretation of the Bioanalyzer graphs was done according to the Agilent 2100 b 
Bioanalyzer data interpretation. The average microvesicle/exosomal RNA yields was 340ng. 
(https://www.urmc.rochester.edu/fgc/documents/Bioanalyzer_Interpretations_forcustomers.
pdf) 
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2.6.4 Amplification 
 
Due to low exosomal RNA yields form some samples, it was decided to amplify all the 
samples prior to multiple gene expression analysis. The NuGEN Ovation PicoSL WTA 
System V2 was used to amplify the whole transcriptome, converting the RNA into double 
stranded cDNA. The Ovation system is capable of amplifying an input amount of RNA in 
the range of 500pg to 50ng. However; based on previous expression pattern validation 
experiments undertaken by Professor Cooper’s group to optimise the quantity of RNA used 
		
Figure 2.3: Examples of the Bioanalyzer chip analysis of urine RNA samples. Images are labeled A to L, A 
being top left, C top right down to L bottom right.  A, B and E are examples of good RNA quality. The best 
example is E as the 28S peak should ideally be 2x the height of the 18S peak.  Where the 18S peak is taller 
than the 28S peak, and the base line is sloping toward the left (ie sloping down from 28 to 18S) it represents 
heavily degraded RNA. L is a plot of the ladder only, and J and K are empty wells.  
18s 
Ribosomal 
peak 	 28s Ribosomal peak 	Marker 	
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for amplification, a range of 10 to 20ng per sample was chosen for this study. Exceptions 
were made for samples collected from advanced patients (patients with PSA>100 and 
clinical stage T3/4 ie local metastasis) from which low RNA yields were obtained in the 
majority of cases (see Results for further explanation of low yields from this group). For 
these patients we used as low as 2ng or 0⋅5ng/µl for amplification. 
The amplification procedure was carried out using the Ovation Kit as per the manufacturer 
protocol in three steps starting with 1) first strand cDNA synthesis 2) second strand cDNA 
synthesis then 3) purification and SPIA amplification. (see 
http://www.nugen.com/nugen/index.cfm/products/cs/microarrays-and-qpcr/ovation-pico-
wta-system-v2/ for details). 20 samples were amplified at one time, which made this 
procedure time efficient. A PCR purification step using the Qiagen MiniElute Reaction 
Cleanup Kit then followed. The cleaning step was again done as per the manufacturer 
protocol (http://www.qiagen.com/gb/products/catalog/sample-technologies/dna-sample-
technologies/dna-cleanup/minelute-pcr-purification-kit/). Samples were stored at -20°C. The 
cDNA was quantified using a Nanodrop spectrophotometer. A total of 352 samples were 
amplified. The RNA input amounts used were based on Bioanalyzer quantification. 325 
samples had sufficient RNA for amplification, (average RNA yields were 9⋅7ng/µl SD= 12). 
Post amplification cDNA yields from these samples were (132⋅6ng/µl SD= 92⋅4). 23 
samples were amplified using low RNA yields with an average of 1⋅2ng/µl.  14 of these 
samples had a post amplification cDNA average of 134⋅9ng/µl and 17 with average of 
61.48ng/µl. Samples with cDNA yield below 100ng/µl were not used for gene expression 
analysis). 
 
 
 
2.7 Expression analyses 	
2.7.1 NanoString Analysis 
 
2.7.1.1 General principles of NanoString analysis 
 
NanoString's nCounter technology is a based on double hybridisation of two adjacent ~50bp 
probes to their target RNA/cDNA (Figure 2.4). The first probe hybridisation is used to pull 
the target mRNA down on to a hard surface. The excess unbound RNA is then washed 
away. The second probe is then hybridised to the RNA. This probe has a multi-colour 
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barcode attached to it. The nucleotides are then stretched out under an electrical current, and 
the image is recorded. The barcodes number and type are counted, and this is the data 
output. Up to 800 different barcodes are possible, and therefore up to 800 different target 
RNAs can be detected in a single assay. 
 
 
 
	
Figure 2.4: The 5 steps of the NanoString analysis procedure. 
Illustration adopted from the manufacturer’s website (https://www.bcm.edu/mcfweb/nanostring)  
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2.7.1.2 NanoString validation 
 
The NanoString system is designed to work with RNA. As we were using cDNA, the system 
was not guaranteed to work. Nugen assured us that both strands of cDNA should be present 
in the cDNA amplification products in equal amounts, and so should work in the NanoString 
system. It was therefore decided that we would run a pilot test with NanoString analysis.  
Pilot NanoString gene analysis using the nCounter human cancer 236-gene reference assay 
on 12 samples (6 from the High risk group: G8-10 PSA>20, 3 from the Benign control: 
PSA<1 and clinically benign prostate, and 3 from the Low risk group: Gleason 6 PSA 0<10) 
were initially undertaken to asses the feasibility of NanoString on our amplified cDNA 
samples. A total of 300ng in 10µl (30ng/µl) per sample was prepared in 0⋅5ml non-stick 
tubes and sent to the NanoString laboratory in Seattle, USA for gene expression analysis.  
 
2.7.1.3 192 samples with 50-gene NanoString analysis  
 
192 cancer and benign samples were analysed using the NanoString technology including an 
LNCaP/VCaP cell line mix RNA sample (LNCaP are an androgen-sensitive human prostate 
adenocarcinoma cell line derived from the left supraclavicular lymph node metastasis. VCaP 
are an androgen independent prostatic human prostate adenocarcinoma cell line derived 
from a bone metastasis).  
For better correlation of the gene analysis with the clinical data, patients were grouped into a 
cancer arm, which was again sub-grouped into smaller groups based on the NICE 
stratification criteria for local metastasis. For information on the PCa groups and the control 
groups see Section 3.4.2 
A total of 300ng in 10µl (30ng/µl) per sample was prepared in 0⋅5ml non-stick tubes and 
sent to the NanoString laboratory in Seattle, USA for gene expression analysis. A total of 50 
genes were used including 5 housekeeping genes (HPRT, B2M, TBP, GAPDH and ALAS1) a 
bladder control gene (UPK2), kidney control (SLC12A) and blood control (PTPRC). Due to 
the lack of publications on exosomal derived prostate cancer transcripts, the choice of our 
genes were based on literature review and a on previous studies conducted in our laboratory 
(more details can be found in chapter 3 (3.1.3)) 
 
The analysed data was return in the form of a spreadsheet including the following:  
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1- Sample ID and scanner ID. 
 
2- Field of View (FOV) count and counted: The digital analyser images the lanes in 
separate units, called fields of view, this critical step can be enabled due to optical issues, 
such as an inability to focus due to bubbles or insufficient oiling of the cartridge, for this 
reason the digital analyser reports the numbers of FOVs successfully imaged as FOV 
Counted, and the attempts of imaging in order to get a successful count as (FOV Count). 
Significant discrepancy between the number of FOV (FOV Count) and (FOV Counted) may 
be indicative of an issue with imaging performance.  In our data set there were no 
discrepancies between the FOV count and FOV counted (mean 280 SD=0 and 279.59 SD= 
1.75 respectively) 
 
3- Binding Density: in order to get accurate molecular counts, the digital analyser 
counts only the codes that are unambiguously distinguishable, for this reason codes that 
overlap with each other do not get counted. The overlapping codes does not usually impact 
the data unless there are too many of them in the image, for this reason, the data analyser 
calculates the binding density for each lane in order to determine image saturation (The 
binding density is a measure of the number of optical features per square micron) which is 
useful for determining whether or not data collection has been compromised by image 
saturation. According to the manufacturer, the range for binding density is between 0.05 and 
2.25 (A binding density greater than 2.25 is indicative of a large number of overlapping 
reporters on the slide surface suggesting that there are significant numbers of codes ignored). 
The mean Binding density of our samples were 0.472 SD=0.12. 
 
4- Gene expression count per sample: in our data-set the range was between 1 
(minimum) and 159,370 (maximum) counted transcripts. 
 
 
2.7.3 Statistical methods 
 
Due to the complexity of data analysis in correlating gene expressions and cancer grade, 
stage and variable clinical finding, the data analysis were carried out by the UEA bio-
informations Dr Dan Brewer and Helen Curley using several analysis techniques. Helen 
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Curley performed these analyses as part of her PhD and has given me permission to show 
them in this thesis: 
For the comparisons of correlations between gene expression levels and the presence of 
cancer, they first used standard statistical methods including: 
 
2.7.3.1 Principal Component Analysis (PCA) 
 
PCA is a statistical procedure used in multivariate analysis. The main purpose of using this 
test was to reduce the dimension of the dataset with minimal loss of information. It works by 
converting a set of observations with correlated variables into a set of values with linearly, 
uncorrelated variables called principal components (PC) that could be visualised. A set of 
orthogonal standardised linear combinations can then be set to explain all of the variations in 
the dataset. We used this analysis with an aim to identify variation differences in our dataset. 
This test has identified 2 clusters of samples and an outlier that did not correlate to the data, 
this was found later to be a contaminated sample and was excluded from further analysis. 
We then used a divisive Hierarchical Cluster Analysis (HCA) to confirm the PCa finding 
and identified the samples in each cluster so that gene expression analysis can be carried out.  
 
2.7.3.2 Hierarchical Cluster Analysis (HCA) 
 
HCA is a method of cluster analysis, in which a hierarchy of clusters can be built producing 
a dendrogram, or other type of tree diagrams, as final output (503,504). Each association 
level of the dendrogram represents a partitioning of the data set into a specific number of 
clusters (503). Based on the dendrogram the number of clusters can be defined. Cluster 
splits is then performed recursively as one moves down the hierarchy. HCA is used to 
identify biologically relevant structure in large data sets.  
Having identified the samples in each cluster we then used the Wilcoxon test (a non-
parametric statistical hypothesis test) to identify the up-regulated genes in these samples (the 
total number of genes identified was 25) and the Chi-Squared test to assess the likelihood of 
samples in with category similar to the identified cluster to belong to the same cluster and 
maintain the same gene expression. These analyses identified two clusters of samples of 
which one was due to poor gene expression secondary to poor RNA quantity, for this reason 
those samples were excluded from further analysis (more details are available in chapter 4).  
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2.7.3.3 Latent Process Decomposition analyses (LPD) 
 
This is a computational technique used to cluster samples in an unsupervised probabilistic 
approach, it uses a combinatorial mixture to represent samples over a limited set of latent 
processes, which are expected to correspond to biological processes. Unlike clustering by 
dendrogram which can not objectively assess the most probable number of structures, which 
underlie the data, LPD can assess the optimal number of sample clusters and represent 
samples and gene expression levels using a common set of latent variables. In contrast to 
clustering by dendrogram, observations are not assigned to a single cluster and thus, gene 
expression levels are modelled via combinations of the latent processes identified by the 
algorithm. Simply put, each sample can have a presence in more than one group, this enables 
us to see how strongly samples fit within the different groups. We used LPD analysis to 
determine whether distinct subgroups of patients could be identified.  
 
2.7.3.4 Kaplan Meier (KM)  
 
Is the most common method used for estimating survival functions. Designed to deal with 
data that has incomplete observations using censoring. It works by using a start point and an 
end point for each subject. In this study, we used the KM analysis to study survival for 
patients on hormones treatment for advanced prostate cancer we use the start point as when 
the hormones treatment began and the end point will be when resistance to the treatment and 
subsequent progression was monitored for each patient. Data is often incomplete due to 
patients dropping out of the study or insufficient follow up of patients, here censoring is 
used to ensure there is no bias. 
 
 
2.8 Second generation sequencing 
In order to get in-depth understanding of the role of PCa exosomes and get a comprehensive 
view of the exosomal transcriptome that will enable us to identify a range of gene expression 
changes and the detection of novel transcripts in both coding and non-coding RNA species; 
we sequenced 18 samples as follows: 7 in the High risk group (Gleason 8-10, PSA<100), 7 
Intermediate risk group (G7, PSA<20) and 4 Benign controls (PSA value normal to patients 
age and clinically benign prostate) using Next Generation Sequencing, known as NGS or 
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RNA-seq. This sequencing method is free from many of the limitations of previous 
technologies, such as the dependence on prior knowledge of the organism, as required for 
microarrays and PCR and have the ability to access allele-specific expression and novel 
promoters and isoforms (505,506). 
RNAseq was performed by Oxford Gene Technologies (Oxford) as follows: 100ng of total 
exosomal RNA from 18 samples were prepared with the Illumina TruSeq RNA Sample Prep 
Kit v2, and sequenced using the Illumina HiSeq 2000 platform and TruSeqv3 chemistry. An 
average of 48,334,002 paired end reads were sequenced per sample. A total of 67.61 
Gigabases (966680055 reads) of sequence data were read and aligned at high quality. 
The Illumina HiSeq2000 sequencing system workflow is based on three steps: libraries 
preparation from nucleic acid sample, amplification to produce clonal clusters and 
sequencing using massively parallel synthesis.  
 
2.8.1 Processing of RNA-seq data 
RNA-seq processing converts samples of purified RNA to cDNA and sequences them on a 
high-throughput platform (507). This process generates millions of short (25 to 300 bp) reads 
taken from both ends of each cDNA fragment. In order to optimise the results, low quality 
bases (q<30) were clipped from the read ends, we also removed the TruSeq indexed adapter 
and TruSeq universal adapter (explanation can be found below) using Cutadapt v1.3. Reads 
containing more than 5% Ns, or less than 32bp or those with low complexity were also 
removed as well as ribosomal RNA. 
TruSeq indexed and universal adapters, are short nucleotide sequences, which allow DNA 
fragments to bind to a flow cell for next generation sequencing, PCR enrichment of adapter 
ligated DNA fragments only and indexing of samples so multiple DNA libraries can be 
mixed together into 1 sequencing lane. 
TruSeq Universal Adapter:  
5’AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCC
GATCT 3’ 
TruSeq Indexed Adapter  
5’GATCGGAAGAGCACACGTCTGAACTCCAGTCAC-NNNNNN-
ATCTCGTATGCCGTCTTCTGCTTG 3’  
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“N” is any nucleotide, and the 6 of them together are a unique sequence which can readily 
be identified as unique to 1 library. (http://tucf-genomics.tufts.edu/ documents/protocols 
/TUCF_Understanding_Illumina_TruSeq_Adapters.pdf). 
 
2.8.2 Analysis of RNA Seq data 
The DESeq2 package (Differential analysis of count data) was used to calculate the 
differential expression between samples and compare benign vs cancer (the cancer group 
was a combination of Intermediate and High-risk samples), and linear trend where each 
group of samples is assigned a numerical value (benign=0, intermediate=1 and high=2). 
DESeq2 package analyses raw counts of sequencing reads in the form of a matrix of integer 
values, as obtained, from RNA-Seq sequencing experiment to allow assessing the 
measurement precision correctly. The value in the i-th row and the j-th column of the matrix 
tells how many reads have been mapped to gene i in sample j. Results tables are generated 
using the function results, which extracts a results table with log2 fold changes, p values and 
adjusted p values. It can also be useful to examine the counts of reads for a single gene 
across the groups (508).  
PRINSEQ were used to filter, the sequence data. It generates summary statistics of the 
sequences in graphical and tabular format. PRINSEQ provides summary statistics for the 
data including read length, GC content, sequence complexity and quality score distributions, 
number of read duplicates, occurrence of Ns and poly-A/T tails, assembly quality measures 
and tag sequences. 
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2.9 Schematic representation of samples used for analysis in this 
study 																					
																	
Benign	Cases	n=	266	 Cancer	Cases	n=	289	
Samples	collected	Aw	FU	data	n=61	 316	cancers		
Samples	contaminated	n=46	
Bioanalyser	done	on	524	samples	
53	samples	failed	471	was	considered	good	for	gene	expression	analysis	
352	samples	were	amplified			
192	Samples	used	for	gene	expression	analysis	Nanostring		
18	samples	used	for	Third	Generation	Sequencing	
on	mRNA		
192	Samples	used	for	analysis			
662	patients	recruited	from	Clinics			
285	benign			
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3. Study Design, Set up, optimisation 
and Implementation in the Hospital and 
Laboratory 
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3.1 Introduction  
 
Prostate cancer (PCa) is a complex disease that exhibits genetic, as well as morphological 
heterogeneity and multifocality that increases with stage and grade. This makes it extremely 
difficult to manage clinically as it can behave completely differently in different patients, 
some of which have an indolent disease that would require no treatment while the others 
may have an aggressive disease that would shorten their life significantly. Due to the poor 
understanding of the natural history of this disease the possibility of achieving specific and 
sensitive early detection is hard particularly when using the available clinical tools which 
include: DRE, PSA testing, TRUS biopsy and MRI imaging, each of which lack specificity 
and/or sensitivity. In order to overcome these challenges, researchers have explored avenues 
for discovery of new prostate cancer biomarkers for decades. However despite some 
progress in developing new biomarkers, including urine biomarkers, none are in routine 
clinical use. Obstacles to clinical implementation of these biomarkers are: 1) the difficulty in 
sampling all areas of the prostate for disease 2) detection of small foci of progressing 
tumour, and 3) the lack of direct correlation of these biomarkers to the clinical outcome and 
disease behaviour.  
For these reasons the study described here was designed to analyse urine from prostate 
cancer patients. PCa biomarkers can be harvested from the urine and could potentially 
contain biomarkers from every part of the prostate. In addition, the urine can be interrogated 
for many different types of biomarker information (RNA, DNA, Protein and metabolite), 
with integration of these multiple data streams as the end point of the study, correlating 
biomarker data with the clinical characteristics of the research subjects with the aim of 
discovering a set of biomarkers that would overcome the problems of heterogeneity and 
multifocality of the disease. This study demanded a robust clinical set up that would link 
continuously with the laboratory analyses, a system to recruit a large number of patients 
whose clinical parameters that would cover all the variabilities generally found in prostate 
cancer patients as well as developing and optimising new methods for biomarkers discovery. 
The focus of this project is to identify new biomarkers that can, at the time of early 
diagnosis, be used to i) detect PCa per se, and ii) distinguish between aggressive cancer that 
requires immediate treatment, and clinically irrelevant disease. The study could improve our 
understanding of the conversion of indolent prostate cells to a rapidly growing prostate 
cancer, and identify the changes that underlie a cancer becoming androgen independent and 
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so untreatable by conventional androgen withdrawal therapy. 
 
 	
3.2 Study setup 
 
This study is part of an international consortium run from UEA/NNUH and funded by 
Movember. The study was set up to get rapid results by using the specialised analytical 
methods of the collaborator’s laboratories. See figure 2.1 (chapter 2) for overview of the 
study. 
The protocol for urine collection and fractionation was designed at UEA. Urine samples 
were fractionated as described in the Methods (section 2) and sent out to the specialist 
laboratories for analysis. UEA specialised in the harvest and analysis of exosomal RNA. At 
the end of the project data will be collated for bioinformatic meta-analysis by Dr Dan 
Brewer at UEA.  
My role in the study was to: 1) gain ethical approval for the study, 2) set up the patient 
recruitment and sample collection from PCa patients and controls, 3) develop the urine 
fractionation protocols for exosomal RNA harvest, 4) Set up and maintain a file of the 
patient numbers and relevant clinical data, 5) collect follow-up data on patients, 5) prepare 
samples ready for Nanostring expression analysis, 6) provide insight and direction into what 
clinical questions needed to be answered.  
 
3.2.1 Patient recruitment 
 
In order to maximise patient recruitment, it was essential to interest the patient in the 
research.  The documents describing the study (Protocol), Letter of Invitation, Patient 
Information Sheet, and Consent form had to be clearly written so that the patient could 
understand the study and what it entailed for them. Clear presentation of the study 
information to the patient would help the patient understand the potential impact of the 
study, clearly describe their role, what we were doing and why, and enable them to make an 
informed decision on whether to take part in the study. The documents were written with the 
patient’s point of view in mind, and written in a layman’s level of understanding, while 
covering all points of clinical and scientific interest. The documents were then assessed by 
public members who took part in a ‘Public and patient involvement in research’ group to 
weigh the public views about the study and to suggest changes to the created documents for 
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better understanding. Changes were then carried out according to the public feed back. It 
was found that the general idea was well supported. All the forms were then reviewed and 
approved by the PPIRES committee and by the Research Ethics Committee (forms are 
included in appendix 5). Agreement to allow the study to be carried out at the NNUH was 
sought from the R&D department.  Full ethical approval for the study was obtained on the 
12/03/2012. NHS approval to start the collection at the NNUH was gained on 15/03/2012. 
 
3.2.2 Effect of the study on the patients normal clinical course 
 
Recruitment into the study was voluntary, and the patient’s clinical course was not altered 
because of the study. No research data from the study is returned to the patient.   
All research participants were patients attending our clinics for evaluation of urological 
symptoms and would normally (outside any research setting) undergo an assessment, which 
includes history, abdominal, genital and rectal examination to exclude any prostatic 
pathology. The only change made for the purpose of this study is with respect to the digital 
rectal examination. The rectal examination is not usually standardised and is often clinician 
dependent; it usually involves a single swipe across the whole surface of the prostate in 
order to identify any underlying pathology (firm tissue or asymmetry). This was altered to 
two or three strokes per lobe –see section 2.3.3 for details 
 
3.2.3 Patient Inclusion and exclusion criteria 
 
In order to cover all the aspects of PCa screening, from diagnosis, prognosis and follow up, 
we tailored our recruitment process to included patients throughout their clinical journey, 
from the initial appointment for investigation, to treatment and follow up. The	nature	of	the	PSA	 assessment	 clinic	 (designed	 to	 see	 patients	 on	 the	 two	 week	 wait	 rule	 when	refered	 due	 to	 raised	 PSA	 or	 clinically	 abnormal	 prostate	 with	 the	 suspicsion	 of	prostate	cancer)	means	not	all	urine	samples	would	prove	to	be	from	cancer	patients,	for	this	reason	the	sample	was	categorized	after	the	assessment,	some	of	which	would	be	 benign	 that	 could	 be	 used	 in	 the	 benign	 arm	 (For	 further	 explanation	 about	 the	different	categories	see	section	3.4). 
All patients attending the Prostate Specific Antigen (PSA) assessment clinic were eligible 
for recruitment. I also recruited patients for the control arm of the study from other 
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outpatient urology clinics for ‘non-PCa’ controls. These were men that were considered to 
be suitable candidates for the research and would normally – as part of their standard clinical 
treatment – have a digital rectal examination. This including patients who presented with 
haematuria (blood in the urine) but were found on further investigation to have no strong 
contra-indications for inclusion in the study; and patients with lower urinary tract symptoms 
caused by benign prostate enlargement in the presence of normal PSA. 
 
 
3.3 Sample collection and labelling 
 
Urine was collected post-DRE as described in Section 2.4. The DRE was performed for 2 
reasons: 1) diagnostic i.e. a clinical requirement, outside the context of this research, and 2) 
to increase the amounts of prostate secretions in the urine. It was important that the samples 
could be centrifuged within 30 min of collection (see 3.8.1.6). In order to do this, I organised 
the setting up of a centrifuge and other essential equipment in a small area in the sluice room 
in the clinical department (see 3.7).  The samples were centrifuged to sediment the cell 
pellet, this was then snap frozen on dry ice for subsequent RNA and DNA extraction in the 
laboratory at UEA. The supernatant was decanted into another sterile tube, placed on ice and 
transported to the laboratory at the end of the clinic (3 hours later) for further processing. 
The sample handling and transportation was in accordance with health and safety regulations 
for the transport of human tissue - in summary, samples were double bagged with absorbent 
material in case of leakage. These were then placed in a secure box.  In case of leakage bags 
were handled at all times using gloves and eye protection. 
Samples were collected straight after DRE for 2 reasons, 1) to minimise delays in the clinic 
so patients would not have to wait to provide a urine sample and 2) to prevent retrograde 
flow of the prostatic secretion into the bladder and dilution into a large urine volume that 
will lead to loss of the genomic material. For the purpose of comparing prostatic biomarker 
levels in pre- and post-DRE samples, a few samples were collected both before, and after 
DRE. 
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3.3.1 Sample labelling and anonymisation 
 
All urine samples destined for the laboratory were labelled with a unique code from which 
only the principal investigator could identify the patients – see Section 2.4.1. I maintained a 
file with the important information linking the patient ID to the unique code identifier in an 
encrypted form and backed up on a secure NHS server with password protection. It was 
necessary to have this information so that clinical follow up data could be gathered on the 
patients. 
 
 
3.4 Patient cohort 
 
3.4.1 Patient motive for PSA check 
 
Men were referred by their general practitioner to the NNUH for further investigation after a 
positive PSA test. There were a number of reasons for the PSA test: 1) screening as part of 
the health care prostate awareness program “Wellmen”. Lower urinary tract symptoms such 
as physical obstruction from benign or malignant prostate cancer manifest as 1) storage 
and/or voiding LUTS including slow urine flow, straining to pass urine, feeling of 
incomplete emptying of the bladder, hesitancy to initiate a flow, frequency and urgency to 
pass urine as well as nocturia, 2) family history of prostate cancer, 3) urinary tract infection 
or, 4) haematuria (blood in the urine) (Figure 3.1).  63% of these patients were diagnosed 
with prostate cancer based on histological findings, which is consistent with the national 
figures. The vast majority of the study population consisted of patients of white background, 
with only 2 patients from an Indian background (no race variability that would affect our 
results). There was no association between cancer diagnosis and reason for PSA check. 	
	
 
Figure 3.1: Patients in the study:  reason for PSA testing. 
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3.4.2 Patient distribution into clinical groups  
 
The cancer and benign arms of patients were designed as follows: 
 
3.4.2.1 Cancer arm 	
The cancer arm was divided into 4 main groups based on the NICE risk stratification criteria 
for localised prostate cancer: 
1- Low risk group: Patients with PSA <10ng/ml and Gleason score of 6 and clinical 
stage of T1a to T2a. 
[T1 is when tumour is not detectable clinically or with imaging i.e. detected only 
histologically by biopsy or TURP. T2a: is when the tumour is clinically detectable (palpable 
on DRE) in half or less than half of one of the prostate gland's two lobes] 
2- Intermediate risk group: Patients with PSA of 10-20ng/ml or Gleason score 7 or 
clinical stage of T2b to T2c (T2b: is where the tumour is clinically detectable in more than 
half of one lobe, but not both, T2c: is when the tumour is in both lobes but still contained 
within the prostatic capsule) 
3- High Risk Group: Patients with PSA> 20 or Gleason score of 8 -10 or clinical stage 
of ≥ T2c (T2c is when the tumour envolve two lobes of the prostate, T3 is when the tumour 
has spread through the prostatic capsule and T4 is when the tumour has invaded other 
nearby structures) 
4- Advanced Group (positive control): PSA ≥ 100ng/ml with any Gleason score and 
clinical stage T3-T4. This group of patients is part of the high-risk group according to the 
NICE stratification criteria, however for the purpose of this study we set this group apart as 
a positive control. The reason for that is it is well known that patients with PSA of 100 or 
above have 100 % risk of cancer metastasis with 100% predictive value as reported in the 
literature (509). 
In order to gain in-depth information and precise correlation of our biomarkers for 
diagnostic and prognostic accuracy, I subdivided some of the NICE groups into smaller 
groups according to disease aggressiveness (Figure 3.2). The reason for these subdivisions is 
because some of these patients fell in between two categories in the NICE stratification 
criteria, for example a patient with Gleason score of 7 and PSA of 20 would be classified in 
the high risk group according to NICE due to the highest variable (PSA>20) however this 
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patient’s disease may not behave similar to a patient with PSA of 20 and Gleason 8-10 
which would be truly in the high risk category. Also, it is well known that PSA readings are 
not always representative of the disease -see Section 2.3.6. 
Similarly patients in the intermediate risk group with Gleason 7 (4+3) disease would be 
expected to behave more aggressively than a patient with a Gleason 7 (3+4) disease as the 
first patient will have more of the less differentiated cells (4 > 3).  Hence we grouped these 
patients into subcategories taking into consideration all these variables (Figure 3.2) in order 
to give our analysis a better diagnostic and prognostic meaning. 
The intermediate risk group is sub-divided into Intermediate-High Gleason  (Ih) (G4+3 and 
PSA<20), and Intermediate-Lower Gleason score (I)(G3+4 and PSA<20) and Intermediate 
Low (IL) (G6 PSA>10).  
We divided the high-risk group into High (H) (G7 PSA>20) and High-High (Hh) (G8-10 
PSA<100). 
No subdivision was made to the low risk group (L) or patients who were found to have 
prostatitis (P) 
 	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3.2: Patient clinical subgroups. 289 cancer patients devided into 4 groups and 5 subgroups 
Advanced	Risk	(A):	PSA	≥	100ng/ml	T3/4	any	Gleason	Score.	n=33	
High	Risk	(H):	PSA	>	20	ng/ml	
or	Gleason	Score	8-10		
or	Clinically	≥	T2c.	n=88	
Intermediate	Risk	(I):	PSA	10-20ng/ml		
or	Gleason	Score	7		
or	clinically	T2b.	n=	148	
Low	Risk	(L):		PSA	<10ng/ml		
and	Gleason	Score	6		
and	clinically	T1a-T2a.	n=20	
Intermediate	Low	(IL)	=		
G6,	PSA>10,	T2b.	n=13		
Intermediate		(I)	=		
G3+4,	PSA<20,	T2b.	n=90			
Intermediate	High	(IH)	=		
G4+3,	PSA<20,	T2b.	n=45	
High	(H)	=	G7	PSA>20.		
n=28	
High	High	(Hh)	=	G8-10	
PSA<100.	n=60	
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All Cancer patients were followed up and offered treatment that is recommended for their 
disease stage and grade and followed up on a 3 monthly basis with a repeat PSA test. 
 
3.4.2.2 Benign Arm 
 
The benign group was sub-divided into: 
1- HG-PIN and Atypia: Patients with raised PSA and histological finding of Atypia or 
high-grade prostatic inter-epithelial neoplasia (HG-PIN). 
2- Prostatitis: patients with raised PSA and histological finding of inflammatory 
changes in the absence of neoplasia 
3- Raised PSA negative biopsy: patients with raised PSA and histological finding of 
normal tissue. 
4- Benign/non-cancer control group: Patients with a clinically benign prostate (ie no 
palpable nodules or size asymmetry between the lobes) and PSA normal to Age or below 
1ng/ml (according to NICE guidelines, PSA of 2.7ng/ml for men aged 40-49, PSA 3.9ng/ml 
for men aged 50-59, PSA of 5ng/ml for men aged 60-69 and PSA of 7.2ng/ml for men aged 
70-75). These patients were recruited outside the context of the PSA-referral clinic, they 
presented with various urological complaints that required a DRE, but did not have prostate 
cancer or a raised PSA.  
This group of clinically benign patients was again subdivided into two smaller groups:  
a) Patients with PSA<1 (CB1) 
b) PSA>1 but normal to age (CBN) 
We used both these sub-categories in the benign control accepting that there is a small risk 
that some of these patients would still have prostate cancer, which is most probably, 
insignificant due to the fact that they are asymptomatic and have clinically undetectable 
disease in the presence of normal PSA. Should these patients have PCa it would be expected 
to be low volume, low-grade disease that would require no clinical attention. The reasons for 
using these sub-groups as ‘non-cancer’ controls is explained in the Discussion.   
 
 
 
 
 
Benign	Cases	
Raised	PSA	neg	Biopsy	n=147	
PSA	<1	Clinically	benign=	33	
PSA	normal	Clinically	benign=	30	Prostatitis	n=26	 GH-PIN	Atypia	n=30	
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All the patients recruited for the benign control group were seen due to haematuria (blood in 
the urine) with normal haematuria investigations.  
All patients with raised PSA and negative biopsy were followed up at 3 months with a 
repeat PSA. Patients whose PSA had normalised were discharged, and those with rising PSA 
were offered a repeat biopsy.  
 
3.4.3.3 Patient’s clinical distribution and risk factors 
 
In order to identify the breadth of the clinical problem we grouped patients according to 
their risk groups (Figure 3.3) and found that the majority of patients in the cancer arm fell in 
the intermediate risk category, while in the benign arm, patients with raised PSA and 
negative biopsy were predominant. These findings clearly highlight the clinical problem 
associated with PSA screening, as it is clearly demonstrated here that a large proportion of 
these PSA referral patients (Raised PSA negative biopsy), had unnecessary anxiety and 
invasive procedures such as TRUS biopsy, as well as creating unnecessary workload and 
financial burden to the health care system. In addition, these patients would require further 
PSA monitoring and possibly more biopsies in order to exclude prostate cancer.  Hence the 
urgent need for novel biomarkers that will help identify these patients.  
All PSA-referral patients underwent trans-rectal prostate biopsy as per the clinical 
requirement except patients in the advanced risk group (27 patients) as their diagnosis was 
made on clinical findings and no biopsies were necessary. Patients in the benign control 
group with PSA<1 or PSA normal for age were also not biopsied, as there was no clinical 
requirement for biopsy in order to exclude cancer.  
	
Figure 3.3: Patient distribution according to clinical groups. 
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3.5 Patient Cohort and rational 
 
In order to get clinically analysable data we initially matched our sample size to that of the 
published urine marker PCA3 (DD3) study of 200 patients (497). However, after a revision 
of the numbers of the various groups of patients we are studying in this project with 
hypothetical statistical analysis it became apparent that the initial number we opted for was 
too small and had to be increased to approximately 1200 patients as explained below.   
The increased numbers of samples is necessary because of the following reasons:    
A) prostate cancer has an extremely diverse range of progression. Therefore we needed to 
collect a large number of samples to enable us to have sufficient statistical power from each 
of the patient groups, which include:  i) negative controls, including patients with PSA 
<4ng/ml and PSA <1ng/ml.  ii) BPH (Benign prostatic hyperplasia)  iii) patients with low risk 
of progression and metastasis (PSA >4 and <10ng/ml or Gleason <6)  iv) patients with 
intermediate risk of progression and metastasis (PSA >10 and <20ng/ml or Gleason 7)  v) 
patients with high risk of progression and metastasis, (PSA >20 or Gleason 8­10) . 
B) The majority of the patients that have prostate cancer will be in the intermediate risk of 
progression, some in the High-risk/advanced category and some in the low risk. 
Approximately 10% of these will progress each year, but we do not know which ones. This 
means that we must collect additional samples so that we have sufficient numbers of those 
that will progress. 
C) Approximately one third of the patients referred to the NNUH PSA clinic were from the 
High PSA negative biopsy group. 
D) Prostate cancer can progress down multiple pathways with varying risk of metastasis. So, 
to fully assess patients' risk of progression in the different risk categories (see above) we 
require large sample numbers. 
To look for multiple comparisons of correlations between gene expression levels and the 
presence of cancer, we used standard statistical methods for assessing correlations and, 
Hierarchical Clustering and Latent Process Decomposition analyses to determine whether 
distinct subgroups of patients can be identified.  In these analyses we specifically looked to 
see whether identifiable patient groups exist that could have avoided prostate biopsy. Dr Dan 
Brewer hypothesised the following: to calculate the power of individual markers the 
statistical question was reduced to a test of equal proportions with a binary outcome (cancer 
present/absent) and a binary variable (biomarker positive or negative; below or above 
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median of expression). We calculated the minimum difference in proportion of patients that 
have cancer in the biomarker positive and negative groups that could be detected by the 
study when using a significance level of 0.05 and a power level of 0.8 using the bpower 
function in the R statistical programming language.  For a 200 patient cohort this percentage 
varied from 30% to 20% for a marker positive in between 10% and 40% of cases. This 
calculation only considers a comparison of two variables.  However in the case of 3 different 
primary cancer risk categories comparison with two non-cancer groups of patients and 
metastatic disease, we needed to increase the numbers so that any two way comparison 
consists of 200 patients in order to get a similar power. Thus for 6 groups we needed to 
collect 600 patients. The fall out rate due to poor sample quality and because risk groups can 
only be determined after the sample has been collected is about 50%. So overall, Dr Brewer 
calculated that we needed to collect 1200 specimens to appropriately power this study. 
The initial expression analysis was performed on 192 samples as a pilot study, which will 
then be followed by a larger number to validate the data. 
 
 
3.6 Clinical Data collection 
 
Biomarker data is of no use when used independently of other information, thus, it is highly 
important to collate appropriate clinical data. For this reason collection of the relevant 
clinical information on the day of the consultation is vital to avoid revising large number of 
patient notes at a later date or even arranging further consultations to gather missing data. 
Taking into consideration the risk factors of prostate cancer, and medical treatments that can 
affect the disease such as 5-alpha-reductase inhibitors, I created a proforma to collect and 
organise the clinical data in a manner that would facilitate statistical analysis. The collected 
data included, patient’s demographic (age and ethnicity) previous and current PSA check 
and the reason for PSA testing, symptoms including lower urinary tract symptoms (LUTS), 
haematuria or urinary tract infection, recent blood results including Urea and Creatinine 
(U&E) and Liver function test (LFT) (Patients U&E’s and liver and kidney function tests 
could be Deranged due to metastatic disease), full blood count (FBC) (anaemia due to bone 
metastasis) as well as past medical history and current medication, family history of prostate 
cancer and social history including smoking, alcohol consumption and occupation. I also 
documented patient ‘detailed histological findings’ including Gleason score information 
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(when PCa was found on biopsy), as well as the number of cores taken during the biopsy 
and the percentage of the disease involved, whether or not there is perineural invasion, the 
ultrasound scan finding and prostate volumes. Investigations including MRI scan, bone 
scans and post-radical prostatectomy histology results were also reported as well as PSA 
follow-up for all the patients. 
An international prostate symptoms score (IPSS) sheet to assess the patients urinary flow 
symptoms was provided in advance to all patients attending the prostate cancer one-stop 
clinic. (See appendix 4 for the IPPS score sheet and appendix 6 for the clinical information 
collected on all patients). 
 
 
 
3.7 Protocol optimisation and results 
 
3.7.1 Functional set up of the Clinic 
 
Two clinics a week were set up for patient recruitment. The success of this project relies on 
clinical and scientific work harmony, for this reason a good clinical set up where clinical and 
lab work can go alongside each other was key. In order to achieve that, I utilised the PSA 
clinic on a weekly basis where I could consult a maximum of 10 patients referred by their 
GP due to raised PSA for further investigations. I also set up a room in an adjacent clinical 
area, which was equipped with the essential tools to carry out the initial steps in processing 
the urine samples including centrifugation and slide preparations for FISH (Fluorescence in 
situ hybridisation) (this was for a parallel line of research running alongside this project in 
our labs). I also accessed the haematuria clinic (where patients were investigated for the 
presence of blood in urine) to collect samples for the benign/non-cancer control arm, as 
these patients would be young men and likely to have a healthy prostate gland (see 3.4.2.2). 
I have also organised regular meetings that gathered scientists and clinicians together to 
discuss the project and ensure that the research aims are based on clinical needs. 
A total of 662 men were recruited at the end of this study period with an average age of 68 
(Age range 35-98).  
We had good compliance from our patients with only 4 patients refusing to consent for the 
study. 
(See appendix 1 to 4 for letter of invitation, consent form and PPRiES sample sheet) 
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3.7.2 DRE optimisation 
 
During the course of this study I noted that the DRE technique we used (PCA3 technique of 
3 swipes) could cause slight discomfort to patients. For this reason I tested different DRE 
techniques comparing the PCA3 3 swipes per lobe depressing the prostate tissue 1cm each 
time to 2 swipes each lobe instead to find out whether a lighter prostate massage would 
affect the RNA quantity and the patients experience. The experiment was carried out on two 
consecutive clinics on seven patients in each clinic. The RNA as measured by a Nanodrop 
spectrophotometer showed no significant difference between the two sets of samples (see 
figure 3.4). However it is worth noting that RNA yield varies significantly between samples. 
Following this experiment I continued using the 2-swipe technique for the rest of the project 
with no change in our RNA yields. Clinically it is quite apparent that there is a variability in 
prostate glands in term of size, anatomy (some are high riding and difficult to reach in order 
to perform a consistent DRE) and texture (cancer tissue feels very hard and patients with 
Advanced cancer had prostates that were impossible to depress during DRE). All of which 
can cause variability in the amount of prostatic fluids that can be persuaded out of the gland 
by DRE.  
We also looked at the difference in the RNA yields between samples before and after DRE, 
Patient was asked to provide a sample on arrival to the clinic and another sample later on 
after DRE (after the consultation). This has proven the prostatic origin of the exosomes 
(Figure 3.4). 
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3.7.3 Urine processing optimisation 
 
Due to the nature of urine as a waste product it does not provide the ideal milieu for cells to 
survive long enough to allow RNA extraction several hours after the sample collection, for 
this reason several issues had to be addressed in order to optimised the protocol (See 
Sections 2.6.2 and 2.6.2).  
In order to improve the exosomal RNA, and speed up the protocol I improved on each of the 
processing steps, and some additional features of the protocol as described below. 
	
A	
	
B	
 
Figure 3.4: A) Shows the mean difference in the RNA quantity in ng/ul between the two groups of patients 
who had 2 and 3 swipe prostate massage prior to the urine sample collection. This is an average of 10 
samples in each group.  3-swipes average 13.7 ng/ul SD +/- 7.58 vs 2 swipes 14.1 ng/ul SD +/- 8.92 
B) Shows the mean difference in the RNA yields in ng/ul between samples Pre and Post DRE taken from 
the same patients. 		
	 100	
These improvements reduced the exosomal RNA harvesting time significantly, which 
enabled us to complete the RNA extraction in the same day. Performing the extraction in a 
single day has itself led to improvements in RNA yields and quality.  
 
3.7.3.1 Cell Pellet extraction  
 
Urine was initially collected from patients immediately after the digital rectal examination 
and stored on ice for 3 hours (ie until the end of the clinic) before processing in the UEA 
lab. The cellular RNA yields at this point were poor (average of 4·6ng/ul), and in many 
cases were not sufficient for multiplex gene analysis. Despite trialling several cooling 
techniques with wet ice, crushed ice, and water/ice mix, no changes in the RNA yields were 
found. Microscopic examination (using the cytospin and H&E staining) of the individual 
sample pellets after centrifugation showed no evidence of cells, both in wet and dry ice, 
However there were abundant numbers of cells when the sample was spun immediately 
(Figure 3.5 A) suggesting that the cells were either affected by freezing the sample which 
caused the cells to burst and lose RNA or that urine was just not suitable for cell survival for 
this period of time. I tested both theories; firstly by testing and correcting the urine medium 
to find out whether I could prolong the cell survival. Urine pH was initially tested on 5 
samples (pH range 6 to 8), and corrected by adding 10xPBS to a neutral pH of 7, however 
this had no effect on the cell survival as measured by no change in the RNA yields, nor 
microscopic detection of cells. The next test was to treat the urine with cell culture media 
(RPMI+++ and 10xRPMI) aiming to prolong cell longevity in urine; here there were a 
noticeable improvement in the cell RNA yields (24.0 ng/ul SD 28.78). 25 samples used in 
this series) from previously 4.6 ng/ul SD 1.60, 8 samples used in this series) with the same  
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RNA extraction technique (Qiagen RNA kit) used in both experiments.  
 
As the prime aim of this study was to investigate exosome/microvesicle derived urine 
biomarkers rather then cell derived biomarkers, my concentration shifted toward optimising 
exosomal RNA extraction using an already established protocol for exosomal extraction 
(developed by Professor Cooper’s group). 
 
3.7.3.2 Urine pH and Exosomal RNA yield 
 
These samples contained cell-culture media (see 3.8.1.2), which controlled the pH to some 
extent. However, a range of pHs were found in samples- see figure 3.6 No significant 
difference in RNA yields from urine samples at different pHs were found  
				
				(A)	
	 	
	
						(B)	
	
Figure 3.5: Microscopic examination of urine samples showing cells and microvesicles. 
(A) Epithelial cells in urine following immediate processing by centrifugation after sample collection, (B) 
Microvesicles post microfiltration harvest (measuring 50-120 nm). The presence of microvesicles in the 
micro-filtered urine samples was confirmed by electron microscope analysis by Rachel Hurst at UEA 
(figure 3.5 B). 
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3.7.3.3 Urine Volume and Exosomal RNA yield 
The existing protocol stated that 30 ml of urine was to be collected per patient. However 
some patients were not able to provide the whole 30 ml sample as well as provide another 
sample for urine dipstick testing (which is a clinical requirement to exclude urine infection 
prior to the TRUS biopsy).  The question was, was 30ml of urine absolutely necessary. In 
order to answer this I compared urine samples from 30 patients, 10 of which had provided a 
10ml sample, 10 had provided 20ml and 10 patients with sample volumes of over 20 ml as 
shown in figure 3.7 below.  This experiment showed that a 20 ml urine sample appears to be 
the optimal amount of urine to gather the prostatic secretion. The smaller sample volume 
appears to gather just over half of the prostatic secretions. This effect may be due to the 
physical urethral volume. The urethral capacity is normally about 10ml, and I hypothesised 
that as we are aiming the get the prostatic secretion from the urethra we would expect the 
first 10ml of passing urine to collect the majority of the prostatic secretions, with the next 10 
ml of flow-through washing the residual secretions. Collection of a large sample volume 
appears to give a poorer yield – reasons unknown. 
 
 
	
Figure 3.6: Effect of urine pH on exosomal RNA yields. 
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3.7.3.4 Urine Dip stick results and Exosomal RNA yield  
 
Results taken from a urine dipstick appeared to have no obvious link with exosomal RNA 
yields. The average RNA yields harvested from urine samples positive for leucocytes only 
were 8.8 ng/ul (of 31 patients), those positive for blood only was 13.5 ng/ul (40 patients), 
protein 7.7 ng/ul (10 patients). The rest of the patients had a combination of leucocytes and 
or protein and blood. Interestingly we found that patients who had positive nitrites 
suggesting bacterial infection had very low yields of exosomal RNA and very high yields of 
cellular RNA (4.2 ng/ul and 455 ng/ul respectively) in comparison to the rest of the samples. 
One explanation for this could be that the exosomes could be removed by the bacterial or 
immunological cells, or are adhering to the bacterial or immunological cells that are 
abundant in these samples, and are thus removed by centrifugation prior to filtration harvest. 
It is also possible that a some of the cellular RNA was bacterial in origin. 
 
3.7.3.5 Processing speed 
 
Acquiring a centrifuge at the clinical site enabled me to harvest the cell pellet by 
centrifugation immediate (within 30min) of collection rather than after 3 hours on ice. 
Immediate centrifugation dramatically improved the exosomal RNA yields while decreasing 
the cell RNA yields. Exosomal RNA yields increased to 32.2ng/ul +/- SD 52.7. (n=25).  
This was the only protocol change, the exosomal RNA extraction itself being unchanged and 
performed 3 hours later as in the original protocol. It was hypothesised that the exosomes 
	
Figure 3.7: The difference in average RNA yields in samples collected using different urine volumes. 
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might be sticking to the cells, and the longer the cells are kept in the urine samples in the 
company of the exosomes; the more exosomes bind to the cells and come over in the cellular 
fraction. See figure 3.8. 
 
 
3.7.3.6 Qiagen RNeasy kit improvements 
 
Small improvements were made to the Qiagen RNeasy protocol: 
a) Increasing the amount of buffer (RLT) used to lyse the exosomes from 350ul to 700ul, 
improved the RNA yields from an average of 7.3ng/ul to13ng/ul.  
b) Wash step: All the centrifugation steps were reduced to 10 minutes each with no effect on 
the RNA yields. 
 
 
3.7.4 Amplification 
 
As yields of RNA from many of the samples were too low to directly perform expression 
analysis on, it became necessary to use an amplification procedure, which converted the 
RNA into cDNA. 
The amplification process was carried out using the NuGEN Ovation® Pico and PicoSL 
WTA Systems V2. According to the manufacturer’s instructions the kit can amplify as little 
as 500 picogram of RNA. However a range of input amounts had been previously tested in 
	
Figure 3.8:  Statistically significant differences in RNA yields when the samples were processed 
immediately in comparison to 3 hours ice incubation (P=0.01) 	
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our labs (data not published) and 10 to 20ng of RNA was found to be a good compromise to 
gain consistent results. Though as little as 1ng could be used if necessary and still maintain 
reasonable consistency of expression. 
I had measured all of the exosomal RNA samples on a Bio-analyzer (Agilent 2100 
Bioanalyzer system) using a Pico RNA Assay Chip to estimate quality and quantity of the 
RNA prior to amplification. Due to the low yields of RNA in the advanced and high-risk 
group we opted to compromise on these samples by amplifying as low as 2.5ng of RNA per 
sample. For the rest of the samples a total of 10-20ng per sample was used. There were no 
significant difference in the post amplification cDNA yields between the high and low input 
amount groups (See table 3.1) and there were no obvious effects on the gene analysis. 
 
Samples Amplified 
 
 
RNA Bio 
analyzer 
ng/ul 
SD 
 
 
 
RIN score 
 
SD 
cDNA 
Nano 
drop 
ng/ul 
SD 
 
 
Total amplified n=334 7.65 8.78 4.84 1.33 180.97 58.94 
RNA yields >2ng/ul n=232 10.60 9.08 4.71 1.14 193.89 50.65 
RNA yields <2ng/ul n=102 0.95 0.52 5.15 1.68 152.99 64.86 
 
 
3.8 Exosomal RNA yields and Clinical category 
 
Exosomal RNA yields varied between samples, ranging from 2 to 57 ng/ul with a mean of 
10ng/ul (SD 10.4 ng/ul). The mean 260:280 optical density ratio was 2.26 (SD 4.04).  
The RNA yields varied significantly with cancer grade and stage, with for example a mean 
of 13 ng/ul in the intermediate risk group to 3.5ul/ul in the advanced risk group, see figure 
3.9.  
Exosomes are well documented to be more abundant in cancer tissue in comparison to 
benign (238,268) which is consistent with my findings that exosomal RNA yields are low in 
benign samples, higher in low risk samples, and peak in the samples from the intermediate 
risk group. Yield then decreases in high, and is lower again in the advanced-risk samples. 
Table 3.1: Average Bioanalyzer measured RNA yields and the RIN scores pre-amplification and 
average cDNA yields post amplification. RIN is the RNA integrity score which is an indication for 
RNA quality (score 1-10) more explanation available in the Chapter 3 (text 2.5). 
	 106	
The cell RNA quantity and quality followed a similar trend.  
This variability could be related to the change in the anatomical structure of the prostate 
gland in these cancer patients. In high-grade disease (Gleason 8-10) there is great disruption 
of the inner prostatic tubules and ducts that normally provide egress of the prostatic 
secretions into the urethra. The passage of secretions into the urine is therefore limited. 
Another reason for the low yields in the high-grade and advanced groups could be the 
prostatic massage by DRE itself. The prostate in high Gleason tumours becomes very hard 
due to packed cancer cells invading the surrounding tissue. This makes it impossible to 
depress the surface of the prostate during DRE to persuade egress of prostatic secretions. 
However in the intermediate risk group, (patients of Gleason 7 disease) there is no great 
disruption of the prostatic anatomy, hence the high RNA yields.  
As can be seen, the amounts of exosomal RNA from patient’s samples post prostatectomy 
are very low, this implies that the majority of the exosomal RNA is prostatic in origin and 
not from the bladder, kidney, urethra etc.  
 
 
 
 
 
 
 
Detailed discussion on the above information is presented in Chapter 5
	
Figure 3.9: Exosomal RNA yields in relation to patient’s disease, and prostatectomy 
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4: Results of the Study 
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4.1 Clinical Parameters and Patient History 
 
A number of features were examined.  
 
4.1.1 Alcohol consumption 
 
66% of patients in this cohort drank alcohol on a regular basis with an average of 19.8 units 
per week (range from 2-100 units). 53% of patients that reported alcohol consumption were 
diagnosed with prostate cancer (figure 4.1). The Χ-square test, which was performed to 
assess the significance of alcohol consumption on the different risk groups, showed a 
significant difference with (p=0.0001 and Χ =27.74) 
The information provided by patients about the amount and the period of alcohol 
consumption in units was not expected to be entirely accurate (see Discussion) For this 
reason the amount of alcohol and the period of alcohol consumption was not taken into 
consideration in the analysis.  
 	
 
		
Figure 4.1: Distribution of patients in relation to alcohol consumption and prostate cancer. 
507 patients 
Benign = CB1 and CBN. (Yes n= 14, No n= 28) 
Abnormal = raised PSA negative biopsies, HG-P, Prostatitis. (Yes n= 147, No n= 56) 
Cancer = Intermediate (IH and I) and Low risk (Yes n=103, No n=49) 
Aggressive Cancer = Advanced and High risk (Yes n=73, Yes Previous n= 1, No n=36) 
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4.1.2 Smoking 
 
Cigarette smoking had been reported to be associated with an increased risk of prostate 
cancer (510). 
175 patients (33%) reported that they smoked or had smoked within the past 15 years. 106 
of them (60%) were diagnosed with prostate cancer (figure 4.2). In the cancer group there 
was no correlation between the numbers of cigarettes smoked daily and cancer grade, it is 
worth noting however that we did not accurately document the length of period these 
patients smoked or their pack years, which may have an effect on these findings.  However 
statistical analysis using the Χ-square test showed that there was a significant association 
(p=0.03 and Χ=14.17) between smoking habits and clinical group. Comparing non-cancer to 
cancer also yielded a significant result (p=0.02, Χ= 12.13). 
 
 
 
 
(a) 
 
 
Figure 4.2: Distribution of patients in relation to smoking and prostate cancer. 
531 patients 
Benign = CB1 and CBN.  (Yes n= 15, Yes Previous n= 13, No n= 32) 
Abnormal = raised PSA negative biopsies, HG-P, Prostatitis. (Yes n= 22, Yes Previous n= 34, No n= 149) 
Cancer = Intermediate (IH and I) and Low risk. (Yes n= 15, Yes Previous n= 35, No n= 104) 
Aggressive Cancer = Advanced and High risk. (Yes n= 15, Yes Previous n= 26, No n= 71) 
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4.1.3 Medication 
 
Beside the social risk factors above, I also examined patient’s previous medication history 
with 5-alpha-reductase inhibitors. The reason for this is because 5-alpha-reductase inhibitors 
have been reported as being preventative for PCa in the Prostate Cancer Prevention Trial 
(PCPT), which randomised 18,882 patients with PSA <3ng/ml to either a placebo arm or a 
chemoprevention arm (patients receiving 5 alpha-reductase inhibitors). A 25% reduction in 
relative risk of developing prostate cancer was reported in the PCPT trial in patients 
receiving 5 alpha-reductase inhibitors, however these patients had higher incidence of 
developing high-grade disease.  
In our study 85 patients (15%) used these medications for a period of time prior to their 
presentation to our clinic (2 months to 15 years). 43 patients (50%) were diagnosed with 
prostate cancer, 11 (13%) of them were on 5-alpha reductase inhibitors of which 8 (9%) was 
diagnosed with high grade disease and 3 intermediate risk disease. This distribution of 
patients between high grade and intermediate grade disease was not mirrored in patients on 
alpha-blockers only, see table 4.1 and 4.2. Patient numbers were too small to make any firm 
conclusions. 
 
 
 Total number 
of patients on 
medication 
Alpha blockers 5 alpha-reductase 
inhibitors 
Combination 
of both 
Neither Drug 
Cancer  43 32 8 3 247  
Non-cancer 31 31 3 5 183 
HG-PIN  11 10 0 1 22 
 
Cancer Patients High Risk Intermediate Low 
5 alpha-reductase inhibitors 6 2 0 
Alpha blockers 16 15 1 
Combination of both 2 1 0 
Neither drug 99 129 19 
 
 
Table 4.1: Distribution of patients in relation to alpha-blockers and 5 alpha reductase inhibitors 
intake. 
Table 4.2: Distribution of cancer patients disease grade in relation to alpha-blockers and 5-alpha 
reductase inhibitor intake. 
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4.1.4 Family history of prostate cancer 
 
12% of patients attending the PSA referral clinic reported evidence of a family history of 
prostate cancer. 54% of men reporting family history were diagnosed with having the 
disease themselves. In contrast 44% of patients who did not have a reported family history 
of PCa were diagnosed with the disease. Statistical analysis using the Χ-square test shows 
no significant association between family history and prostate cancer (p=0.53 and Χ =2.21) 
(Figure 4.3 A, and table 4.3). Most of the patients who reported a family history of PCa and 
who were diagnosed with the disease had an affected young close relative (32% had an 
affected brother or father by the age of 60) (Figure 4.4). An affected brother was 
predominantly reported (50% affected brother, 38% affected father). Most of these patients 
were diagnosed with intermediate risk disease in a similar age range to their affected 
relatives (Figure 4.5). However the group of patients who had an affected father (13 patients 
38%) were diagnosed themselves with predominantly higher risk disease (69% high risk) in 
comparison to the ones with affected brother (12.5% high risk) (figure 4.6). The statistical 
analysis reported no significance when patients had a close relative affected with the disease 
Χ-square test (p=0.66 and Χ =1.6) (Figure 4.3 B and table 4.4).  
 
Table 4.3: Distribution of patients according to their diagnosis and their family history of PCa  n=542 samples 
 Yes No 
Benign 4 58 
Abnormal 26 179 
Cancer 21 135 
Aggressive Cancer 15 104 
Χ-square test shows there is no significance (p=0.53 and Χ =2.21) 
 
	
Figure 4.3: (A) Patient distribution according to their family history of prostate cancer. (B) Distribution of 
patients in correlation to immediate family history of prostate cancer.  
A B 
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Table 4.4 Family History First Order Family – 542 samples 
 Yes No 
Benign 4 58 
Abnormal 22 179 
Cancer 19 135 
Aggressive Cancer 13 104 
Χ-square test shows there is no significance (p=0.66 and Χ =1.6) 
 
 
	
Figure 4.4 Prostate cancer patients with positive family history, distribution in relation to their reported 
positive relatives. The red group is patients who had positive family history and were themselves 
positive for PCa. The blue are patients who had a positive family history but were negative themselves. 	
	
Figure 4.5: Distribution of cancer patients (number of patients) according to the age of their affected 
relatives at the time they were diagnosed with the disease. 	
	
Figure 4.6 Distribution of cancer patients according to their disease grade (Low, Intermediate and high) 
in relation to the affected relatives. 
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4.2 NanoString Expression Analysis 
 
Further information on NanoString technology can be found in chapter 2. 
 
4.2.1 NanoString: Pilot NCounter human Cancer Gene Set analysis 
 
NanoString probes are single stranded, designed to hybridise and detect mRNAs, and are not 
able to hybridise to the complementary strand of cDNA. As sample amounts were limited, it 
had been necessary to amplify them as cDNA. We were therefore unsure how effectively 
NanoString technology would work. The Nugen Company that manufactures the Ovation 
amplification kit assured us that it amplified both strands equally, and the cDNA and its 
complement would be in the amplification products in equal proportions. However, 
NanoString Inc informed me that this sort of sample had never been tested with NanoString 
before, and so, I carried out a pilot analysis on 12 samples (6 in the high risk group: G8-10 
PSA>20, 3 benign control: PSA<1 and clinically benign prostate, and 3 in the low risk 
group: Gleason 6 PSA 0<10) prior to analysing large number of samples. This pilot was 
using an off-the-shelf ‘cancer gene’ assay, which would tell us: i) whether the overall 
process was working, ii) whether prostate specific genes would be detectable and iii) 
whether we can differentiate cancer from benign disease. However this pilot study was not 
aimed to identify cancer markers nor significant variable expression as we used very small 
number of samples from the extreme ends ie High risk and Benign with no normalisation. 
 
The nCounter human cancer 236-gene reference assay detected expression of 189 out of 236 
genes in our samples In addition, 20 genes showed differential expression between cancer 
and non-cancer samples including AR, PTEN, and RAF1 (see figure 4.7 Data analysis by 
Dan Brewer). This initial study confirms the utility of these analyses in that i) the 
NanoString analysis method seemed to work well on these samples, and, the NanoString 
company reported that they thought that the analyses had worked very well; ii) there are 
many transcribed mRNAs harvestable from microvesicles with the methods used; iii) there 
are differences in expression between samples with PCa and samples from patients with no 
evidence of PCa.  
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4.3 NanoString: Custom 50-probe analysis  
 
A total of 192 samples and a positive PCa control consisting of an equal mixture of RNA 
from metastatic PCa cell lines LnCaP and VCaP were used for the NanoString analysis of 50 
gene transcripts. 
The sample distribution was as follows:  
• Benign Arm:  42 samples i) 18 CB1 (PSA<1 and clinically benign prostate gland) ii) 
24 CBN (PSA normal to age and clinically benign prostate). 
• Cancer Arm: 150 samples of which 132 divided into; 10 Low, 71 Intermediate and 
51 High-risk groups as per NICE stratification criteria (see table 1.2 chapter 1 for more 
 
 
Figure 4.7: Differential gene expression between benign and cancer patients. 
The data analysis was done using LIMMA (LInear Models for Microarray and RNA-sequence data Analysis. 
Software used for the assessment of differential expression used in count data) shows the differential gene 
expression between cancer and benign samples in 20 out of 236 genes of the n-counter reference assay. 
‘Normal’ are samples from patients with no evidence of PCa. 
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details).  The remaining 18 were in the advanced/metastasised risk group (Patients with 
clinically T3/T4 prostate and PSA >100) as a positive control arm (Figure 8). 
 
50 genes were analysed in this cohort based on previous literature review, and genes 
suggested by members of the Movember funded GAP1 Urine Biomarker consortium. (see 
chapter 1, and table 1.4 for further information on the genes and their functions.) 
 
4.3.1 Gene Probe Selection 
 
The choice of the gene transcripts investigation in the study was based on 1) previous 
studies conducted in our lab (data not published), and 2) genes reported as being 
differentially expressed in PCa tissues, 3) control genes. (See table 1.4, section 1.10 for 
more detailed information on the gene transcripts investigated, and the rational for choosing 
each gene.) 
Gene transcripts identified in the laboratory of my supervisor Dylan Edwards include a 
subset of degradome components that were altered in expression in prostate cancer. These 
include some up-regulated transcripts: members of the serine protease family, Hepsin, and 
MMP family member MMP26. Down-regulated transcripts genes include Maspin and 
TIMP4. Another 41 genes were chosen based on a literature review for transcripts that were 
	
 
Figure 8: Showing the distribution of samples used for Nanostring analysis according to risk groups 	
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published as having diagnostic and prognostic potential.  
The final group of transcripts were controls, and included 5 housekeeping genes (HPRT, 
B2M, TBP, GAPDH and ALAS1) and transcripts that are specifically expressed in the 
following tissues: bladder (UPK2), kidney (SLC12A) and blood (PTPRC). Genes were also 
included that were prostate specific (KLK3, PCA3), and prostate cancer specific 
(TMPRSS2/ERG fusion gene). The tissue-specific genes were chosen to provide 
fundamental information on the origin of the microvesicles in the urine from which we were 
extracting the RNA. 
This initial set of 50-gene transcript analysis was designed as a pilot study to confirm the 
validity of the approach, and to identify the potential of these markers, which, if they proved 
to be useful would be extended to a wider cohort in a continuation study.  
 
 
4.3.2 Data Analysis: Identifying genes of interest and sample clustering 
according to disease groups. 
 
PCA and LPD analyses that I present and have discussed below were performed with the 
assistance of Dr Dan Brewer and Helen Curley. 
 
4.3.2.1 Principal Component Analysis (PCA) 
 
Principal component analysis (PCA) is a statistical procedure to analyse large multivariate 
datasets by reducing their dimentionality. It transforms a matrix of data so that the majority 
of the structure (i.e. variance) in a dataset can be viewed in a 2D plot. This transformation is 
defined in such a way that a sample’s expression profile is represented by variables (called 
principal components) that account for as much of the variability of the data. Each principle 
component had the constraint that it is linearly uncorrelated to all other principal 
components. For example principal component 1 (PC1) will have the largest possible 
variance and PC2 will have the second largest possible variance and be uncorrelated to PC1.  
The PCa analyses plotting PC1 against PC2 are shown in Figure (Figure 4.10). In addition to 
the main cluster two separate clusters (Clusters A and B) appeared to be present. One sample 
was identified as an outlier from the initial analysis (“H19.5” from the advanced group 
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category) (Figure 4.9). After further investigation, it became apparent that this sample was 
contaminated at the mRNA extraction step, and so was removed from further analysis.  
The two potential outlaying clusters (Cluster A and B) looked interesting as they stood apart 
from the rest of the samples. These were therefore tested further by K-means to confirm that 
they were distinct groups. K-means clustering aims to partition the data into K-groups such 
that each observation belongs to the group with the nearest mean. K-means clustering (k=5) 
confirmed that Cluster A and Cluster B were distinct (Figure 4.10)  
 
Figure 4.9: PCa data analysis reveals a remote outlier (H19.5).  
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Figure 4.10 A) PCa identified three clusters. A) main cluster and two separate clusters A and B. 
PC1 has 28% of the variance and PC2 8%. Sample clinical groups are: A=Adv, CB1 and CBN are 
clinically benign samples, L= Low, I= Intermediate, H= high-risk of metastasis, B) K-means 
clustering identifying the 5 clusters shown in different colours.   Cluster A corresponds to as K-
means group 4 and Cluster B corresponds to K-means group 2.  
	
Cluster	B	
Cluster	A	
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The 5 groups revealed by K-means clustering are shown in different colours in Figure 
4.10B. Notably Cluster A corresponded to K-means group 4 while Cluster B corresponsed to 
K-means group 2. Samples from Cluster A and Cluster B also grouped together when 
hierarchical clustering was performed (Figure 4.11) 
 		
4.3.2.2 The composition of samples belonging to Cluster A  	
Cluster A contained 17 samples, the majority of which were from the Advanced and High-
risk clinical groups (9 Advanced, 6 High risk and 2 in the Intermediate risk groups), no 
benign samples were in this cluster. This suggests that there is a biological reason 
underlying the cluster formation. There is a significant over-representation of Advanced or 
High-risk cases in Cluster A compared to the remaining samples (Chi-squared test; p = 
6.67x10-06).   
 
 
 
Figure 4.11. A dendrogram showing samples belonging to the PCa identified clusters A (17 samples) 
and B (6 samples).  
A=Advance risk, I= intermediate risk, H= high, CB= benign risk groups. 
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4.3.2.3 Genes differentially expressed in Cluster A. 
 
25 genes were found to be significantly differentially expressed (Mann–Whitney U test;p < 
0.05) in Cluster A samples in comparison to the rest of the cohort (table 4.5). 21 genes were 
up-regulated and 4 down-regulated. 
DLX1, AR_truncation_exon, MMP26, and Timp4 are the most significantly up-regulated 
genes. DLX1 and AR are known to be significantly expressed in prostate cancer and have 
been associated with cancer progression and metastasis in several studies (See Chapter 1.9). 
MMP26 is also known to be up-regulated in PCa and plays an important role in disease 
progression (511). Timp4 promotes cancer progression by degrading the extracellular matrix 
that is integral in tumourigenesis. However Timp4 is known to directly inhibit MMP26 and 
its intensity and expression has been reported to diminish in higher cancer grades (See 
paragraph 1.9). In contrast to this, our analysis reports that the expression of Timp4 is 
increased (fold change +1.29) – though it has to be noted that although the majority of our 
samples are from patients in a Advanced risk group (metastatic) and High risk group rather 
then Intermediate risk disease disease. These differences may also reflect the use of 
exosomes in our studies rather than cellular mRNA in published reports.  
SPINK1, SLC12A1, UPK2, are the most down-regulated genes in Cluster A. SPINK1 is 
known to be overexpressed in PCa at the cellular level particularly in association with high 
grade disease and ETS-negative cancers (See paragraph 1.7.3), in contrast to the data 
presented here. This could again be due to an exosome v cell comparison, or due to the fact 
that the high risk cancer in our group were selected from the cancer subgroup that did not 
over-express SPINK1.  
SLC12A1 and UPK2 are kidney-specific and bladder-specific transcripts previously reported 
to be present in urinary exosomes (See paragraph 1.9.1). Their expression has not been 
documented in prostate cancer. Their relative downregulation in Cluster A is likely to be 
due, at least in some part, to over-representation of prostate derived exosomal RNA in the 
PCa samples having the effect of diluting out the kidney and bladder markers. 
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Table 4.5. The 25 significant (p<0.05) genes identified by the Wilcoxon test when comparing Cluster A (PCA 
and K-means) against all other samples. ‘+’ and ‘-‘ mean relatively up and down-regulated respectively. 
Gene Wilcoxon P-value Fold Change 
SPINK1 1.46E-10 -0.50 
KLK3_PSA_exons2-3 4.24E-10 +0.25 
UPK2 5.06E-10 -0.80 
SLC12A1 2.50E-09 -0.74 
KLK4 6.06E-09 +0.13 
KLK2 1.19E-08 +0.17 
STEAP2 1.22E-08 +0.18 
OR52A2_PSGR 2.64E-08 +0.55 
KLK3_PSA_exons1-2 4.93E-08 +0.24 
FOLH1_PSMA_NAALAD1 6.05E-08 +0.21 
PPAP2A 3.53E-07 +0.13 
ARexons4-8 7.92E-07 +0.19 
AR_truncation_exon 7.30E-06 +1.26 
MMP26 7.38E-06 +1.13 
STEAP4 8.48E-06 +0.13 
GOLM1 1.43E-05 +0.49 
CLU 6.39E-05 +1.02 
B2M 0.0001 +0.21 
Timp4 0.0001 +1.29 
PCA3 0.0002 +0.46 
SERPINB5/Maspin 0.0003 +0.29 
CDC20 0.0003 +0.54 
DLX1 0.0007 +1.50 
HPRT 0.0019 +0.10 
HPN 0.0040 -0.12 
 
 
 
4.3.2.4 Cluster B: gene identification 
 
Cluster B contained 6 samples with one advanced case one high, two intermediate and two 
benign) There appeared to be no obvious clinical distinction of patients present in this 
cluster. However I noted that all samples in this group except one had low RNA yields RNA 
yields (mean for 5 samples with low RNA= 0.7492ng/ul, SD= 0.41 prior to amplification). 
For this reason these samples were removed from further analysis. 
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4.3.2.5 Latent Process Decomposition (LPD) analysis 
 
Latent Process Decomposition (LPD) is a unsupervised clustering technique developed by 
Colin Campbell at Bristol University using a statistical Baysian approach to group samples 
(512). Our group has previously used this technique to confirm that breast cancers contain 
basal and ERBB2 overexpressing subgroups and to show that metatstatic cancers can be 
divided into two clinically distinct groups (513).  The first step is to find the optimal number 
of groups that the data should be divided in to. In the second step, the gene expression 
profile for each sample is decomposed and a probability that the sample belongs to each 
group is obtained. If the probability of membership is greater than 0.5 the sample is assigned 
to that group. The LPD analysis was completed on the nanostring dataset using all the 
samples excluding the LNCAP, H19_5, and the cluster B samples. The optimal number of 
processes was four (result not shown).  Assignments to the four groups is shown in Table 
4.6 and in Figure 4.13 (Further information on these analyses can be found in Chapter 2) 
 
18 out of 185 samples were not assigned to one of the four LPD groups as shown in table 
4.6 (LPD-NA), the rest of the samples were clustered into 4 clinically different LPD 
processes with an uneven distribution of clinical categories (X-squared = 94.0012 P-value = 
2.665e-07).  
 
LPD group 1 (LPD1) predominantly consists of patients in the high-risk group; LPD2 
predominantly contains patients in the benign risk group, LPD3 has patients in the 
intermediate and high-risk group and LPD 4 are mainly cancer patients in the intermediate 
risk group (Figures 4.12, 4.13). 
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Table 4.6: LPD representing all samples except the LNCAP, H_19_5 and the 5 cluster B samples.   
The total number of samples is shown, as well as the number of samples from the clinical sub groups. X-squared 
= 94.0012 P-value = 2.665e-07. Pearson’s chi squared test for LPD groups 1-4 across all clinical categories. A = 
Advance, H = High risk, IG = Intermediate risk Gleason 4+3, I = Intermediate risk Gleason 3+4 and Gleason 6 
PSA>10, L = Low risk, CB1 = clinically benign PSA < 1, CBN = clinically benign PSA normal to age. 		
 A H IG I L CB1 CBN Total 
LPD1 9 1 0 1 0 0 0 11 
LPD2 3 5 2 2 2 6 12 32 
LPD3 3 7 5 9 1 2 0 27 
LPD4 10 16 11 37 7 10 8 99 
LPD-NA 4 9 0 4 0 0 1 18 
Total 29 38 18 53 10 18 21 187 	
		
 
Fig 4.12: LPD Graph colour representation: A= Advanced, H= high risk, IG (IH)= Intermediate high risk, I= 
Intermediate, L= low risk, CB1= benign PSA<1, CBN= benign PSA normal to age. 
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The expression levels of the samples in one LPD group were compared to all the other 
samples (tables 4.7-4.10). This was done for each LPD group in turn; for example, table 4.7 
is where samples in LPD1 was compared to all the other samples. This method was used to 
identify probes with differential expression using the Wilcoxon test. FC means log2 fold 
change. A negative log2 fold change means that the expression of that RNA was lower in 
the samples belonging to LPD group 3 compared to its expression in all other samples.  
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Figure 4.13: Samples belonging to each LPD group. Each of the 187 samples is represented in the same 
order in each of the four plots.  
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These analyses yielded some very interesting results. In particular, samples in LPD1 
exhibited high levels of expression of the bladder marker UPK2 and of SPINK1 – the latter 
being not only overexpressed in a proportion of prostate cancer but also in the normal 
kidney.  One possible interpretation of this result is that in advanced disease, the prostate is 
usually very firm, and thereby difficult to massage during DRE. This could lead to a relative 
Gene name LPD1 P- 
value 
LPD1 FC 
KLK3_PSA_exons2_3_  6.87E-08 -0.308 
KLK4  8.32E-08 -0.166 
STEAP2  3.58E-07 -0.183 
UPK2  5.61E-07 0.829 
KLK2  7.12E-07 -0.377 
SPINK1  7.77E-07 0.560 
FOLH1_PSMA_NAALAD1  2.20E-06 -0.171 
SLC12A1  2.26E-06 0.726 
KLK3_PSA_exons1_2_  2.53E-06 -0.310 
PPAP2A  8.03E-06 -0.143 
Gene name 
 
LPD2 P-
value 
LPD2 FC 
Timp4 2.12E-08 -1.207 
DLX1 1.34E-07 -1.561 
HPN 3.54E-07 -0.159 
TDRD 1.22E-06 -0.908 
ERG_3prime 6.24E-06 -1.536 
KLK3_PSA_exons1_2_ 1.53E-05 -0.121 
CDC20 1.71E-05 -0.515 
HOXC4 2.04E-05 -1.054 
STEAP2 2.72E-05 -0.050 
   
Gene name LPD4 P-
value 
LPD4 
FC 
KLK3_PSA_exons2-3 3.26E-12 0.081 
KLK3_PSA_exons1-2  1.82E-10 0.115 
KLK4  3.84E-07 0.052 
CLU  5.47E-07 0.666 
B2M  6.57E-07 0.096 
STEAP2  1.11E-06 0.047 
CDC20  1.78E-06 0.516 
SERPINB5/Maspin  3.90E-06 0.175 
AR_truncation_exon  8.75E-06 0.817 
ARexons4_8  5.17E-05 0.073 
Gene name LPD3 P-
value 
LPD3 FC 
HOXC6  3.01E-13 0.253 
ERG_5prime  7.05E-13 0.405 
TDRD  1.50E-09 0.760 
PCA3  1.10E-08 0.223 
IMPDH2  1.89E-08 0.097 
AMACR  4.17E-08 0.188 
FOLH1_PSMA_NAALAD1  8.13E-08 0.102 
Timp4  4.02E-07 1.341 
HOXC4  5.65E-07 0.648 
Table 4.7: LPD Group 1 (Predominantly patients 
from the Advanced and High risk group)  
Top significant genes 
Table 4.8: LPD Group 2 (predominantly 
patients in the Benign group)                            
Top significant genes 
Table 4.9: LPD group 3 (predominantly cancer 
patients in the High-Intermediate risk and 
Intermediate risk groups) 
Top significant genes:  
Table 4.10: LPD group 4 (predominantly 
cancer patients in the Intermediate risk)  
Top significant genes:  
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increase in the representation of markers from the kidney and bladder.  It may be possible to 
overcome the differences in the efficiency of DRE by normalisation of the data to a prostate 
specific marker such as KLK2 or KLK3. Further analysis would be needed to test the 
efficacy of this approach.  
LPD group 3 (predominantly intermediate risk) is characterised by the overexpression of the 
HOXC6, TDRD1, DLX1, NAALADL2, IMPDH2 FOLH1	 and AMACR genes. HOXC6, 
TDRD1, and DLX1 have recently been reported as a three gene urine panel overexpressed in 
patients with aggressive disease (514).  NAALADL2 and IMPDH2 overexpression is linked 
to aggressive prostate cancer (476,515) and FOLH1 and AMACR are established prostate 
markers. LPD2, which contains many of the cases of benign cancer, had relative 
underexpression of genes known to be associated with prostate cancer including 3’-ERG, 
DLX1, HPN and CDC20. 
 
 
4.3.2.7 Wilcoxon Test on all samples 
       
With Dan Brewer and Helen Curley we applied a one-way "Wilcoxon Rank Sum" test on all 
the samples to identify genes that had significantly different expression across categorical 
groups. The Wilcoxon test is a non-parametric rank so works with data that is not normally 
distributed. The test allows the arrangement of genes based on the significance of the 
changes between 2 selected classification groups. 
 
The groups compared in this test are as the following: 
1. Prognostic genes: Aggressive vs. Non-Aggressive (A, H vs. I, L, CBN and CB1).  
2. Diagnostic genes: Cancer vs. Non-Cancer/clinically benign (A, H, I, L vs. CBN and 
CB1). 
3. Control groups: Advanced vs. Clinically benign. 
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The result of the Wilcoxon test was as follows: 
1- Prognostic genes: 17 genes that can differentiate between high risk disease (where it 
is significantly differentially expressed) and lower grade and benign disease as 
shown in table 4.11. 
2- Diagnostic genes: 15 genes were identified that are significantly over expressed in 
cancer sample in comparison to benign and two under expressed genes as shown in 
table 4.12 3- 	Control groups: 21 genes were identified that are significantly differentially 
expressed in advanced (positive control group) in comparison to the benign control 
group. These genes can also be utilised as prognostic genes, as shown in table 4.13
Aggressive vs. Non-Aggressive 
Gene Name P-value FC 
SPINK1  1.86E-07 0.2081515 
SLC12A1  2.25E-06 0.415704 
UPK2  0.000126187 0.2558604 
KLK4  0.000246849 -0.03544626 
KLK2  0.000257111 -0.0346426 
HPN  0.000316275 0.08247698 
STEAP2  0.00039577 -0.03398385 
SULT1A1  0.000536153 0.1499247 
PPAP2A  0.003973885 -0.01849959 
ARexons4_8  0.007376703 -0.04742768 
BRAF  (melanoma) 0.007910603 -0.04782195 
STEAP4  0.01281419 -0.03681462 
KLK3_PSA_exons2-3  0.01722231 -0.01606706 
KLK3_PSA_exons1-2 0.02712317 -0.03678167 
AGR2  0.03086049 -0.09692415 
HOXC4  0.03369962 0.1502574 
PTPRC  0.04916936 0.1339369 
Cancer Vs. Non-Cancer 
Gene Name P-value FC 
DLX1  4.07E-07 1.371327 
HPN  2.05E-06 0.1314081 
Timp4  1.05E-05 1.013754 
ERG_5prime  1.39E-05 0.2522371 
ERG_3prime  1.52E-05 1.258378 
PCA3  2.80E-05 0.227959 
HOXC6  6.70E-05 0.2403505 
HOXC4  0.000101547 0.6434544 
SULT1A1  0.001282921 0.1177117 
TDRD  0.002203598 0.6536242 
HPRT  0.009890869 -0.03327144 
GAPDH  0.02326512 0.01399529 
PPAP2A 	 0.02424608	 -0.02004526	
CLU 	 0.02707516	 0.2870932	
CDKN3  0.03217008 0.2278353 
KLK3_PSA_exons1-2  0.03895625 0.07032925 
PTPRC  0.04451618 0.1367218 
Table 4.11. Genes where p<0.05 when the Wilcox 
test is used (on log2 transformed data) to compare 
the aggressive/non-aggressive samples.  
Table 4.12. Genes where p<0.05 when the 
Wilcox test is used (on log2 transformed data) 
to compare the cancer/non-cancer samples.  
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Again in this data set, UPK2 and SLC12A1 (bladder and kidney markers respectively) 
appear to have prognostic value. Although they are not known to be expressed by prostate 
cancer, their expression in the advanced and high risk samples (whether it is due to reduced 
exosomal RNA from the prostate at this stage as explained above or due to other unknown 
reasons) is significant to differentiate between high risk cancer and low risk or benign as 
shown in table 4.11 and 4.13. Interestingly KLK2 and KLK3 underexpression also appears to 
differentiate between the same groups as for UPK2 and SLC12A1. Even though these men’s 
serum PSA-protein levels are high, their urine exosomal KLK3 levels appear to be the 
opposite, again possibly due to relatively lower levels of prostate exosomal RNA in these 
High-risk samples. Looking at the LPD analysis  (table 4.7, 4.8, 4.10) we can see that KLK3 
is under-expressed in the advanced group in comparison to the intermediate risk group and 
benign samples (as expected) which again supports the theory that the more advanced the 
Advanced vs. Clinically Benign 
Gene Name P-value FC 
SPINK1  9.35E-07 0.4654994 
SLC12A1  3.98E-05 0.671614 
KLK4  0.000192694 -0.128272 
UPK2  0.000350423 0.5319335 
STEAP2  0.000441177 -0.1456561 
PPAP2A  0.000441177 -0.1163773 
KLK2  0.000855373 -0.1147816 
HOXC4  0.000951311 1.128014 
HOXC6  0.002358381 0.3051628 
HPRT  0.003133012 -0.1692933 
GOLM1  0.004125507 -0.2682384 
SULT1A1  0.004513196 0.2458821 
STEAP4  0.005386093 -0.09001821 
ARexons4_8  0.005875767 -0.1588067 
HPN  0.01053577 0.0941864 
FOLH1_PSMA_NAALAD1  0.01053577 -0.1165729 
ERG_5prime  0.01252864 0.356371 
TMPRSS2/ERG  0.0144308 -0.4794675 
KLK3_PSA_exons2_3_  0.02098788 -0.1021957 
NAALADL2  0.0260251 -0.1135113 
OR52A2_PSGR  0.02791597 -0.3714729 
Table 4.13. Genes where p<0.05 when the Wilcox test is 
used (on log2 transformed data) to compare the extreme 
(CBN/Advanced) samples. 
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tumour the less representation of the epithelial exosomes in urine as unable to reach the 
urine. This may apply to most epithelial genes as well, such as AMACR.  
 
 
 
4.4 Identification of prognostic genes capable of predicting 
response to hormone manipulation and progression in patients 
with metastatic disease  	
Patients in the advanced and high-risk group that were treated with Androgen Deprivation 
Therapy (ADT) by LHRH agonist/antagonist, (Leuprorelin, Goserelin/Degarelix) were 
followed up at three monthly intervals with repeat PSA testing.   
Some of the patients with aggressive disease fail to respond to ADT, their PSA shows a 
marginal drop within the first 6-months but never drop below 60ng/ml (failed initial 
response).  Others have an initial response (PSA drops to normal) and relapse within the first 
6 months (early relapse), or relapse within 7 to 24 months (late relapse). Some men respond 
significantly longer than this (delayed relapse). Therefore, it is of clinical importance to be 
able to identify patients in those different clinical groups and offer them different treatment 
strategies such as maximum androgen blockage (adding anti-androgens such as ceproterone 
acetate or Bicalutamide) or chemotherapy if they become castrate resistant. For these 
reasons I proposed that we examine gene expression patterns in this groups of patients. 
EAU and NICE guidance did not specify time intervals for relapse. The criteria that I chose 
in this study and the choice of clinical groups are as follows: i) failure to respond, ii) early 
relapse iii) late relapse and iv) delayed relapse. According to EAU guidelines, patient 
survival expectancy after seven months of ADT treatment depends on the minimum 
treatment-related PSA levels exhibited by the patient: i) patients with PSA below 0.2 ng/mL, 
have an expected median survival of 75 months, ii) patients with PSA < 4 ng/mL, 44 months 
and iii) patients with PSA> 4 ng/mL, 13 months (516). However, the guidelines state that 
these predictions need further confirmation. NICE guidance has more sophisticated criteria 
taking into consideration patients presenting with a PSA under or over 60, a Gleason score 
below or over 8, patient performance status less than or more than one, and presence of 
distant metastasis (axial and visceral). Again the survival results are similar to the EAU 
guidance. None of the guidelines specified relapse time to specific ADT treatment.  
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4.4.1 Prediction of Failure to Respond to Hormone Manipulation Therapy 
 
40 patients 21 with local metastasis and 19 with distant metastasis underwent androgen 
depreviation therapy with LHRH agonist, leuprorelin/goserelin (NB: these patients get 
started on antiandrogen initially such as Bicalutamide for 4 weeks only to prevent disease 
flare up when the LHRH agonist commenced). All patients were monitored at 3-monthly 
intervals with repeat PSA testing. In this cohort of 40 patients we identified 8 patients (20%) 
who failed to respond to the initial treatment; 7 whose PSA remained above 60ng/ml (most 
had presenting PSA >100 ng/ml) and one man whose PSA dropped to 20 at 3 months and 
rose again to over 60. 7 of these patients had extensive widespread bone metastasis (as per 
their bone scan results) and none of the patients had visceral metastasis (Figure 4.14).  
 
To identify genes that can predict response to hormone treatment, with Helen Curley we 
compared gene expression levels in 32 patients who had good initial response and the 8 
patients who failed to respond (failed initial response). The Wilcoxon test identified two 
genes that significantly differentiated between the two groups, SERPINB5/Maspin and 
HPRT. Further analysis by scatterplot (Figure 4.15) also revealed a difference in the 
expression of these genes between the two groups: low expression values of 
SERPINB5/Maspin and HPRT in patients with poor response to hormone treatment and 
relative over-expression in patients with good response (Figure 4.15). 5 out of the 32 
patients had early relapse (PSA reduced to normal levels but rose again within 6 months). 
These 5 patients as well as the 8 who failed the initial treatment were given maximum 
androgen blockage by adding anti-androgens. Expression analyses were not performed on 
them separately due to the small numbers. A	 scatterplot	 shows	 that	 there	 is	 no	 correlation	 between	 the	 expression	 values	 for	these	two	genes	across	all	samples	receiving	HT	(p-value	=	0.11).	The	two	genes	had	lower	expression	values	for	negative	responses	to	HT	and	higher	expression	values	for	positive	responses.						
 
	 130	
 
 
 
 40 patients on hormone 
At 3 month 
8 (20%) patients failed 
hormone 
Started on Max ADT 
19 distant mets 21 local mets 
7	1	
At 6 month 
5 patients had early relapse 
Started on Max ADT 
 
At 3 month  
32 patients had good 
response 
 
13 patients on Max ADT 
At 12 month  
8 patients developed 
castration resistance 
Figure	4.14:	showing	patients	response	to	hormone	treatment	over	12-month	period	
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Figure 4.15: (A) A scatterplot of the 2 genes (HPRT expression vs. SERPINB5/Maspin) 
expression for all patients undergoing ADT. Samples of patients that responded to ADT are 
indicated in green, and red for patients who did not respond to ADT. (B) A boxplot showing the 
expression values of HPRT and SERPINB5/Maspin in the two patient groups (Green for patient 
responding to ADT and Red for patients who did not respond}. 			
	
						
		 																					
Table 4.14: Comparison of the two genes identified by the Wilcox tests as significantly expressed between 
patients who responded and the once who failed to respond to initial hormone manipulation, their p-value, 
adjusted p-value and fold change.  	
Gene P-value Adjusted P-value 
(Hochberg) 
Fold Change 
SERPINB5_Maspin 0.02 0.92 -0.26 
HPRT 0.03 0.92 -0.17 		
4.4.2 Development of Early Castration Resistance  	
It is known that patients with advanced disease will inevitably develop castration resistance 
however, this is much earlier in some than in others, and depends on the extent of the 
disease and response to treatment. For this reason we looked at patients who developed 
castration resistance - these are patients who failed initial ADT treatment (LHRH 
agonist/antagonist alone) or had an early relapse, and who were therefore given maximum 
androgen blockage by combining a LHRH agonist/antagonist with an anti-androgen such as 
A	 B	
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Cyproterone acetate or Bicalutamide. In this cohort, we had 13 patients (7 distant metastasis 
and 6 local metastasis, see paragraph 4.4.1 for more information on these patients). 
Eight	 of the 13 patients on maximum androgen blockage developed castration resistant 
(rising PSA despite maximum androgen blockage with combination of antiandrogen and 
LHRH agonist) in the first 12 months indicating early development of castration resistance 
and disease progression (Figure 4.14).  
The Wilcoxon test identified three gene probes: STEAP4, ARexons4_8 and NAALADL2 
(Figure 4.16) (Table 4.15) as being significant before adjustments to the P-values were made 
(Table 4.15). In these Early Castrate Resistance analyses, neither HPRT (p=0.05), or 
SERPINB5/Maspin (p=0.14) were significant. 
All genes were relatively under-expressed in the samples that relapsed in 12 months (figure 
4.15).  
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The Kaplan Meier (KM) estimator (Figure 4.16) test was used to examine links between the 
expression of SERPINB5/Maspin and/or HPRT, and the development of resistance (rising 
PSA) over 24 months. 
Patients were then divided into low and high expression groups for each of the 5 genes 
(ARexons 4-8, NAALADL2, STEAP4, HPRT and SERPINB5/Maspin) using cut-offs 
measured by K-means clustering. The Kaplen Meier (KM) curves were then constructed for 
the low and high expression groups to establish if there was a link with progression. The test 
Figure 4.16: Boxplot showing the differences in expression for the three significant genes in patients 
who became castrate resistant in the first 12 months (red, P=Progressed) and those who didn’t (Green, 
N=Not progressed). Expression for all three genes is down regulated in samples that progressed.  
	
	
Table 4.15: Comparison of the genes identified by the Wilcox test between samples of patients who relapsed 
in the first 12 month after been given maximum androgen blockage and those who didn’t. We also included in 
the two genes that were previously significant when comparing positive and negative initial responses. *Fold 
change is lower in Negative Response Samples.  
 
Gene P-value Adjusted P-value 
(Hochberg) 
Log2 Fold Change 
STEAP4 0.03 0.96 0.11 
ARexons4_8 0.04 0.96 0.14 
NAALADL2 0.04 0.96 0.14 	
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showed that lower expression of ARexons 4-8 and higher expression of NAALADL2, HPRT 
and SERPINB5/Maspin is linked with an improved chance of staying progression-free in the 
24-month period. STEAP4 expression however was not linked to progression due to the 
interweaved probabilities for high and low values. However, it is worth noting that these 
analyses were limited by a high number of censored subjects due to limited follow up time.  
 
 
 
 		
A B C 	
D E 	
	
Figure 4.17: Kaplan Meier Curves for the 5 genes, independently using the red line for high expression and 
the green for low expression. A vertical drop in the red and green lines signifies disease progression in 
individual patients. (A) AR exons 4-8 high expression gives a higher probability of progression over the 24-
month period and its low expression lower probability of progression. (B). Similarly NAALADL2 its high 
expression gives a higher probability of progression for the first 16 months only and its low expression a 
lower probability of progression for the first 16 months. (C) STEAP4, high and low expression interwines, 
thus neither of which can give probability of progression. (D) HPRT high expression gives a lower 
probability of progression over 24 months and its low expression gives a higher probability of progression. 
(E) SERPINB5/Maspin, high expression gives a lower probability of progression compared to low 
expression. 
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Table 4.16:  Log rank and Cox test showing the statistical difference between the two groups (patients who 
progressed and who didn’t progress) in the above KM curves (figure 4.15).  	
 Log Rank - 
Kmeans 
Cox - Kmeans Cox - Continuous 
 P-value Chi-Sq P-value Hazard 
Ratio (exp) 
P-value Hazard 
Ratio (exp) 
AR exons 4-8 0.69 0.2 0.68 0.67 0.46 0.87 
NAALADL2 0.74 0.1 0.75 1.28 0.95 0.99 
STEAP4 0.62 0.2 0.63 1.35 0.65 0.91 
HPRT 0.1 2.8 0.13 0.4 0.21 0.82 
SERPINB5_Maspin 0.05 3.8 0.05 3.05 0.02 0.73 		
4.5 Exosomal RNA Next-Generation Sequencing  
 
Exosome/microvesicle gene expression is understudied, particularly in microvesicles 
derived from prostate.  The gene probes that have been used so far in the study were selected 
by being differentially expressed in prostate cancer compared to normal prostate or by 
comparing aggressive to non-aggressive disease. As we are actually dealing with RNA 
extracted from exosomes rather than prostate tissue it was decided that we needed to know 
what range of RNA species were actually present in the urinary exosomes. Therefore in 
order to get an in-depth understanding of the role of these microvesicles and identify gene 
transcripts that would potentially be used for diagnostic and prognostic purposes, we used 
Next Generation Sequencing (NGS) to assess 18 exosomal RNA samples. I selected samples 
from the following clinical groups: 7 in the high risk group (Gleason 8-10, PSA<100), 7 
intermediate risk group (G7, PSA<20) and 4 benign control (PSA value normal to patients 
age and clinically benign prostate). Further information on sequencing and analysis methods 
can be found in chapter 2. My clinical knowledge was central to sample selection, I prepared 
all the RNA samples ready for NGS analysis, and helped in data interpretation.  
 
4.5.1 NGS data analysis  
 
Dr Dan Brewer’s analysis of the NGS data found 45 genes to be significantly differentially 
expressed between benign (4 cases) and cancer samples (14 cases) (p < 0.05 after multiple 
testing correction), with a log2 fold change ranging from 0.3 to 2.5 (Figure 4.18) of those 
genes 28 are up regulated and 17 down regulated in cancer.  33 genes showed a significant 
linear trend in association with cancer risk (27 genes showed increasing expression and 6 
showed decreasing expression with increasing risk (Figure 4.18, 4.19)).  
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Figure 4.18. Boxplots showing statistically significant gene transcripts (n=45) that are differentially 
expressed between benign and cancer samples. ‘DESeq’ is the number of reads assigned to a specific gene 
normalised by the estimated size factor of the sample.  	
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Figure 4.19. A) Boxplots showing statistically significant gene transcripts that show an increase or 
decrease trend with risk status. B) Boxplot showing in cancer vs benign samples. 	A	
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PCA3 and DLX1 were identified by the analyses as being significantly overexpressed 
between PCa and benign. This was reassuring, as both these genes are known to be 
overexpressed in PCa vs benign in whole-urine and exosomal RNA as reported in the 
literature and our LPD analysis respectively. This confirms that the system is working. 
DLX1 was also selected, and this has been reported to be useful in urine analyses particularly 
as a diagnostic gene in urine sediments in patients with aggressive prostate cancer (514). 
Furthermore DLX1 was recently identified to be a prognostic gene as a good predictor of 
high grade prostate cancer (using whole urine) as well as HOXC6 although in our gene 
analysis (NaNostring) both these genes were identified as strong diagnostic genes 
(differentiate between benign and malignant) but not as prognostic genes (517). (Table 
4.12). Similarly DLX1 appear to be significantly over expressed in cancer patients in the 
third generation sequencing but did not correlate to high grade disease. 
Matrix metalloproteinase 25 (MMP25) is another gene that was identified by the analysis to 
link to Gleason score, these finding are in agreement with a another study that demonstrated 
that the expression of MMP25 correlates positively with Gleason score (511). The exact 
function of those transcripts in exosomes found in PCa patients remain to be identified.  
 
The rest of the genes identified as differentialy expressed by analysis of RNAseq data did 
not match with the gene probes that had been chosen for the NanoString analysis and which 
were selected on published analyses of cell tissue samples. This difference emphasises the 
potential importance of this sequencing study in producing novel candidates for PCa 
diagnosis and prognosis. 
 
Other genes identified by the analysis are the apoptotic genes BIK and AATF.  
BIK (BCL2-Interacting Killer) is known for its pro-apoptotic activity (518), It was noted to 
be up-regulated in a number of cancer types inluding lung, prostate, colon, blood 
(leukemia); its induction is used in some cancer treatment (519). In Breast cancer it plays a 
critical role in inducing apoptosis by promoting estrogen starvation (520), its knock-down 
signicantly inhibits apoptosis (521). In prostate cancer its apoptotic function was also found 
to to be effective in both hormone sensitive and castrate resistant cells, the authors of the 
study concuded that it may have therapeutic function in PCa (522), beside cancer 
suppression it plays a role in controlling spermatogenesis (523). 
 
AATF (Apoptosis Antagonising Transcription Factor): is a nuclear phosphoprotein known 
for its envolvement in cell cycle control and gene transcription, it exhibits a dual role, 1) the 
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regulation of cell proliferation and 2) growth arrest by apoptosis. It interfere with apoptosis 
via interaction with Dlk/ZIP kinase (a serine/threonine kinase known to induce apoptosis) 
leading to inhibition of apoptosis (524). It has also been found to correlate positively to Oct4 
inhibition of apoptosis in stem cells, regulating cell growth in embryos (525).  Its apoptotic-
inhibitory function has also been documented in prostate cancer in patients on androgen 
deprivation therapy.  The study concluded that the gene could be used in the prediction of 
outcomes in PCa patients on ADT (526). The encoded protein also exhibits DNA-binding 
transcription factor activity by the interaction of its leucine zipper contents with the Gal4 
DNA-binding domain (524). It also plays a role in cell to cell adhesion in neuronal cells, and 
can function through interaction with different transcription factors, promoting cell cycle 
progression by binding to ribosomes and activating factor E2F and enhancing steroid 
receptor-mediated transactivation. By functioning in co-operation with TSG101 (tumor 
susceptibility gene product, a co-regulator of nuclear hormone receptors) it was also shown 
to have coactivator activity on androgen receptor-mediated transcription (527) (528).  
Some of the top genes identified by the sequencing analysis are shown in table 4.17. 
	 140	
 
 
 
Table: 4.17: Shows interesting genes identified by the sequencing analysis, their function and role in cancer 
Gene name  Brief Function (Data 
taken from Gene 
Cards) 
Involvement in Cancer 
in general  
Involvement in 
Prostate Cancer 
Expression 
in exosomal 
RNA 
Up regulated genes includes 
ACTR5 Actin-Related Protein 5 
Homolog (Yeast) 
DNA Double-Strand 
Break Repair and 
Transcription-Coupled 
Nucleotide Excision 
Repair  
Cell cycle progression 
coactivation of nuclear 
receptors.  
Overexpressed in several 
types of cancer (529) 
Overexpressed in 
LNCaP cell line 
after exposure to 
androgen and 
anti-androgen 
(530) 
Up-regulated. 
Higher 
expression in 
intermediate 
and high risk 
group 
ARHGEF25 Rho guanine nucleotide 
exchange factor (GEF) 
25 
Positive regulation of 
Rho GTPase activity 
  Up-regulated 
C16orf91 Chromosome 16 Open 
Reading Frame 91 
Protein Coding gene   Up-regulated 
C1orf216 Chromosome 1 Open 
Reading Frame 216 
Protein Coding gene   Up-regulated 
CTA-211A9.5 Transfer RNA 
Suppressor transcript 
Non coding RNA   Up-regulated 
EMC9 ER membrane protein 
complex subunit 9 
Ubiquitination and de-
ubiquitination activity 
within the cell 
  Up-regulated 
HIST1H2BF Histone cluster 1, H2bf Innate immune 
response in mucosa, 
chromatin organization, 
nucleosome assembly, 
antibacterial humoral 
response, defense 
response to Gram-
positive bacterium. 
 
Up-regulated in non small 
cell lung cancer cell line 
(methylation 
modification)(531)and 
breast cancer (532) 
 Up-regulated 
HPSE2 Heparanase 2 (inactive) Encodes a heparanase 
enzyme that act on the 
extracellular matrix and 
cell surface.  It is also 
envolved in the 
remodeling of the 
extracellular matrix, 
angiogenesis and tumor 
progression (533) 
Has been reported in 
breast cancer (533), 
pancreatic and prostate 
cancer, as well as 
malignant melanoma 
where it is used as a 
molecular marker of cell 
invasion (534). 
In pancreatic cancer it 
regulates VEGF-C 
expression a cytokines that 
promote metastasis and 
angiogenesis (535) 
Shown to be 
marginaly up 
regulated in 
plasma DNA in 
prostate cancer 
(536). 
It may have a role 
in PCa metastasis 
(537) 
Up-regulated 
MFSD2A Major facilitator 
superfamily domain 
containing 2A 
Transmembrane 
protein, which may be 
responsible for uptake 
and transport of fatty 
acid, phospholipids. 
Lung cancer tumour 
suppressor gene.  
It has been shown to alter 
mRNA levels of genes 
involved in cell cycle and 
interact with the 
extracellular matrix 
attachment. (538) 
 Up-regulated 
in high risk 
group 
MIR146A MicroRNA 146a Non-coding RNAs that 
are involved in post-
transcriptional 
regulation of gene 
expression 
 Tum suppressor, 
and suppressor of 
metastasis, by 
regulating cell 
growth (539) 
Up-regulated 
in high risk 
group 
NUDT6 Nudix (nucleoside 
diphosphate linked 
moiety X)-type motif 6 
Is thought to be the 
FGF2 (Fibroblast 
growth factor 2) 
antisense gene. 
FGF2 expression is 
Multifunctional:  
heparin-binding growth 
factor neuroectoderm 
development, 
angiogenesis, and 
wound healing. 
Elevated levels of FGF2 
are associated with 
proliferation of smooth 
muscle in atherosclerosis 
and with proliferation of 
tumors. The fibroblast 
growth factor-2 antisense 
gene inhibits nuclear 
accumulation of FGF-2 
and delays cell cycle 
progression in C6 glioma 
cells. (540) 
FGFs play a role 
in the growth of 
normal prostate 
tissue. Over 
expression of 
FGF2 was 
observed in 
prostate cancer 
epithelial cells 
with poor 
differentiation 
(541) 
Up-regulated 
PALM3 Paralemmin 3 ATP-binding protein. It 
negatively regulate 
  Up-regulated 
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cytokine-mediated 
signaling pathway 
PSTPIP1 Proline-serine-
threonine phosphatase 
interacting protein 1 
Protein coding gene 
involved in 
endocytosis, 
inflammatory response, 
cell adhesion, signal 
transduction nucleotide-
binding domain and 
innate immune response  
 Chromosome 
translocation that 
result in the loss 
of PSTPIP1 gene 
leading to its 
downregulation in 
LNCaP cells has 
been documented 
(542) 
Up-regulated 
in high risk 
group 
RP11-
244H18.1 
LincRNA P712P prostate specific 
transcript. non-coding 
mRNA located on 
chromosome 22. 
 
 Androgen driven 
in LNCaP cells 
(543).   
Up-regulated 
RP9 Retinitis pigmentosa 9 RNA splicing and 
Cognition, mainly. Its 
exact role is not fuly 
understood. Mainly 
expressed by B cells. 
  Up-regulated 
SMIM1 Small integral 
membrane protein 1 
A type II 
transmembrane 
phosphoprotein, 
responsible for the Vel-
negative blood type. 
(544) 
  Up-regulated 
in high and 
intermediate  
risk group 
ST6GALNAC1 ST6 (alpha-N-acetyl-
neuraminyl-2,3-beta-
galactosyl-1,3)-N-
acetylgalactosaminide 
alpha-2,6-
sialyltransferase 1 
Affect cell to cell 
interaction, and cell 
interactions with the 
matrix.  
It is mainly expressed in 
adenocarcinomas leading 
to the synthesis of sialyl 
Tn (sTn) antigen 
particularely in gastric 
CA, however, its role 
remain unknown (545) 
  
 Up-regulated 
Some of the up regulated genes that trend up with cancer grades include 
ABCB9 ATP-binding cassette, 
sub-family B 
(MDR/TAP), member 
9 
 
Member of the 
MDR/TAP subfamily 
that act as a membrane 
transporter involved in 
multidrug resistance as 
well as antigen 
presentation. It is 
expressed in all tissues 
with its highest 
expression is in CD71 
 
Inhibition of ABCB9 by 
microRNA 31 lead to 
decrease in DDP-induced 
apoptosis in lung cancer 
(546) 
ABCB9 was 
identified as one 
of 16 genes 
predictive of 
prostate cancer 
recurrence after 
prostatectomy in 
DNA microarray-
based gene 
expression 
profiles (547) 
 
Trend-Up in 
High risk 
Group 
CKAP2L Cytoskeleton 
associated protein 2-
like 
 
Involved in mitotic 
progression.  
 
Very highly expressed 
in CD71  
  Trend-Up in 
High risk 
Group 
CLIC2 Chloride intracellular 
channel 2 
 
A member of the p64 
family that regulate 
cellular processes 
including stabilisation 
of cell membrane 
potential, transepithelial 
transport, and 
regulation of cell 
volume. (548) 
 
Very highly expressed 
in CD31 
 
A microarray gene 
expression profiling 
demonstrated its 
involvement in lung 
cancer metastasis (549) 
 Trend-Up 
NLRP3 NLR family, pyrin 
domain containing 3 
 
Involved in 
inflammatory response 
and apoptotic process 
by activation of 
cysteine-type 
endopeptidase activity, 
defense response, signal 
transduction and 
detection of biotic 
Its activation can enhance 
proliferation and migration 
cancer cells by activation 
of the IL1 beta that Curtail 
anti cancer activity 
(552,553) 
 
 Trend-Up in 
High risk 
Group 
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stimulus. 
Negative regulation of 
NF-kappaB 
transcription factor 
activity and 
interleukin-1 beta 
production. (550,551) 
Very highly expressed 
in CD33 myeloid, 
CD14 monocytes 
PLCB2 Phospholipase C, beta 
2 
 
Some of this gene 
function is the 
activation of 
phospholipase C 
activity synaptic 
transmission and 
phospholipid metabolic 
process as well as 
intracellular signal 
transduction. 
 
Expressed by Blood 
cells, myeloid, 
monocytes, NKs, Cd4, 
CD8 T-cells 
 
Lung cancer tumor 
suppressor gene that 
regulates cell cycle 
progression and matrix 
attachment. (538) also 
identified to be expressed 
in leukemia(554) 
 Trend-Up in 
High risk 
Group 
PRR5L Proline rich 5 like 
 
Regulation of protein 
phosphorylation and 
negative regulation of 
signal transduction it 
also regulate fibroblast 
migration.  
It also  positively 
regulats 
phosphatidylinositol 3-
kinase signalling, 
control cell 
proliferation by 
promoting cell 
apoptosis via 
interaction with 
mTORC2 (555). 
 
Its is highly expressed 
in CD56 NK cells. 
 
PRR5L degradation lead 
to PKC-delta 
phosphorylation and cell 
migration mediated by 
mTORC2 (556) 
 Trend-Up 
Some of the down regulated genes includes 
ERMP1 Endoplasmic reticulum 
metallopeptidase 1 
Is a transmembrane 
metallopeptidase. In rat 
ovaries it is required for 
folliculogenesis, where 
its underexpression 
resulted in loss of 
follicules and structural 
disorganisations of the 
ovaries (557) highly 
expressed in  B-
lymphoblasts, NK cells 
Over-expressed in breat 
cancer (identified as breast 
cancer oncogene) (558) 
where its silencing has 
been shown to 
significantly 
reduceinvasiveness and 
proliferation (559) 
 Down 
regulated 
HMBOX1 Homeobox containing 
1 
Telomere involved in 
maintenance and 
inhibition of the NK 
cells acticity (560) 
It also has 
transcriptional repressor 
activity (561) 
 
Expressed in prostate, 
pancreas, thymus, testis 
and other tissues (562) 
 
Overexpression of 
HMBOX1 significantly 
inhibited NK cell 
activities, including 
natural cytotoxicity 
against tumor cells (563). 
 Down 
regulated 
KNTC1 kinetochore associated 
1 
Mitotic cell cycle 
protein complex 
assembly regulation of 
exit from mitosis chromosome	
  Down 
regulated 
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Further detailed discussions on the above information is presented in 
Chapter 5. 
 
 
 
 
kinetochore 
B-lymphoblasts (564) 
(565) 
Cell division (566) 
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5. Discussion 
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5.1 Prostate cancer screening and diagnosis 
 
Prostate cancer poses a number of clinical challenges in terms of its diagnosis, prognosis and 
treatment. The challenge posed by PCa is the clinical inability to accurately predict the 
disease’s course of progression in individual patients. There are many indolent prostate 
cancers that could be safely left completely untreated, if only they could be reliably 
recognised as such. There are also aggressive types of PCa that for optimal survival would 
require early identification and possibly a more aggressive treatment regime. The 
mechanisms of development of castration resistant- and of androgen independent- disease 
are also poorly understood and such patients cannot be identified early enough to consider 
other treatment modalities. Under current clinical practice these patients are very 
challenging, and in many cases are managed by palliation. As accurate prediction of 
individual prostate cancer behaviour at the time of diagnosis is not currently possible, 
immediate radical treatment is considered in many cases (130), at the cost of numerous 
complications including impotence and incontinence.  
We therefore set out in this study to identify a set of urine biomarkers that would potentially 
answer the following questions:  (i) are there novel urine based RNA molecules that can 
assist in cancer diagnosis? (ii) can the detection of specific RNA transcripts be used to 
distinguish aggressive from non-aggressive cancer? (iii) can these biomarkers predict 
response to ADT treatment? and  (iv) can these biomarkers predict resistance to ADT 
treatment? 
 
 
5.2 Risk Factors for PCa  
 
There are a number of risk factors documented in the literature associated with an increased 
risk of developing prostate cancer. I aimed to investigate some of these risk factors in this 
study however our study patient population from the Norwich and Norfolk University 
Hospital was not diverse or large enough for a thorough investigation.  
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5.2.1 Race 
 
It is well documented in the literature that the incidence of PCa differs between men with 
different racial origin (36,37). However, the NNUH cohort was not diverse enough to draw 
any conclusions (only 0.8% of the population included in this cohort where of non-caucasian 
origin). Having a more diverse population could have strengthened the outcome in terms of 
developing a test that could be effective for men of all races, particularly those with a higher 
associated risk.  It is unlikely in Norfolk that we would ever generate a large enough cohort 
to address this issue systematically. 
 
5.2.2 Alcohol  
 
There have been a number of conflicting results from studies with respect to alcohol 
consumption risk and PCa. A prospective study in the USA of 238 men showed no 
associated risk (510,567). In contrast, a study on 753 men showed a reduced risk of PCa in 
wine drinkers, thought by the authors to be due to hormonal milieu alterations as a result of 
chemical substances such as flavonoids in red wine (568). This study also investigated the 
consumption of other types of alcoholic drinks, none of which appeared to be significantly 
associated with an increase in PCa risk. This was in contrast to a Canadian study that 
showed an increased risk in men consuming beer (569). In my study, I documented alcohol 
consumption as units per week regardless of the type of alcohol consumed or the number of 
years these men had consumed alcohol. Our findings showed a statistically significant risk 
in alcohol consumption and PCa - however these results need to be carefully interpreted 
particularly in the absence of in-depth data and documentation. 
 
5.2.3 Smoking 
 
Several studies have reported an increased risk of PCa in smokers (9,510,567).  Some 
studies reported an increased risk of High grade disease, metastasis, biochemical recurrence 
and development of castration resistance (570). It has also been reported that cigarette 
smoking whilst undergoing a course of external beam radio-therapy treatment is associated 
with an increased risk of prostate cancer-specific mortality and treatment-related toxicity 
(571).   
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The findings of my study were that 60% of patients who admitted to smoking were 
diagnosed with prostate cancer.  However the prevalence of PCa was similar or even higher 
in non-smokers, and there were no correlation between the cigarette numbers smoked daily 
and cancer grade. However, due to anti-smoking publicity campaigns, and the government 
ban on smoking in public places, it has become an embarrassment for patients to admit to a 
clinician that they smoke. I had aimed to document smoking accurately in this project in 
order to assess any relationship with smoking, including any effect of smoking on our 
biomarker expression. However for the reasons mentioned above and due to an elderly 
patient-population presenting with prostate cancer, recording accurate history of smoking 
proved to be extremely difficult, and I am uncertain if the data are a true representation of 
the smoking population or not. One way around this problem could be to perform a blood 
test for nicotine, or other smoking-related chemicals, but this would only assess current 
habits and not previous history or how long a patient had been smoking. I also did not have 
ethical approval for taking a blood sample for such a test, and so it was outside the scope of 
this study. 
 
5.2.4 Family history 
 
It has been reported that the risk of getting PCa increases with the number of close relatives 
that have already been affected by the disease. The overall risk of familial PCa is 
documented to be 9% (18). Our findings are consistent with the reported figures with 12% 
of our patients reporting a family history of PCa. Most of these patients had an affected 
young close relative, and most of these patients were diagnosed with Intermediate risk 
disease in a similar age range to their affected relatives (information about the relative’s 
disease grade and stage were not obtained in this study as we did not have ethical aproval to 
collect this information).  
 
 
5.3 Urine as a source of PCa Diagnostic and Prognostic markers 
Urine is a carrier of prostatic secretions and other biomaterials, and a source of prostate 
cancer biomarkers (572). The literature contains many examples of urine-based biomarkers 
that have been reported to have diagnostic (mainly) and in a few cases prognostic 
usefulness. DNA, RNA, protein and metabolite levels have all been reported as promising 
markers. However, despite significant progress only one urine biomarker (PCA3) to date has 
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succeeded in reaching clinical use. Despite it being easy to use, the PCA3 test is still in 
limited clinical use mainly due to the lack of large clinical trials to validate its proposed 
prognostic power (573) and guide the course of patient treatment towards surveillance or a 
radical approach. Its utility as a marker of treatment response has also been questioned since 
the PCA3 test showed variable results on patients with localised prostate cancer on 5-alpha 
reductase inhibitor dutasteride, on a pilot study with nine patients (573).  
Other RNA urine biomarkers reported include GOLPH2/GOLM1, SPINK1, AMACR, TFF3, 
TMPRSS2/ERG fusion, HOXC6 and DLX1, some of which have been shown to outperform 
serum PSA in the diagnosis and prognosis of PCa (157,206,517,574). Some of these markers 
such as the TMPRSS2/ERG fusion gene transcripts, when used in combination with PCA3 
have proved to enhance the utility of serum PSA for predicting prostate cancer risk as shown 
in a large multicenter study on 1312 men (575).  An assay combining serum PSA with 
urinary PCA3 and TMPRSS2/ERG (574) has shown similar results with 90% specificity and 
80% sensitivity in diagnosing PCa. Although it has high specificity it is lacking in sensitivity 
and prognostic ability. Recently prostate cancer derived urine exosomes have shown to be a 
promising source of biomarkers; however to date there are only 3 studies published, all of 
which are on small cohorts of patients, the largest having 11 subjects. Two have reported the 
presence of genetic information specific for PCa including PCA3 and TMPRSS2/ERG 
(576,577), and the third has reported an ability to predict treatment response on patients 
undergoing radiotherapy treatment (268). To date, single biomarkers from any origin have 
failed to combine high specificity and sensitivity in detecting prostate cancer, nevermind 
predict prognosis and response to treatment. It was therefore hypothesised that multiple 
biomarkers could be used, each supplying a small amount of clinical information, which, 
when used together could provide superior detection of PCa per se and more accurate 
prognostic information. This hypothesis has been investigated by many, including a study 
who showed that a multiplexed model, including GOLPH2, SPINK1, PCA3 and 
TMPRSS2/ERG, outperformed serum PSA and PCA3 alone in detecting prostate cancer 
(206). Another study showed that the combination of EZH2 and TRPM8 added diagnostic 
power to PCA3 (492). Both of the studies were performed using urine sedimentary fractions 
rather then exosomal mRNA.  
Despite all these efforts none of those urine markers, with the exception of PCA3 have 
progressed to clinical use. The reasons for this are many-fold and include: i) the chemical 
nature of urine itself which makes it difficult to optimise protocols for preservation of the 
biomaterials needed for testing - this is particularly true in the case of cell-based biomarkers; 
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ii) the heterogeneity of prostate cancer with multiple routes to progression that cannot be 
represented by one biomarker and iii) the lack of repeat and conformational studies. The 
current study was planned taking into consideration all the above, namely good clinical 
information on which we based our data analysis, a urine-stable biomaterial as the source of 
biomarkers (exosomes) and a large cohort of patients (192 in the current study and 1000 in 
the overall project) as well as a large number of biomarkers (50 in this pilot study) chosen as 
a panel for diagnostic and prognostic purposes. Our next-generation sequencing of urine 
exosomal RNA samples has opened the door to the development of new RNA biomarkers 
tailored to exosomes themselves rather than chosen because they have differential 
expression in tumour and normal tissue. 
Our initial results showed that prostatectomy patients exhibited very low yields of exosomal 
RNA suggesting that most of the exosomal RNA prepared in our study was derived from the 
prostate. This result has given us the confidence in the source of our gene transcripts for 
analysis. However, as shown by samples in-group LPD1, high levels of Uroplakin 2 and 
SPINK1 RNA are detectable, suggesting an increase contribution from bladder and kidney 
respectively in patients at the clinically extreme categories of benign and advanced disease. 
Exosomal shedding from normal prostate cells has been reported to be less than from cancer 
cells (578), hence the relative increase in renal and bladder derived exosomes in advanced 
cancer patients is hypothesised to be due to an inability of prostate exosomes to reach the 
urethra due to the distorted luminal anatomy of advanced disease. To assess bladder 
contamination Uroplakin 2 was specifically included (485,486). Midkine is another gene we 
included as both a test, and a control as it has been reported to be over expressed in the urine 
of patients with renal and bladder cancer as well as eight other cancers 
(http://www.cellmid.com.au/content_common/pg-cancer-treatment-and-detection.seo). We 
suspect that this issue would be more accentuated when analysing the whole urine. 
The 662 samples generated in my study will generate a considerable amount of information 
on the relative uses of exosomal and sedimentary fractions as sources of prostate biomarkers 
in future analytic studies. My samples have provided a core set of samples for the 
Movember GAP1 initiative who’s overall aims are to develop better markers for detecting 
prostate cancer and for distinguishing aggressive from non-aggressive disease. The samples 
have been analysed in the following ways (see figure 2.1): 
1. 3,347 aliquots of whole urine have been analysed by 5 teams (Bristow- Toronto, Pandha- 
Guildford, Whitaker- Cambridge) for 11 different proteins by ELISA, and also for Mass 
Spectrometry analysis (Leung- Glasgow). 
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2. 414 aliquots of Cell cDNA has been analysed by 4 teams (Pandha - Guildford, Olivan -  
Barcelona, Mills - Oslo) for 7 RT-PCR targets, plus 167-probe analysis by NanoString 
(Cooper - Norwich). 
3. 1,436 aliquots of exosomal cDNA have been analysed by 3 teams for 7 RT-PCR targets 
(Pandha - Guildford, Olivan - Barcelona, Cooper - Norwich), plus 167-probe NanoString 
analysis of 499 samples by Cooper, and 60 by Sanda -Atlanta. 
4. 980 aliquots of cell DNA have been analysed for DNA-methylation patterns in 10 genes 
by Bapat - Toronto), and Perry - Dublin. 
When all the data from the above analyses has finally been collated, then it will be meta-
analysed to see what the best combination of markers is for PCa detection and prognostic 
markers. 
 	
5.4 Exosome, cell sediment and whole-urine biomarkers  	
To better understand the relative contributions of the cell and exosomal components we 
aimed to study each fraction separately rather than whole urine as such. This was a 
fundamental principal of the Movember GAP1 Urine Biomarker study. Also, knowing the 
source of the RNA is crucial in my opinion in order to appropriately interpret the 
information with maximum confidence.  
Exosomal RNA may be more clinically informative than cellular RNA from urine. 
Exosomes are part of an inter-cellular communication system that can promote cancer 
proliferation and metastasis through their signaling pathways in recipient cells (230,238).  
They may therefore contain molecules directly associated with these processes. It is reported 
that exosomes from a prostate cancer cell line can contain αvβ6 integrin which, can be taken 
up by recipient cells and become expressed on their cell surface – the integrin appeared to be 
functional and enhance cell adhesion and migration (579). Some studies have also shown 
that exosomes can also be responsible for transferring drug resistance to other cells in 
prostate cancer (580). For these reasons studying exosomes could have a number of 
advantages as they have the potential to provide a vast array of information beyond 
diagnosis, such as prognosis, response to treatment, and possibly cancer resistance to certain 
medications including hormone ablation therapies.  A biomarker comparison between urine 
sediment and exosome showed that exosomes were a more stable substrate in comparison to 
urinary sediment (particularly post-DRE), where gene expression analysis was compromised 
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by amorphous precipitation in 10% of the specimens (502). Similar findings were reported 
by another study that showed that expression of KLK3, PCA3 and ERG were higher in 
exosomes (501).  
The isolation of RNA from pure exosomal or pure cell pellet fractions may not be as clear-
cut as it first appeared to be. It was noticed that the longer the whole urine was kept before 
sedimentation of the cell pellet, the higher the cell RNA yield was and correspondingly the 
lower the exosomal RNA yield. It was hypothesised that this was due to exosomal vesicles 
adhering to the cells over time, and their RNA becoming harvested with the cell RNA. This 
implies that RNA content from the sedimentary fraction could vary with time so for a clearer 
division, there needs to be rapid urine processing.  
 
One could argue on the significance of studying exosomal RNA alone when instead we 
could study RNA from whole-urine as the PCA3 test does. This would negate any changes 
in RNA between the sediment and supernatant fractions, and could be a future avenue of 
exploration. 
In this study, it was decided to focus on exosomal RNA, as whole-urine RNA poses some 
challenges, particularly the efficient extraction of RNA from large urine volumes. However 
it is noted that very little RNA is needed for amplification with a Nugen Ovation kit, and, 
only 1ng of RNA is needed for Illumina sequencing, so, poor yields may not be an obstacle 
for future analyses of whole-urine RNA if single or small number of genes need to be 
examined.  
A study comparing urine exosomes and whole urine showed advantages in term of analytical 
limits with whole urine in comparison to exosomes and cell pellet. For example, the 
amounts of KLK3 and PCA3 were highest in whole urine, then exosomes and lowest in cell 
sediment. But for diagnostic use the cell pellet appeared to be of more use than whole urine 
and exosomes. For example the PCA3/KLK3 ratio was significantly higher in the PCa 
samples in the cell pellet, while in the whole urine and exosomes there was no significant 
different between cancer and benign.  ERG mRNA levels were also significantly higher in 
the PCa cell pellet (diagnostic) but not in the whole urine or exosome samples. However the 
number of samples used were small (29 patients in total, including 15 PCa, 4 of which were 
excluded from the analysis), the PCa predominantly being Low and Intermediate risk (3 out 
of 15 had T3-T4 disease). This study also did not include bladder and kidney control genes.  
mRNA amplification was not used in this study which may explain the higher sample 
dropout for the exosome fraction (501) (we know from our experience that exosomal mRNA 
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level drops in High grade disease as explained previously and that needs to be taken into 
account). The authors also concluded that the exosomal fraction has an advantage in term of 
stability which I think is one the most important factors in developing a clinically robust 
test.  
Urine can vary significantly between individuals and even in the same individual between 
different times of the day (see 5.5 for more information). The effects of these variables on 
urine biomarkers is expected to vary according to fraction. The cell pellet fraction appears to 
be the most unstable, as urine does not provide a healthy medium; cell survival is limited 
and will vary with exposure time. The cell pellet has also been shown (data by Rachel Hurst, 
UEA, not presented here) to largely consist of white blood cells, with only a very small 
proportion staining for prostate and prostate cancer cell markers. In addition, when prostate 
cells become detatched and lose cell:cell and cell:ECM contact they will initiate anoikis cell 
death. Thus the expression patterns of the cell pellet can vary enormously from sample to 
sample. In contrast RNA from the exosomal fraction is a stable snapshot of molecules as 
they were produced by the mother cells. Exosomal mRNA is stable in the urine at room 
temperature or frozen for over 48 hours (data not shown in this thesis) which is consistent 
with other study’s findings (501). 
  
 
5.5 A Urine test for the detection of prostate cancer: pros and 
cons 
 
Urine has gained research attention as a non-invasive source of biomarkers with the 
potential to represent multiple foci of PCa. As mentioned above, I have tested exosomal 
RNA yields in patients pre- and post- prostatectomy, RNA yields dropped from >100ng to 
~1ng indicating the prostatic origin of the majority of the RNA. 
 
However there are several points that need to be taken into consideration if a urine test is to 
be available for future clinical use. The first point is practicality: urine consistency is 
variable from day to day or even from hour to hour in individual men. It is dependent on 
numerous factors both physiological and pathological.  Physiological factors include 
hydration and nutrition status, and pathological conditions include pH, glucose, bilirubin, 
ketone, protein, specific gravity blood, urobilinogen, nitrites, and leucocytes – all reasonably 
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assessable by dipstick. Indeed a potential limitation of this study is that I did not 
systematically examine multiple samples taken from the same patient over time. Such a 
study would however have been complicated due to the requirement for a prostate massage 
prior to each sample collection, which would have been quite difficult to achieve in a 
clinical setting, and outside our ethical approval limitations. Changes in urine composition 
may affect the prostate biomarkers directly, or may interfere in the test results eg the 
presence of a large amount of bacterial cells. Attempting to standardise some of these 
variables, such as pH was not found to be of great benefit in this project. The primary way I 
found that improved the quality and quantity of the prostate RNA biomarkers was by speedy 
processing of the urine, which indeed will pose a great challenge for a urine test to be 
practically used in the primary and secondary care. These difficulties are reflected in the 
PCA3 test that has a limited time from collection to processing, as well as an expensive kit 
to aid preservation of the RNA in urine. For the PCA3 test the patient has to provide 20 to 
30 ml of first catch urine following DRE - giving more then the required 30 ml may 
invalidate the test. The urine must then be kept at 2-8°C or on ice, and then transferred to a 
urine specimen transport tube containing preservation media within four hours of collection 
otherwise the sample is rejected. Shipping arrangements must ensure that the sample arrives 
at an analysis lab within 5 days of collection or it will be rejected (see 
http://www.hologic.com/sites/default/files/) (498) These aspects need to be taken into 
consideration as they have financial implications particularly if the test is to be used on large 
patient numbers for screening.  
The second point is sensitivity. I identified TMPRSS2/ERG gene expression in ~20% of 
clinically benign samples from men that had a normal serum PSA reading suggesting that 
the technique is sensitive, and that these patients probably have low volume clinically 
undetectable disease that was sampled by exosomes, or a larger tumour that does not have an 
associated raised sPSA. Positive TMPRSS2/ERG in urine has been reported to have 94% 
positive predictive value for detection of prostate cancer (187).  
 
 A third point is how does tumour position within the prostate affect sampling? Due to the 
anatomical luminal network of connections within the prostate that connect to the urinary 
tract it is thought that biomaterial from most of the prostate could reach the urine after a 
DRE (581). The DRE technique has been reported to be important in boosting PCa 
biomarkers in the urine (581), however DRE efficiency may be dependent on several 
factors, such as site of tumour within the prostate. It is known that 75% of prostate cancer 
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arises in the peripheral zone, the remaining 20% arising in the transition zone and 5% in the 
central zone. In the clinic, transition and central zone tumours can be missed, as they are 
hard to detect in the biopsy procedure. Theoretically tumours in the central and transition 
zone are more difficult to massage in comparison to peripheral zone disease. For this reason 
the PCA3 test described a particular DRE requirement to depress the surface of the prostate 
by one centimeter aiming to produce pressure in most of prostatic tissue (superficial and 
deep). However it is not known to which extent these tumours are being represented in our 
samples. 
Point four: High grade and advanced disease: Something that has been clearly apparent in 
my clinical experience is that the prostate becomes hardened in advanced disease (T4 
disease). The prostate becomes packed with cancer cells and fixed to the pelvic floor. This 
renders it physically very firm and un-depressable during DRE, thereby reducing the 
effectiveness of the DRE. In addition, biomarker access to the urethra will be affected by 
luminal access, and this maybe curtailed in poorly differentiated/High Gleason tumours 
which can have blind-dended lumen as demonstrated by several studies (502,582). 
Point five: clinical factors affecting DRE efficiency: i) patients can have a large prostate 
with a cancer focus that can be difficult to reach e.g. at the base of the gland, ii) a ‘high 
riding’ prostate, which is an anatomically high prostate that is difficult to reach by digital 
rectal examination; iii) obese patients whose prostate can be difficult to reach, iv) the 
effectiveness of the clinician performing the DRE, a factor not relevant to this study as I 
performed all the DRE and sample collections myself. 
In order to obtain accurate information on the above I suggest for future study that urine 
expression analysis should be examined in patients undergoing radical prostatectomy to 
identify two groups of patients:  i) patients with peripheral disease only and ii) patients with 
anterior disease only. A direct comparison could then be made with exosomal biomarker 
readout, to assess the efficiency of tumour biomarker sampling in cancers from different 
locations.  This would also allow insight into assessment of multifocal disease, and to the 
efficiency of detection of tumours with different Gleason patterns.  
 
To examine the function of a DRE, I examined samples from the same patients with and 
without a DRE. I showed a significant difference in the RNA yields in urine samples taken 
from men pre- and post- DRE which is consistent with other studies (498-501) (Discussed 
further in 3.7.2). However when I examined the difference in RNA yields in two cohorts of 
patients: one with a DRE according to the PCA3 protocol (vigorous 3-swipe massage) (498) 
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and one with a less aggressive DRE using only two swipes, there were no difference in the 
yields or cancer gene expression analysis between the two groups. This suggests that as long 
as a DRE is performed, prostatic secretions including exosomal RNA will be present in the 
urine and perhaps able to represent the prostate entirely.  	
To further examine the use of exosomal material in patients with no DRE compared to DRE, 
I prepared 10 paired pre- and post-DRE samples that in future studies are scheduled to be 
analysed by NanoString for a comparison of PCa biomarkers.  At the time of writing these 
analyses were not available.  
 
As discussed above, the expression data showed that cancer specific genes were not highly 
expressed in samples from men with advanced disease (see tables 4.7, 4.9, 4.10). However, I 
have also shown in this study that exosomal RNA from patients with High-risk disease is 
still detectable in urine, even though it is in smaller amounts, and the expression signature 
was usable in predicting response to hormone treatment. Wilcoxon test analysis comparing 
advanced to non-advanced disease showed that expression of KLK’s as well as PCA3 and 
HOXC6 were not significantly over expressed. However when we compared cancer to 
benign samples these transcripts were significantly overexpressed in cancer samples as 
expected (tables 4.11, 4.12).  
 
 
5.6 PCa Clinical Groups and subgroups 
 
The lack of understanding of the disease’s natural history on an individual basis is reflected 
in the complexity of prostate cancer management, which poses a real clinical challenge. The 
intricacies of the NICE risk stratification can change depending on the understanding we 
gain about the disease through clinical experience and research; for example the NICE 
Guidelines for PCa risk stratification in 2012 changed to upgrade T2c from the Intermediate 
to the High-risk group. A systematic literature review in 2012 (583) showed that there are 
some further clinical subcategories that should be taken into consideration, such as i) the 
creation of a very-low risk category; ii) splitting the Intermediate-risk into low-Intermediate 
- and high-Intermediate risk groups; and iii) further clarification of the boundary between 
Intermediate and High-risk disease.  Rodrigues also suggested that more prognostic 
parameters should be taken into consideration when it comes to assessing risk of metastasis 
and prognosis, such as percentage of positive-core biopsies and evidence of perineural 
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metastasis. In this study we adopted the NICE stratification criteria for PCa to facilitate our 
data analysis and to assess the differential gene expression between different risk groups. 
However in addition I felt that further sub-classification of the risk groups see paragraph 
3.4.2) was necessary.  However due to low numbers of patients in some of the subcategories 
we have mainly used subclassification in the Intermediate risk and High risk groups in order 
to gain in-depth information and precise correlation of our biomarkers for diagnostic and 
prognostic accuracy. Hence for the LPD analyses (paragraph 4.3.2.5) I subdivided the 
Intermediate risk group into Intermediate (G3+4 PSA 10-20 and T2c) and high-Intermediate 
(G4+3 PSA 10-20 and T2c) as my clinical experience has led me to expect these 2 
subgroups of patients to behave differently and have different prognoses (defined as I and 
IH respectively).  The high-Intermediate (G4+3) have more of the less-differentiated cancer 
cells and behave more aggressively than the low-Intermediate (G3+4) who in turn have 
more of the relatively well-differentiated cells. However, our data analysis showed no 
significant difference between the two sub-groups in term of gene expression which could 
be due to the low number of samples in the IH group (only 18 samples) vs I group (53 
samples) as represented in table 4.6.  
I subdivided the High-risk group into i) High risk (PSA>20 and <100 or G8-10 or T2c and 
above) and iii) Advanced (T3-4, G8-10 PSA>100 and patients with PSA >100 and clinically 
T3-4 with no available histology). The reasons for this are: i) it is well known that patients 
with PSA>100 have 100 % risk of cancer metastasis as reported in the literature (509), and so 
should be differentiated from the high risk group with lower PSAs; ii) some of these patients 
get diagnosed based on clinical findings ie PSA>100 and clinically T3-4 without 
histological evidence (for further explanation see paragraph 3.4.2). While these subgroups 
would be expected to behave clinically differently, all these patients would be offered 
clinically the same treatment (hormone deprivation therapy). For this reason NICE does not 
separate them. 
 
Due to a lack of funding for expression analysis at the start of the project (these funds are 
available now and further analysis will taking place), we did not include the most clinically 
challenging group of patients. These patients present with a high PSA, but are negative for 
PCa on biopsy analysis. This group makes up 50 to 70% of patients in the US, (135,584) and 
approximately 30% of NNUH patients at the PSA clinic. There is a real clinical challenge in 
their management, particularly in the presence of continued rising PSA levels, as we know 
that 10-20% of these patients may still have cancer that was missed by the initial biopsy. 
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Much of this undiagnosed PCa will probably have only a limited clinical impact (585) while 
some can be aggressive disease (15), hence urologists have a low threshold for repeating a 
biopsy in cases of rising PSA. Rising or persistently raised PSA creates great anxiety for the 
patients and their clinicians, even though PSA cut-off is subjective. 10% of patients with a 
PSA below one can still have cancer (ERSPC Study), and most of these patients require 
routine follow up with serial PSA testing and repeat biopsies which carry significant 
morbidity. In the presence of negative serial biopsies we sometimes accept that the PSA 
level is high for these patients – PSA can be raised for an unknown reason, can reflect the 
prostate size, or is due to inflammatory changes (586) -  as long as it remains stable without 
substantial variation (587).  All these dilemmas created by PSA testing also have a significant 
financial side-effect on the health service, and stress on large numbers of men. For these 
reasons we will include this group of patients in the next set of analysis (samples from this 
group of patients have been collected and stored ready for analysis). Indeed this project, 
which I formulated during my clinical fellowship, is being used as the basis for a PhD 
project for a current clinical fellow. Specifically urine that I collected from men with raised 
PSA but negative for cancer on biopsy is being used to assess whether molecular approaches 
can be used to detect men who subsequently develop cancer.  
 
Another interesting group of patients to study would be to follow-up patients found with 
High-Grade PIN and/or atypia in their initial biopsy, to identify whether our gene expression 
can predict progression in this group of patients. Again these patients will normally be 
candidates for repeat biopsies under current clinical practice. 
The percentage of positive cores was not taken into consideration in these analyses (data was 
recorded and is available) as I thought it was likely to complicate the analyses.  However, 
further analysis will take place in the future when the full data analyses has been completed, 
and, biopsy cores as well as other variables will be considered e.g. disease percentage, and 
Gleason grade found in the radical prostatectomy patients (Data also recorded).  
 
Adding in further clinical data, combined with sub-division of patient subgroups should not 
only help us to study our gene expression signatures more accurately to provide a superior 
prognostic value, but may also be useful in prediction to treatment response.   
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5.7 Benign control group 
 
Choosing a benign control group was very challenging due to the fact that there is no 
guarantee that any patient with a normal PSA will not have prostate cancer. The PCPT trial 
showed that there is 6.6% prevalence of PCa in patients with PSA<0.5ng/ml, 10.1% in PSA 
0.6-1ng/ml, 17% in PSA 1.1-2 ng/ml, 23.9% in PSA 2.1-3 and 26.9% in PSA 3.1-4 ng/ml 
(588,589).  Very young patients in their early adulthood may have been a good alternative, 
but their recruitment is not ethical, and also a comparison of their gene expression with men 
in their 60s may not be appropriate, as it would not reflect the benign changes that the 
prostate develops in older men. Similarly as stated above, patients with a raised PSA and 
negative biopsy cannot be guaranteed to be cancer free, as at least 23% of these would still 
have PCa (134,590). However, it should be noted that both the above groups of clinically 
benign patients are unlikely to have significant disease that would require treatment. For 
these reasons I opted to use two sub-groups of men with clinically benign prostate as non-
cancer controls: i) those men with a PSA normal for age, and ii) men with a PSA below 
1ng/ml.  
I followed up some of these patients by checking the results of their PSA for a period of two 
years to identify subjects that had rising PSA indicating possible PCa, but none were found. 
However, it is worth noting that a proportion of these patients, particularly the younger ones 
did not have further PSA testing suggesting they are asymptomatic for prostate cancer and 
therefore had no clinical indication for further testing. Looking at the literature I found that 
different strategies for identifying a benign group have been adopted by different authors. 
For example a PCA3 study, used patients below the age of 45 with no known prostate cancer 
risk factors (498). It is however not clear whether these men had a PSA check at all. Another 
study, used patients with a benign histology on TRUS biopsy (206) while others used female 
and young men (age<27) (591) and some used men with a PSA below one. This shows that 
there isn’t a well-defined benign control group that could be used across the board. For this 
reason different authors choose what is thought to be most appropriate.  
5.8 NanoString Expression analysis 
 
The large number of samples generated by this study, and the 50 gene probes that had been 
chosen for analysis meant that a cost effective but reliable means of analysis needed to be 
found. Four available options were considered:  
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• TaqMan quantitative RT-PCR gene expression analysis: this is a well-validated 
method of gene expression analysis but has negative aspects which include i) expense: cost 
for 50 gene probes was ~£110 per sample, a total of £21,300 for 193 samples, ii) time 
efficiency: sample preparation for the procedure is time consuming and prone to operator 
error. An alternative to setting up each assay by hand would be to use custom made TaqMan 
microfluidic cards, however, this would be even more expensive, and the card designs come 
with restrictions on the number of genes that can be interrogated, namely, combinations of 
12, 24, 32 genes only.  It would not be possible to purchase cards with 50 gene probes on 
them. This meant that number of genes would need to be compromised.  
• Next Generation sequencing: is a good method for gene expression analysis due to 
the fact that it will analyse the whole transcriptome in order to identify the genes in question. 
However it was again thought not to be cost effective - around £1,340 per sample. 
Bioinformatics analysis is also time consuming because of the amount of data generated  -  
approximately 30 million reads per sample. 
• Microarray analysis: a good tool for evaluating differential gene expression, but 
again costs are around £450 per array, and the data from ~30,000 gene probes was 
considered to be more than we needed for this pilot study. 
• NanoString: we have opted to use NanoString for several reasons including time 
efficiency i)- a large numbers of samples and genes can be analysed by NanoString inc. in a 
very short period of time, ii) it is a cost effective assay for large numbers of samples and 
multi-gene analysis in comparison to TaqMan, microarrays and next generation sequencing 
(NanoString £125 per sample inc labour, TaqMan Cards £110 plus labour, Microarray £450 
per array, Next Generation sequencing £1,340) iii) gene expression data (including PCa 
analysis) has been reported to be of good quality (592,593), iv) NanoString is now in use for 
the FDA approved Prosigna test for breast cancer. 
 
As NanoString is designed for RNA analysis, and we had Nugen Ovation WTA2 amplified 
cDNA, which had never before been analysed by NanoString, I performed a pilot test of 12 
samples using the off-the-shelf nCounter human cancer 236-gene reference assay. These 
cDNA samples worked very well in the assay, and expression of 189 out of 236 genes were 
detectable. In this pilot, 20 genes showed differential expression between cancer and non-
cancer samples including, AR, BM11, BRAF, CCND2, CDKN1A, DEK, ERBB4, ETV5, 
HDAC1, IFNGR1, MTA1, NRAS, PLG, PRKAR1A, PTEN, RAF1, RRM1, SCD1, STAT3. 
(figure 4.7) Some of these genes are known to be expressed in prostate cancer such as AR, 
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BRAF, and RAF. It is worth noting that this data was normalised to internal controls probes 
such as GAPDH (cell house keeper not exosomes). As discussed below, exosomal RNA in 
urine can come from a number of cell sources. Thus the expression of cancer markers is 
likely to be improved by adjusting them to be relative to a prostate tissue specific probe such 
as KLK2, or KLK3 – the latter as used by the PCA3 test (498).  However, KLK probes were 
not present on the nCounter human cancer assay, and therefore full expression analysis was 
not possible. The nCounter analysis did enable me to determine that amplified cDNA from 
urine exosomal RNA samples was adequate for analysis by NanoString, and that a wide 
range of transcripts were detectable in our samples. 
These pilot analyses highlighted the need for a normalisation gene: Urinary exosomes are 
expected to originate from a number of cellular sources besides PCa itself, these include: 
prostate stromal tissue, immune cells, bladder, urothelium and kidney. Thus normalisation of 
the expression data relative to prostate or PCa is critical to fully understand the data. KLK2 
and KLK3 (594,595) have been used as their expression is relatively even between normal 
prostate and PCa. Use of an appropriate normalising transcript will be particularly useful for 
examination of high-grade disease where exosomal representation may be compromised as 
discussed above. Groskopf et al., (498) has shown that normalisation of PCA3 to KLK3 
((PCA3/KLK3)x1000) has improved PCA3 test diagnostic capability. The ratio being 
significantly higher in cancer samples in comparison to benign. It has also improved the 
specificity of the test, and similar finding have been reported by other authors (497). The 
data in the study presented here has not been normalised to KLK2 or 3, but this will take 
place in the larger project. 
 
NanoString expression analysis (50 gene-transcript probes. See Chapter One Table 1.4 for 
gene information summary) of exosomal cDNAs identified genes that were significantly up 
regulated in cancer patients, mainly in the High risk and Advanced risk group (Cluster A). 
These included Kallikreins (2, 3 and 4), MMP26, STEAP2, STEAP4, ARexons4_8, 
AR_truncation_exon, SERPINB5/Maspin, PPAP2A, CLU, OR52A2_PSGR and CDC2 which 
are expected to be upregulated in prostate cancer and in particular with high grade disease in 
consistence with a study at the cellular level (Table 4.5 Chapter 4). B2M was initially chosen 
as a house-keeping gene as some studies reported it to have an even expression between 
bladder, blood, and prostate (493,496) and was used as a housekeeping gene on a study on 
urine sediment (596) although other studies reported it to be up regulated in prostate cancer 
in particular with high grade disease with distant metastasis (493,597) which is in 
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consistence with our results particularly as most of the samples in this set are from the 
Advanced risk group.  In contrast SPINK1 and Hepsin (HPN) which are known to be up-
regulated in prostate cancer tissue (see paragraph 1.9) were found to be down regulated in 
our data although the PCA analysis did not directly compare cancer vs benign disease 
(Cluster A vs all data). In this study HPRT was selected as a housekeeping gene as several 
studies had shown similar expression of this gene in bladder, blood, and the prostate, tissue 
and it has been frequently used as in multi-gene expression profiling of prostate cancers (See 
paragraph 1.9.2). However, in these analyses HPRT was upregulated in exosomal RNA in 
cluster A (High risk and Advanced risk group). Our results are in consistant with several 
studies that have shown that mutations in the X-linked HPRT gene are associated with 
metastatic prostate cancer 	
(107,598,599). 
 
UPK2 and SLC12A1 were used as bladder and kidney controls respectively although they 
were also differentially expressed in this analysis (Down-regulated).  
 
Latent Process Decomposition (LPD) analysis was then utilised to look at the data in a 
different way. LPD clusters data in an unsupervised, probabilistic approach. LPD analysis 
was applied to all the samples except those identified in cluster B due to their low mRNA 
yields (6 samples). We identified 4 statistically different groups: LPD1 that predominantly 
consisted of samples in the High-risk and Advanced risk groups and was similar to cluster A 
identified in the PCA analysis; LPD2 contained patients in the Benign risk group, LPD3 had 
patients in the Intermediate and High-risk group; and LPD 4 which mainly contained cancer 
patients predominantly in the Intermediate risk group as shown in table 4.6.  
 
The expression of the genes identified in LPD1 (High risk/Advanced patients) contrasted to 
those highlighted by the PCA analysis. Interestingly all the prostate and prostate cancer 
associated genes including KLK2, KLK3, KLK4, STEAP2, PSMA, PPAP2A were all 
relatively underexpressed compared to the other LPD groups, while the bladder and kidney 
control genes UPK2, SLC12A1 and SPINK1 were all overexpressed. A possible 
interpretation of this result is the difficulty in efficiently massaging the prostate in men with 
advanced tumours and the distorted intraprostatic anatomy that is likely to prevent PCa 
exosomes from reaching the urethra. This can lead to a relative increase in the representation 
of markers from the kidney and bladder as discussed in paragraph 4.3.2.5.  Although 
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SPINK1 is known to be overexpressed in a proportion of prostate cancer it is also known to 
be expressed in the normal kidney, which may explain its overexpression.  
AMACR, PCA3, HOXC6, TORD, ERG, PSMA and IMPDH2 were identified as being 
overexpressed in LPD3, a group that predominantly contained Intermediate risk patients. 
The expression of these genes is known to be associated with prostate cancer as discussed 
previously. Interestingly bladder and renal genes do not appear to be overexpressed which is 
in agreement with the discussion above regarding DRE efficiency and intraprostatic 
anatomical distortion, which is expected to be at a lesser extent in this group of patients.  
The non-parametric rank Wilcoxon test results were in agreement with the LPD findings in 
terms of gene expression. A comparison between cancer and benign risk groups identified 
15 genes that looked promising diagnostically as they appeared to be upregulated in cancer 
including; ERG, PCA3, DLX1, HOXC6, HOXC4, HPN, SUL1A1, TDRD, GAPDH, CLU, 
and CDKN3 (Table 4.12) and two downreguated genes including HPRT and PPAP2A. These 
were reassuring results particularly as PCA3, ERG, TDRD, HOXC6, HOXC4 and DLX1 are 
well known gene transcripts associated with prostate cancer, particularly in urine sediments 
(514,517). In contrast, HPRT was again found to be underexpressed in agreement with our 
PCA analysis discussed above (which may be due to samples selected by the different 
analysis ie PCA selected mainly high risk sample while Wilcoxon test compared cancer to 
benign). 17 prognostic genes were identified as significantly differentially expressed in High 
risk and Advanced disease in comparison to the Lower grade disease and Benign (table 
4.11). Again these results are in agreement with the LPD analysis were we find that the 
prostate cancer genes are mainly under expressed including AR, KLK’s and STEAP2, and the 
bladder and renal control genes are overexpressed. 21 genes were significantly differentially 
expressed in Advanced in comparison to the Benign control group (see section 4.3.2.6). 
Again, here the prognostic genes are in consistence with our previous results (LPD1 
analysis) and included SPINK1, KLK2, 3 and 4, SLC12A1, STEAP2 and 4.  
The data from these analyses has created a solid ground for further analysis, which will be 
performed on the planned bigger project. In these future analyses, transcript expression 
patterns will be integrated with clinical parameters in order to maximise performance in 
terms of diagnostic and prognostic accuracy. The Prostate Cancer Prevention Trial Risk 
Calculator (PCPTRC) uses a multimodal risk assessment score to predict risk on an 
individual basis; parameters include PSA, DRE, age, family history, and previous biopsy 
information (600,601). A recent study showed a higher detection rate of clinically 
significant PCa was achievable when combining the clinical risk assessment score (ie PSA 
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Density, DRE, age, family history) with a two-gene risk score for whole urine expression 
levels of DLX1 and HOXC6. Inclusion of the expression data significantly outperformed the 
PCPTRC on its own and improved the diagnosis and management of PCa patients (517). 
Van Neste found that the PSA Density (PSAD) PSA ng/ml divided by prostate volume in 
gram) was an important factor. It is known that prostate cancer cells do not secrete more 
PSA relatively to normal cells (594,595), and it is disruption of the basement membrane in a 
cancerous prostate that enables more PSA to enter the circulation system leading to an 
increase in the PSA level. Adjusting sPSA relative to the prostate volume (471,602) in 
several studies has shown a significant improvement in the prediction of TRUS biopsy 
results in comparison to sPSA alone, thus improving the diagnostic accuracy (603-605).  
PSA volume data has not yet been obtained for our cohort, but will be used in the larger 
study. 
 
Patients with metastatic disease are primarily treated with hormone deprivation therapy. 
However, the cancer invariably becomes resistant to treatment leading to disease progression 
and eventualy death. Treatment of patients with metastatic prostate cancer is clinically very 
challenging for a number of reasons, which include: 1) the variability in patient response to 
hormone treatment ie time prior to relapse and becoming castrate resistant, 2) the 
detrimental effects of hormone manipulation therapy on patients, 3) the myriad new 
treatment options available for castrate resistant patients. 
 
The response to hormone manipulation/ablation therapy is highly variable (discussed in 
paragraph 4.4). Some men fail to respond to treatment while others relapse early i.e. within 6 
months, the majority relapse within 18 months (late relapse) and the rest respond well to the 
treatment often taking several years before relapsing (delayed relapse). Early identification 
of patients who will have a poor response will provide a clinical opportunity to offer them a 
different treatment approach that may perhaps improve their prognosis. However there is no 
means currently to identify such patients except for when they exhibit biochemical 
progression with rising serum PSA, or become clinically symptomatic, in which case they 
get offered a different treatment strategy. This regime however goes hand in hand with a 
number of detrimental effects (606) such as bone loss (607) increased obesity, decreased 
insulin sensitivity increasing the incidence of diabetes, adversely altered lipid profiles 
leading to cardiovascular disease (608,609) and an increased rate of heart attacks (610). For 
these reasons offering hormone manipulation requires a lot of clinical consideration 
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particularly as most of the patients requiring such treatment are elderly patients and such 
treatment could overall be detrimental rather than beneficial (611). 
 
 
Due to ever-emerging new treatments or second line therapies for patients with advanced 
metastatic cancer in the past decade, the treatment of men with castrate resistant prostate 
cancer is dramatically changing. Prior to 2004, the only treatment option for these patients 
was medical or surgical castration then palliation. Since then several chemotherapy 
treatments have emerged starting with docetaxel (612,613) which has shown to improve 
survival for these patients. This was followed by five additional agents (FDA-approved) 
including new hormonal agents targeting the androgen receptor (AR) such as the AR 
antagonist Enzalutamide, agents to inhibit androgen biosynthesis such as Abiraterone, two 
agents designed specifically to affect the androgen axis (614,615) sipuleucel-T, which 
stimulates the immune system (616) cabazitaxel chemotherapeutic agent (617) and radium-
223, a radionuclide therapy (618).  Other treatments include targeted therapies such as the 
PI3K inhibitor BKM120 and an Akt inhibitor AZD5363 (619-621) all of which are still 
under clinical trials.  Therefore it is crucially important to be able to identify patients that 
would benefit from these expensive treatments and those that will not.  While these agents 
have been tested in multiple disease states of castration resistant patients to determine if or 
when patients might benefit, the answer at present to this question is still not available. 
Identification of prognostic indicators capable of predicting response to hormone 
manipulation and to the above list of alternative treatments is very important and would have 
great clinical impact in managing these patients.  In addition, the only current clinically 
available means to diagnose metastasis is by imaging. Markers that are being put forward 
include circulating tumour cells and urine bone degradation markers, both of which are still 
under research (622), A test for metastasis per se could radically alter patient treatment. The 
data within this thesis suggests that exosomal RNA may have the potential to overcome 
these issues, particularly as studies have shown a role fro exosomes in aiding metastasis 
(623) 
 
To my knowledge exosomal gene expression analysis on patients treated with hormone 
manipulation to identify response to treatment has not been done before. In the current 
study, all patients treated with hormone ablation had their urine sample analysed and 
processed for gene expression analysis on the same day that they later started treatment. Any 
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patient presenting with clinically advanced PCa ie PSA>60 and a clinically malignant 
prostate T3/T4 on biopsy (if considered not suitable for other treatment strategy) was started 
on hormone deprivation therapy on the day of presentation. A 3-monthly follow up was 
arranged for all patients, with repeat PSA testing as an indication of progression. 40 patients 
(17 Advanced and 23 High-risk) that had local (21 patients) and distant metastasis (19 
patients) were treated with hormone manipulation in this cohort. LHRH agonists or 
antagonists such as Goserelin or Leuprorelin acetate. 8 patients (20%) failed to respond to 
initial treatment with their PSA remaining above 60ng/µl, 7 of which had extensive 
widespread bone metastasis (as per their bone scan results) none of the patients had visceral 
metastasis. 5 patients had early relapse (PSA reduced to normal levels but rose again within 
6 months). These 5 patients as well as the 8 who failed the initial treatment were 
subsequently given maximum androgen blockage by adding anti-androgens, followed by   
PSA follow up on a 3 monthly basis to detect whether they progress and become castrate 
resistant. 
Gene expression analysis identified two genes (SERPINB5/Maspin and HPRT) that 
differentiated between two groups of patients: i) those who failed initial response (low 
expression values) and ii) those with a good initial response. Maspin is known as a class II 
tumour suppressor, which specifically inhibits uPA (urokinase-type plasminogen activator) 
that promotes tumour growth by osteolysis and angiogenesis leading to cancer growth and 
bone metastasis. uPA also affects expression of interferon regulatory factor 6 (IRF6) (302), 
β1-integrin (303,304) collagen I (305) and glutathione-S-transferase (GST) (306); all of 
which play an important role in cancer growth and metastasis. Maspin is known to be up-
regulated in premalignant prostate cancer epithelial cells (309) and constantly down-
regulated at the critical transition from noninvasive, low-grade to highly invasive, high-
grade prostate cancer (309). To my knowledge Maspin exosomal expression has not been 
reported in the literature however our results suggest it is underexpressed in patients with 
poor response to hormonal treatment in comparison to patients with a good response. LPD 
analysis identified Maspin as overexpressed in Intermediate disease (table 4.10). In the LPD 
analysis Maspin was not identified as underexpressed in the advanced samples, however the 
LPD group confined mixture of patients with different response to treatment.  
HPRT (Hypoxanthine-guanine phosphoribosyltransferase 1). This is an established 
housekeeping gene for PCa tissue that is frequently used in multi-gene expression profiling 
of prostate cancer (492,493). However its use as a housekeeping gene has been questioned 
as some studies have implicated it as tumour suppressor gene after finding mutations in this 
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gene that lead to cancer progression and metastasis (107,598,624). Although its role in 
exosomes is not yet known, our results may suggest that it has a role in castrate resistant 
cancer at the exosomal level. Further analysis in a larger number of samples will be required 
in order to validate our finding. On the LPD analysis HPRT was found to be underexpressed 
in the advanced disease group (table 4.13) and was also found to differentiate between 
cancer and benign disease, although KLK3 normalisation was not applied to these data to 
obtain a clear picture of gene expression representation. 
 
Three gene probes were identified that were differentially expressed in early development of 
castration resistance patients (paragraph 4.4.2): STEAP4, ARexons4_8 and NAALAD2, (not 
predicted by HPRT and Maspin which were associated with failure to initial response to 
treatment). The down-regulation of these genes predicted development of castration 
resistance and relative over-expression was associated with a prolonged response to 
hormone therapy (See paragraph 4.4.2 for further explanations). The Kaplan Meier (KM) 
estimator test to evaluate prognosis showed an 85% chance of survival at 24 months in 
patients with gene overexpression in comparison to 45% in patients with downregulation.  
STEAP4 is known as a tumour suppressor gene, its encoded protein inhibits independent cell 
growth through regulation of phospho-Y397 on focal adhesion kinase (FAK). In androgen-
independent prostate cancer cells, some studies reported that that CpG sequences of the 
STEAP4 promoter region were frequently methylated, and that demethylation treatment 
induced the expression of STEAP4 in this cell line. This was in contrast with the androgen-
dependent prostate cancer cell line LNCaP in which no methylation was reported (395). Our 
results are in general agreement in that STEAP4 underexpression was found in patients with 
poor response to hormone manipulation treatment and early relapse (castrate resistant) in 
comparison to castrate sensitive samples. 
The androgen receptor is known to be associated with castration resistant prostate cancer 
(hormone insensitivity). AR plays an essential role in prostate cancer from cell viability to 
proliferation and invasion (374-376,384,385). Interestingly however its expression in 
NanoString analysis of exosomal cDNA was found to be down-regulated at the exosomal 
level in patients with poor response to hormone treatment, and relatively over-expressed in 
those with good response. This is contradictory to the reports documented on cellular RNA. 
Its expression in exosomes is not documented in the literature and further investigations are 
required.  
Two AR probes were included in our analyses however while both probes gave a range of 
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signal strengths (ie appeared to be working), only one of them was associated with castration 
resistant PCa. This highlights the importance of targeting known specific transcript splice 
variants in expression analyses. It is well documented that castrate resistant PCa remains 
driven by AR signaling which remains activated through various mechanisms; one of which 
is AR transcript splicing resulting in shortened AR isoforms which mainly affect the dual-
function COOH-terminal ligand-binding domain/AF-2 (AR is a protein with an NH2-
terminal (NTD) transcriptional activation domain, a central DNA-binding domain (DBD), 
and a dual-function COOH-terminal ligand-binding domain) (385,625,626). 
These shortened AR isoforms are constitutively active and can support various features of 
the CRPCa phenotype that play an important role in disease progression. However some of 
these AR variants have also been reported in benign cells as well as in androgen naïve PCa 
(385,625,626). Some studies have reported several AR splice variants (384,385) (627) that 
increase in expression during progression to castrate resistant PCa (384). Each of these AR 
variants has been associated with distinctive functional properties, which are thought to 
synergise to form a castration-resistant phenotype independent of the full-length AR. A 
recent study reported a set of genes that was regulated uniquely by AR variants, but not by 
full-length AR in the absence of androgen, some of which were directly modulated by the 
AR-variants (628). This study also reports a difference in the AR variant signature between 
benign, malignant and metastatic castrate resistant prostate cancer. Some studies have 
reported a correlation between AR variant and response to chemotherapy. Ome study (629) 
reported that men in which AR-V7 was detected in circulating tumour cells had a better 
response to taxanes in comparison to enzalutamide and abiraterone therapy whereas AR-V7 
negative men all those treatments had comparable efficacy. 
NAALADL2 is known to be over-expressed in hormone sensitive prostate cancer. Its over-
expression has also been shown to predict poor survival following radical surgical treatment 
for PCa. It is known to promote cancer progression by endorsing adhesion to extracellular 
matrix proteins, migration and invasion by regulating the levels of Ser133 phosphorylated 
C-AMP-binding protein (CREB) (476). However, its expression in castrate resistant cancer 
cells is not well documented nor is its correlation to androgen receptor expression. Our 
findings suggest that its expression is under-regulated in castrate resistant PCa perhaps due 
to AR signalling changes or other unknown factors. 
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5.9 Sequencing of Exosomal RNA 
 
There is a lack of publications on exosomal RNA expression, particularly prostate-derived 
exosomes. This meant that our choice of gene probes for this study had to be based on 
differentially expressed genes in prostate cancer tissue as compared to normal prostate 
tissue. However my study was based on exosome derived RNA rather than prostate tissue, 
and so it was decided that the range of RNA species present in urinary exosomes had to be 
explored to attain new diagnostic and prognostic biomarkers, and also provide a better 
understanding of the role of these microvesicles in PCa.  
Due to the improvement in exosomal RNA yields it was possible to carry out sequencing 
analysis on 100ng RNA without resorting to sequencing amplified cDNA samples. It was 
thought that sequencing amplified cDNA samples would possibly cause some doubt on the 
final data, however one could argue that sequencing amplified cDNA could be better for 
probe selection for NanoString gene analysis, which is, after all, performed on amplified 
cDNA. As there were no other published prostate exosomal sequences available for 
comparison, we opted to analyse the native RNA, using Next Generation Sequencing (NGS) 
to assess 18 exosomal RNA samples, comparing High- Intermediate- and Benign samples. 
 
The analysis identified 45 genes that were significantly differentially expressed between 
benign and cancer samples (figure 4.18). There is little in term of match between the gene 
probes chosen for the NanoString analysis and the NGS except for the overexpression of 
PCA3 and DLX1. This is not surprising, 1st as the gene choice for the Nanostring analysis 
was based on prostate tissue expression patterns rather then exosomal mRNA and 2nd cDNA 
was used in NanoString compared to mRNA in the NGS.  Reassuringly PCA3 and DLX1 are 
known to be overexpressed in cancer, in particular, PCA3 that has been reported to be over 
expressed in exosomal RNA from prostate cancer patients by several authors (576,577) 
which to some extent validate our data.  
DLX1 up-regulation in urine is known to be associated with prostate cancer, and aggressive 
disease in particularly as reported by several authors (517).  One study has identified DLX1 
as a promising biomarker for the diagnosis of prostate cancer, on an expression profiling on 
urine sediments (514).  
 
Of the 45 genes identified by the NGS, 28 are up regulated and 17 down regulated in cancer 
showing a significant linear trend in association with cancer risk (Table 4.17). Of the up 
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regulated are the apoptotic genes BIK and AATF which are known to be significantly over 
expressed in many solid tumours such as lung, breast, colon and prostate (519,520). BIK 
apoptotic function was reported in both hormone sensitive and castrate resistant cells, and it 
was thought that its induction could have therapeutic potential (522). ATTF is known for its 
role in cell cycle regulation and growth arrest by apoptosis via interaction with Dlk/ZIP 
kinase (524). Its expression in prostate cancer was reported to be associated with higher 
mortality in patients on ADT (526) (see 4.5.1 for further explanations).	Although both these 
proteins appear to work in opposition to each other they were both up-regulated in cancer 
exosomal samples. However, unlike BIK, AATF had a trend with cancer stage (table 4.17).  
Other upregulated genes included ACTR5 that plays a role in cell cycle progression and 
nuclear co-activation, its overexpression has been documented in LNCaP Cells (529,530). 
Genes that play a role in tumour proliferation and progression such as HPSE2 (remodelling 
of the extracellular matrix and cell surface promoting disease progression and metastasis 
(533,537)), NUDT6 (541) and ST6GALNAC1 (545).  
 
MMP25 was identified to link positively to Gleason score (table 4.17). It is one of a large 
family of MMP’s that promote cancer progression and metastasis by its proteolytic function 
leading to degradation of the basement membrane and extracellular matrix, as well as 
induction of the epithelial-mesenchymal transition, neovascularisation, and regulation of 
growth factor and chemokine activity (630). Althought its expression has not been 
documented in urine, we demonstrated that MMP25 and MMP26 are overexpressed in 
exosomal RNA, in the NanoString analysis (MMP26) (table 4.5) and the third generation 
sequencing (MMP25). These finding are in agreement with several studies at cellular level in 
particular their correlation to gleason score (511,631).  
 
Inflammation is known to induced carcinogenesis in several epithelial organs (632,633) as 
for example Helicobacter Pylori infection induced gastric cancer and hepatitis incuding 
hepatocellular carcinoma. Similarly infection induced stimuli are reported to cause prostate 
cancer through prolonged chronic inflammation that is the primary driver of this effect 
(447,449,634) by inducing tumour growth, angiogenesis and metastasis although the 
mechanism of this process is still not fully understood (3). 
The PCPT (Prostate Cancer Prevention Trial) reported a link between inflammation and 
prostate cancer particularly high grade disease, where they showed that patients with chronic 
prostatitis has 1.79 time the odds in developing high grade disease (635). Other studies has 
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shown similar finding, for example, in a study on 71 patients on ADT (androgen 
depreviation therapy) (636) it was shown that tumour associated macrophage (TAM) 
infiltration detected on TRUS biopsy was associated with high grade disease, high clinical 
stage and in patients with biochemical failure (failed to respond to treatment with rising 
PSA), these macrophages are thought to be a part of inflammatory circuit that promote 
tumour progression. Similar finding was reported by other authors (637) (638). Another 
study demonstrated that serum elevation of IL6 is associated with aggressive prostate cancer 
and that it plays a role in the development of castration resistance in patients on ADT 
through activation of AR by ligand-independent mechanisms (639). Similarly on a mouse 
model it was shown that infection induced chronic inflammation in the prostate is associated 
with increased cell proliferation and reduced AR and Hmebox1 expression (640). These 
chronic inflammation lead to acceleration of prostate cancer progression by conversion of 
basal cells into luminal cells and disruption of the basal cell layer (641). Thus multiple trials 
on immunotherapy for PCa has taken place some showing promising results such as the 
Sipuleucel-T trial which showed an overall survival advantage in castration resistant patients 
(642), although it thought that immunotherapy in the treatment of PCa in general may not be 
overall very useful as PCa is commonly diagnosed late in life, where age-related decline in 
immune response is common (643). Exososomes are known to promote tumour metastasis 
through several mechanisms, one of which is impairment of the immune function. Some 
studies, for example, determined that prostate cancer derived exosomes impair lymphocyte 
cytotoxic function and promote tumour excape by down-regulating the activating receptor 
NKG2D on natural killer cells and CD8+ T cells (644). To date prostate cancer derived 
exosome effect on the immune system and tumerogenicity is still under studied, nevertheless 
our third generation sequencing has identified numbers of genes that may have baring on 
immune including the downregulated genes; HMBOX1which is known for its inhibition of 
the NK cells activity (560), ERMP1 that has been identified as lung tumour marker (645). 
Endoplasmic reticulum plays an important role in the immune response, their chaperones 
has been shown to have utility in anti-tumour vaccination when purified from tumour tissue 
(646) including ERMP1  (protein) (647), although it expression in prostate cancer exosomes 
has not been previously reported. Other down regulated genes includes KNTC1. Up 
regulated genes, include PRR5L (CD56 NK cells.), PLCB2 (Expressed by Blood cells, 
myeloid, monocytes, NKs, CD4, CD8 T-cells), NLRP3 (Negative regulation of NF-kappaB 
transcription factor activity and interleukin-1 beta production), CLIC2 (CD31), CKAP2L and 
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ABCB9 (CD71) and RP9 (B cells) (as presented in table 4.17). The function of these genes 
has not been previously reported in prostate cancer and is an avenue for further research. 
 
 
5.10 Future Work 
 
To validate our data, further gene expression analysis is planned on another 400 samples, 
and an addition of a further 117 gene probes to the 50 genes used in the present analysis. 
These additional gene probes have been suggested by further literature research and personal 
experience of members of the Movember consortium. Future work will also include selected 
genes from the exosomal RNA Next Generation Sequencing data discussed above.  
In addition to this, various whole urine aliquots and biological fractions extracted from the 
samples that I have collected are being analysed by members of the Movember GAP1 Urine 
Biomarker consortium. This is an international consortium examining urine biomarkers for 
prostate cancer, involving 11 teams in 7 different countries, and set up and run from UEA. 
Analyses will consist of Mass Spectrometry, ELISA for 11 different proteins, DNA-
methylation analysis, metabolite analysis, and expression analysis for cell and exosomal 
RNA. Collation of the data and its meta-analysis will be undertaken later this year. These 
analyses will look for the best combination of markers within urine for PCa diagnosis and 
prognosis, optimising the opportunities of producing a successful urine test for PCa.  
The initial study period has been extended, and sample collection extended to 1200 samples 
in order to improve the chance of statistically significant results. As well as the urine 
samples collected from the NNUH, further samples are being collected from 5 other cohorts 
from 4 different nations.  This should enable data to be validated in samples from different 
populations with a variety of diet and life styles. I have also arranged ethical approval for 
extended patient follow up (up to 5 years). 
In order to ascertain whether the exosomal transcript expression data truly represents the 
prostate as a whole and can outperform TRUS biopsy by sampling the multiple cancer foci, 
a comparison of the final histology results in patients undergoing radical prostatectomy is 
planned. Further work should collect the prostate gland volume as documented by a 
histopathologist, along with the percentage of benign and cancer tissue and their volumes, 
and positions within the prostate. This could then be compared to the exosomal RNA 
expression signatures to identify whether, for example, benign prostate hyperplasia has any 
effect, and whether urine biomarker sampling is influenced by tumour size and position, and 
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location in the Transition zone. 
A series of 125 exosomal RNA samples obtained from active surveillance patients at the 
Royal Marsden Hospital is available for study at UEA.  Many of the patients have had serial 
urine sample collections (DRE as per PCA3 protocol), and these samples could be studied to 
identify how accurate our gene set is in identifying cancer progression.  
Clinical follow up is critical to proper disease anlaysis, and the UEA patients, especially 
those treated with hormone manipulation should be followed up for longer periods (up to 5 
years) with serial urine samples to assess the sensitivity of the gene set in predicting late 
progression. Clinical follow up for the benign/no-evidence of PCa men, and patients with 
raised PSA and negative first biopsies will be included in the analyses. A proportion of the 
latter will have second biopsies in which approximately 20% will be found positive for PCa. 
These samples will be extremely useful to confirm the specificity of our gene set for PCa 
detection and to assess whether there is any influence of histologically identified 
inflammatory changes and HG-PIN to the results. 
 
We will also consider using a secondary validation method for a subset by RT-PCR. 
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5.11 Conclusions 
 
The aim of this project was i) to discover a robust set of molecular markers with a superior 
sensitivity and specificity for identifying prostate cancer, superior that is, to the currently 
clinically available tests (PSA, PCA3); ii) to be able to differentiate between aggressive and 
non aggressive disease; iii) to predict which tumours will become aggressive. 
There is a clinical need for a safe screening test for PCa so that patients with aggressive 
disease can be offered further investigations and treatment, and those with indolent disease 
can be reassured and possibly monitored with further urine testing, avoiding invasive 
biopsies as required under current practice. 
A valid set of new biomarkers could revolutionise screening, prognosis, post-treatment 
monitoring, and even prediction of response to treatment, so that patients would be offered 
the best treatment modality earlier on in their journey with PCa. This would enable 
clinicians to optimise prognosis and prevent unnecessary treatments for patients with 
indolent disease, thus preventing exposing them to unnecessary side effect. 
The data that I have strongly indicates that exosomal RNA is a great source of such 
biomarkers. I have demonstrated the presence of PCa specific transcripts such as 
TMPRSS2/ERG, PCA3 and DLX1 in urine exosomal RNA.  Preliminary analysis has found 
clinical structure in the data, and High-risk patients can be identified in unsupervised 
analysis. Most importantly, response to therapy is reflected in even this limited number of 
tested exosomal biomarkers.   Implementation of further probes selected from the exosomal 
RNA sequence data could improve this system even further.  
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Appendix 1 
 
 
 
 
 
 
 
Urine and blood tests for detection of Prostate Cancer 
 
 
Dear Sir 
 
As you will shortly be attending our urology outpatient clinic, I would like to take this 
opportunity to invite you to participate in a research study, which we are conducting in the 
urology department at the Norfolk and Norwich University Hospital NHS Trust in 
combination with the University of East Anglia looking at urine and blood tests for prostate 
disease. 
I would be grateful if you could take the time to read the information sheet provided with 
this letter, which outlines the study’s aims. Further details will be provided on the day of 
your visit and any further questions you would like to ask to help you decide whether or not 
to take part can be answered at that time or by contacting me directly beforehand using the 
contact details on the enclosed information sheet. 
 
Yours sincerely  
 
 
Mr Marcelino Yazbek Hanna 
Chief investigator, MD student and clinical fellow in urology. 
Norfolk and Norwich University Hospital 
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Appendix 2 
 
 
 
Information Sheet                          
 
What is the purpose of the study? 
Currently the only test widely available on the NHS to screen Men for prostate cancer is the 
serum PSA (prostatic specific antigen) blood test. This test is not sensitive or specific for 
prostate cancer which means the level of PSA may rise due to several other conditions 
including benign enlargement of the prostate, infection and several other reasons, leading to 
potentially unnecessary prostate biopsies which carry significant risk to patients health, such 
as severe life threatening infections (sepsis), inflammation, bleeding and retention of urine.  
The purpose of this study is to look in urine and blood for prostate cancer markers in an 
attempt to find a better test for cancer than the one currently available (PSA, as a blood test).  
Some previous studies suggest that this might be possible as prostate tissue including cancer 
cells and microvesicles (small pockets containing cellular material such as RNA, DNA and 
protein that cells exchange for communication) are shed in the urine and blood after prostate 
examination, and by testing these for potential cancer markers there is a possibility of 
finding a new test to diagnose prostate cancer. This study will be undertaken by clinicians at 
the Norfolk and Norwich University Hospital (NNUH) and investigators at the University of 
East Anglia (UEA). 
 
Why have I been invited? 
To achieve our aim we need to collect and test urine and blood from patients with and 
without prostate cancer, so a comparison can be made to evaluate the sensitivity of the 
potential marker in question. 
Now as you are aware your Doctor has referred you for a urological assessment in our 
clinics, this may or may not be due to a prostate concern, but as we need urine and blood 
from patients with and without cancer of the prostate you have been considered for the 
study. 
 
Do I have to take part? 
Participation is optional. This is a pilot study to help develop new tests and as such will not 
benefit you, but may help men in a similar situation to you in the future. 
It is your decision whether to take part or not. When you attend the clinic we will describe 
the study and go through this information sheet with you and any other questions you wish 
to ask. If you wish to take part, we will then ask you to sign a form. You are free to 
withdraw at any time, without giving a reason. A decision not to participate would not affect 
the standard of care you receive. 
 
 
What will happen to me if I take part? 
	 176	
After you have read this information sheet, and gone through it with your consulting doctor 
on the day of your outpatient clinic and all your questions been answered. If you decide to 
take part you will have to sign a consent form, which will also be explained to you in detail. 
You will then have your routine consultation and examination including internal 
examination, which is part of your routine examination in this clinic. For the purpose of this 
study the prostate examination will be systematic rather than random and will include 3 
swipes on each side to enhance cell shedding into the urine, at the end of the clinic you will 
be asked to provide us with a urine sample, which will be used for the purpose of the 
research. This would then be sent off to a laboratory and analysed for cells and biomolecules 
such as DNA, RNA, protein, and metabolites for evidence of tumour cells. The data would 
be anonymised so that people who would be analysing the urine sample would not be able to 
identify any patients who have supplied a urine sample.  
 
In addition, and only with your consent, you will be asked to provide us with some blood 
which will be used for the same purposes as for the urine (as described above). 
 
Will I be paid any expenses? 
Participation for the study is voluntary and as such you will not be paid any reimbursements. 
 
What are the possible disadvantages and risks of taking part? 
There are no potential disadvantages or expected side-effects by taking part in the study as 
all it will involve for you will be the supply of urine and blood samples after a physical 
examination however if you are worried about any issues please feel free to discuss it with 
the doctor who would be taking your consent. 
 
What are the possible benefits of taking part? 
This is an experimental study and as such will not have any obvious immediate benefit for 
you however the data that we would gather may help us in the future to better diagnose the 
patients suspected of prostate cancer and avoid unnecessary prostate biopsies. 
 
Will my taking part in the study be kept confidential? 
All the details about you will be kept confidential and will only be accessible by the research 
team. It is very likely that the results of the study will be published or presented in the future 
in medical journals, however the data will be anonymised so that your confidentiality is not 
breached. 
 
What will happen if I don’t want to carry on with the study? 
Participation for the study is completely voluntary and as such you may withdraw from the 
study at any point without the need to give a reason. This will not affect your routine care or 
any care that you would receive before, during or after your hospital stay. In case of your 
withdrawal from the study we will ask you if the data collected from your urine sample 
could be still used or if you wish us to destroy it, and we will act upon your decision. 
 
 
Who is organising and funding the research? 
The urology department and the University of East Anglia are jointly carrying out the 
research, however a third party may also provide funds (A third party may be a big 
organisation such as the Big C who fund cancer research in Norfolk and Waveney). Ethical 
approval has been received for this study.  
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What will happen to the samples and information at the end of the study and how long 
will they be kept? 
Urine and blood samples will be used as a source of markers and genetic materials, some of 
which will be used in the above research, and the rest will be kept to be used at a later date 
in future research projects. Samples including DNA, RNA and protein may be stored for up 
to 20 years after the end date of this project. The anonymised information collected from 
this study will be stored for up to twenty years for use in future studies designed to improve 
patient care and treatment. Samples and anonymised information may be shared with other 
collaborating laboratories for further specialised analysis in the UK or in other countries. 
 
Links with other organisations 
If you agree, we may send stored material or products derived from it to other approved 
laboratories or companies in the UK or abroad to support their research programmes. We are 
not, however, allowed to sell tissue or other samples in order to make any financial profit. 
We will release tissue or other samples to laboratories or companies only if they work to 
appropriate ethical and scientific standards. 
 
Who has reviewed the study? 
The study design and protocol has been reviewed by the research and development 
department at the Norfolk and Norwich University Hospital, Public and Patient Involvement 
in Research (PPIRes) and the Norfolk Research Ethics Committee. 
 
 
If you need further information please contact: 
Chief Investigator and Clinical fellow in Urology  
Norfolk and Norwich University Hospital 
Mr Marcelino Yazbek Hanna on 
Phone: 07886302762 
E-mail: marcelino.yazbekhanna@nnuh.nhs.uk 
Post: Norfolk and Norwich University Hospital NHS Trust, 
         Urology Department, 
         Colney Lane, 
         Norwich, 
         NR4 7UY 
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Affix an addressograph label here 
or complete the following details: 
 
Patient’s name………………………...  
Date of birth…………………………… 
Hospital no. …………………………...	
Appendix 3 
  
  
 
 
 
ADULT INFORMED CONSENT 
For a Research Study  
 
Diagnostic urine and blood biomarkers for prostate cancer 
 
1. I confirm that I have read and understand the information sheet (version 4 dated 06/08/2012) for the 
above study and have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time, without 
giving any reason, without my medical care or legal rights being affected. 
 
3. I understand that an internal examination will be done as described in the information sheet (Version 
4 dated 06/08/2012). 
 
4. I understand that the urine sample I provide will be used for the analysis of tumour cells, DNA, 
RNA, protein and metabolites. 
 
5. I agree to provide blood samples for the purpose of this research, and I understand that it will be 
used for DNA, RNA protein, metabolite and cell analysis. 
 
6. Anonymised information about my case may be kept on a secure database for up to twenty years 
after the end date of this study for use in future research studies to improve patient care. 
 
7. Anonymised information may be passed on to persons outside the NNUH and UEA in connection 
with research and may be published with any research findings. 
 
8.  I understand that urine, blood and biological extracts of my samples will be kept for up to 
twenty years after the end date of this study and may be used in other future studies designed to 
improve patient care. 
 
9. The samples may be transferred to other approved laboratories and/or companies, which may be in 
the UK or abroad, in properly approved research programmes. 
 
10.        I agree to take part in the above study.                   
                     
 
Signed __________________(Patient) _________________________ Date ________ 
 
I have explained the research and have answered such questions as the patient has asked. 
 
Signed _________________ Clinical Investigator ________________ Date ________   
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Appendix 6 
Proforma	of	the	clinical	information	gathetered	from	all	the	patients		
	
Clinical Information 
 
Urine 
 
Social History Treatment and follow 
up 
Histology 
Finding 
 
Radiology 
Finding 
 
Lab Number Pre DRE urine 
volume 
Alcohol consumption 
in unit per week 
 
Radiotherapy Gleason Major TNM 
staging MRI 
Date of presentation PostDRE urine 
volume 
Smoking history 
(Sig/day and period 
of smoking) 
 
Hormone manipulation Gleason Minor Bone Scan 
results 
Etnicity Urine Color (Yellow, 
Orange, Red ,  Pale, 
Dark) 
Ex smokers (How 
long are they smoking 
free) 
 
Radical prostatectomy Gleason Score  
Age Speed of processing  Ocupation  Follow up PSA after 
treatment 
Number of 
positive cores vs 
number of total 
cores on each 
lobe 
 
 
Reason for PSA Check Method of processing 
(Ie Centrifuged 
immediately, Placed 
on wet ice, dry ice 
etc) 
 Further management (ie 
change in hormone 
manipulation and 
chemotherapy) 
 
Perineural 
invasion 
 
Symptoms (LUTS, 
Haematuria, Bone pain, 
focal neurology, Hx of 
BPH and treatment for 
it) 
How soon was the 
sample given after 
DRE 
  Neurovascular 
invasion 
 
IPSS score Dip stick Finding 
 
  TRUS finding  
PSA at presentation Nitrites   Volume of cancer 
% in positive 
cores 
 
 
Previous PSA Leucocytes   Prostate Volume 
in gram 
 
 
Blood Results 
(UE,FBC,LFT) 
Proteine   Post 
prostatectomy 
histological 
results 
 
 
Past Medical History Blood     
Medications Ketone 
 
    
Treatment with 5 alpha 
reductase 
PH     
DRE Finding  
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